DK2185589T3 - FC RECEPTOR BINDING AGENTS FOR immunoglobulin constant - Google Patents

Description

DESCRIPTION BACKGROUND OF THE INVENTION Field of the Invention [0001] This invention relates generally to the fields of immunology, inflammation, and tumor immunology. More specifically, the present invention relates to biologically active biomimetic molecules comprising immunoglobulin Fc domains, compositions comprising such biomimetics, and methods of using such biomimetics.

[0002] The invention also relates to the treatment and prophylaxis of pathological conditions mediated by monocyte-derived cells, and more particularly to the use of stabilized functional portions of IgG Fc fragments for such treatment and prophylaxis.

Description of the Background Art [0003] Immune globulin products from human plasma have been used since the early 1950's to treat immune deficiency disorders and more recently, and more commonly, for autoimmune and inflammatory diseases.

[0004] Initially, immune globulin products were administered by intramuscular injection. More recently, intravenous immune globulin (MG) has been used and was initially shown to be effective in treatment of the autoimmune disease idiopathic thrombocytopenic purpura (ITP) (Imbach P, Barandun S, d'Apuzzo V, et al: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981 Jun 6; 1(8232): 1228-31). Human IVIG (referred to herein as "hIVIG") is a formulation of sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma that typically contains more than 95% unmodified IgG, with only small and variable amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM) (see, for example, Rutter A, Luger ΤΑ: High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001 Jun; 44(6): 1010-24). Today the single most common clinical use of hIVIG is in the treatment of ITP.

[0005] While hIVIG has been an effective clinical treatment, there are several shortcomings to hIVIG formulations, including the potential for inadequate sterility, the presence of impurities, lack of availability, and lot-to-lot variation. In particular hIVIG preparations can vary greatly in their immunoglobulin A (IgA) content which can be of concern because IgA can cause allergic and anaphylactic reactions in IgA-deficient recipients.

[0006] In view of the negative aspects of hIVIG, there exists a need for an improved means of treating autoimmune and inflammatory diseases.

[0007] For example, the formation of immune globulins which contain additional Fc domains in one linear branch as a result of fusion to an existing Fc domain is described in W02005/077981.

[0008] In addition, multiple pathological conditions of a wide variety of types are mediated by cells derived from monocytes. A simple therapeutic and/or prophylactic agent for use in many, if not all, such conditions would be invaluable.

SUMMARY OF THE INVENTION

[0009] The immuno-regulatory properties of IVIG reside in the Fc domain of IgG molecules. For example, in murine models of ITP, both unmodified IVIG and the Fc fragment alone demonstrate therapeutic efficacy in restoring platelet counts, while isolated IVIG Fab fragments are not therapeutic (Samuelsson, A., Towers, T.L. & Ravetch, J.V. Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor. Science 291, 484-486 (2001)). Moreover Fc, but not Fab fragments of IVIG, is also therapeutically effective in the treatment of both childhood and adult idiopathic thrombocytopenic purpura (Follea, G. et al. Intravenous plasmin-treated gammaglobulin therapy in idiopathic thrombocytopenic purpura. Nouv Rev Fr Hematol 27, 5-10 (1985); Solal-Celigny, R, Bernard, J., Herrera, A. & Biovin, P. Treatment of adult autoimmune thrombocytopenic purpura with high-dose intravenous plasmin-cleaved gammaglobulins. Scand J Haematol 31, 39-44 (1983); Debre, M. & Bonnet, M.-C. Infusion 1 of Gcgamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945-49 (1993); Burdach, S.E., Evers, K. & Geurson, R. Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: Comparative efficacy of 7S and 5S preparations. J Pediatr 109, 770-775 (1986)).

[0010] The therapeutic effect of MG is initially mediated through the Fc gamma receptor (FcyR) and relies on Dendritic Cell (DC)-macrophage cross-talk for its long term tolerogenic effects. FcyRIIIa plays a requisite role in the initiator phase and FcyRIIb is required for the effector phase in murine models of ITP (Samuelsson, A, Towers, T.L. & Ravetch, J.V. Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor. Science 291, 484-486 (2001) ; Siragam, V. et al. Intravenous immunoglobulin ameliorates ITP via activating Fc[gamma] receptors on dendritic cells. Nat Med 12, 688 (2006)). Similarly, human studies demonstrate that anti-Fcy receptor antibodies are effective in the treatment of refractory ITP (Clarkson, S. et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 314, 1236-1239 (1986)). Importantly, long term tolerogenic effects are mediated by cell-cell interactions, as adoptive transfer of IVIG-treated DCs is effective in treating murine models of ITP (Siragam, V. et al. Intravenous immunoglobulin ameliorates ITP via activating Fc[gamma] receptors on dendritic cells. Nat Med 12, 688 (2006)).

[0011] The immunomodulatory effects of IVIG require aggregation of the FcyR. Aggregation of FcyR is mediated by IgG dimers present in IVIG (5-15% of the total IVIG) (Bleeker, W.K. et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 95, 1856-1861 (2000)). For example, in a murine model of ITP, treatment with IVIG with a high content of "dimers" (dimers of whole immunoglobulin molecules) enhanced platelet counts while IVIG "monomers" (whole immunoglobulin molecules) were not effective (Teeling, J.L. et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 98,1095-1099 (2001)). Furthermore, despite the fact that ion exchange resin and polyethylene glycol fractionation are routinely used in the manufacture of IVIG to remove IgG aggregates, the clinical efficacy of IVIG correlates with the presence of dimers in the patient's sera (Augener, W., Friedman, B. & Brittinger, G. Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)? Blut 50, 249-252 (1985)). Importantly, the percentage of dimers also correlates with vasoactive side effects, which are treatable with acetylhydrolase (Bleeker, W.K. et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 95, 1856-1861 (2000)).

[0012] The present invention relates to biologically active biomimetic molecules, compositions comprising the same, and methods of using the same. These biomimetics have broad application for treating immunological and inflammatory disorders including but not limited to autoimmune diseases, and they have utility as bioimmunotherapy agents for cancer. Further, certain of these biomimetics also have utility as reagents, such as for use in immunological assays for testing immune cell function and in the diagnosis of disease. Moreover, the biomimetics and compositions of the present invention have the advantage of overcoming the above-listed limitations of hIVIG. The invention also relates to the treatment and prophylaxis of pathological conditions mediated by monocyte-derived cells, and more particularly to the use of stabilized functional portions of IgG Fc fragments for such treatment and prophylaxis.

[0013] The present invention is as defined in the claims, specifically a compound comprising two or more multimerized units, wherein each of said units comprises a multimerizing region and a region comprising at least one Fc domain that is capable of binding to a Fey receptor, wherein each of said units comprises two dimerized monomers, wherein each of said monomers comprises a multimerizing region monomer and a region comprising at least one Fc domain monomer, wherein the dimerization of the two monomers forms a multimerizing region and a region comprising at least one Fc domain that is capable of binding to a Fey receptor, wherein the multimerizing regions of the two or more units multimerize to form the compound, and wherein the compound is capable of binding to a first Fey receptor through a first Fc domain and to a second Fey receptor through a second Fc domain, wherein the multimerizing region is selected from the group consisting of an lgG2 hinge, an IgE CH2 domain, a leucine zipper, an isoleucine zipper and a zinc finger, and wherein each of the regions comprising at least one Fc domain that is capable of binding to a Fey receptor comprises an lgG1 hinge, an lgG1 CH2 domain and an lgG1 CH3 domain.

[0014] The present invention also provides the composition, pharmaceutical composition, and compositions for uses as defined in the claims.

[0015] The present disclosure also provides a number of embodiments as set out below. Insofar as any embodiment is outside of the claims it is illustrative and part of the disclosure for reference purposes. 2 [0016] In a first embodiment the present disclosure provides isolated serial stradomers comprising two or more associated stradomer monomers, wherein each of the stradomer monomers comprises two or more Fc domain monomers, wherein the association of the two or more stradomer monomers forms two or more Fc domains, and wherein the serial stradomer specifically binds to a first Fey receptor through a first of the two or more Fc domains and to a second Fey receptor through a second of the two or more Fc domains. In a preferred embodiment, the two or more stradomer monomers are associated through a covalent bond, a disulfide bond or chemical cross-linking.

[0017] In a preferred embodiment of the isolated serial stradomers of the present disclosure the isolated serial stradomers are comprised of two associated stradomer monomers. In an equally preferred embodiment, the isolated serial stradomers are comprised of two associated stradomer monomers wherein both of the stradomer monomers comprise two Fc domain monomers, and wherein the association of the two stradomer monomers forms two Fc domains. In a first particular example of these embodiments directed to isolated serial stradomers, at least one of the two Fc domains comprises an IgG hinge and an IgG CFI2 domain. In a second particular example each of the two Fc domains independently comprises an IgG hinge and an IgG CFI2 domain. In a third particular example at least one of the two Fc domains comprises an IgG hinge, an IgG CFI2 domain and an IgG CH3 domain. In a fourth particular example each of the two Fc domains independently comprises an IgG hinge, an IgG CH2 domain and an IgG CFB domain. In a fifth particular example at least one of the two Fc domains comprises an lgG1 hinge or an lgG3 hinge, an lgG1 CFI2 domain or an lgG3 CFI2 domain, and an lgG1 CFI3 domain or an lgG3 CFI3 domain. In a sixth particular example at least one of the two Fc domains comprises an lgG1 hinge or an lgG3 hinge, and an lgG1 CFI2 domain or an lgG3 CFI2 domain. In a seventh particular example each of the two Fc domains independently comprises an lgG1 hinge or an lgG3 hinge, an lgG1 CFI2 domain or an lgG3 CFI2 domain, and an lgG1 CFI3 domain or an lgG3 CFI3 domain. In an eighth particular example each of the two Fc domains independently comprises an lgG1 hinge, an lgG1 CFI2 domain, and an lgG1 CFI3 domain. In a ninth particular example each of the two Fc domains independently comprises an lgG3 hinge, an lgG3 CFI2 domain, and an lgG3 CH3 domain. In a tenth particular example each of the two Fc domains independently comprises an lgG1 hinge, an lgG1 CFI2 domain, and an lgG3 CFI3 domain.

[0018] Also in this first embodiment, the two or more Fc domains are each of a same immunoglobulin Fc class, and the immunoglobulin Fc class is selected from the group consisting of lgG1, lgG2, lgG3, and lgG4. Alternatively, the two or more Fc domains arc each of a different immunoglobulin Fc class, and said immunoglobulin Fc class is selected from the group consisting of lgG1, lgG2, lgG3 and lgG4.

[0019] Further in this first embodiment, the first and second Fey receptors are each independently an Fey receptor I, an Fey receptor II, an Fey receptor III or an Fey receptor IV. Preferably the first and second Fey receptors are each Fey receptor Ilia.

[0020] In a second embodiment the present disclosure provides isolated serial stradomers comprising two associated stradomer monomers, wherein each of the stradomer monomers comprises two Fc domain monomers, wherein the association of the two stradomer monomers forms two Fc domains, wherein each of said two Fc domains independently comprises an IgG hinge, an IgG CH2 domain and an IgG CH3 domain, and wherein the serial stradomer specifically binds to a first Fey receptor through a first of the two Fc domains and to a second Fey receptor through a second of the two Fc domains. In a preferred embodiment, the two or more stradomer monomers are associated through a covalent bond, a disulfide bond or chemical cross-linking.

[0021] In a first particular example of this second embodiment the two Fc domains are each of a same immunoglobulin Fc class, and the immunoglobulin Fc class is selected from the group consisting of IgG 1, lgG2, lgG3, and lgG4. In a second particular example the two Fc domains are each of a different immunoglobulin Fc class, and said immunoglobulin Fc class is selected from the group consisting of lgG1, lgG2, lgG3 and lgG4. In a third particular example at least one of the Fc domains comprises an IgG hinge and an IgG CH2 domain. In a fourth particular example each of the Fc domains independently comprises an IgG hinge and an IgG CH2 domain. In a fifth particular example at least one of the Fc domains comprises an IgG hinge, an IgG CH2 domain and an IgG CH3 domain. In a sixth particular example each of the Fc domains independently comprises an IgG hinge, an IgG CH2 domain and an IgG CH3 domain. In a seventh particular example at least one of the Fc domains comprises an IgG 1 hinge or an lgG3 hinge, an IgG 1 CH2 domain or an lgG3 CH2 domain, and an IgG 1 CH3 domain or an lgG3 CH3 domain. In an eighth particular example each of the Fc domains independently comprises an lgG1 hinge or an lgG3 hinge, an lgG1 CH2 domain or an lgG3 CH2 domain, and an IgG 1 CH3 domain or an lgG3 CH3 domain. In a ninth particular example each of the Fc domains independently comprises an IgG 1 hinge, an IgG 1 CH2 domain, and an lgG1 CH3 domain. In a tenth particular example each of the Fc domains independently comprises an lgG3 hinge, an lgG3 CH2 domain, and an lgG3 CH3 domain. In an eleventh particular example each of the Fc domains independently comprises an lgG1 hinge, an IgG 1 CH2 domain, and an lgG3 CH3 domain.

[0022] In a third embodiment the present disclosure provides isolated serial stradomers further comprising a Fab domain, wherein each of the stradomer monomers comprises an Fab fragment heavy chain and two Fc domain monomers, wherein the Fab fragment heavy chain is in a position amino terminal or carboxy terminal to the two Fc domain monomers, wherein an Fab fragment light chain is independently associated with each Fab fragment heavy chain, and wherein the Fab domain has antigenbinding activity. In a preferred embodiment, each of the stradomer monomers further comprises an immunoglobulin hinge monomer, and wherein the immunoglobulin hinge monomer is in a position between the Fab fragment heavy chain and the two Fc domain monomers.

[0023] In a fourth embodiment the present disclosure provides core stradomers comprising a core moiety linked to two or more core stradomer units, wherein each of the two or more core stradomer units comprises at least one Fc domain, and wherein each of the core stradomer units is independently selected from the group consisting of: 1. (a) an Fc fragment, wherein said Fc fragment comprises two associated Fc fragment monomers, wherein each of said Fc fragment monomers comprises an Fc domain monomer, and wherein the association of the two Fc fragment monomers forms an Fc domain, 2. (b) an Fc partial fragment, wherein said Fc partial fragment comprises two associated Fc partial fragment monomers, wherein each of said Fc partial fragment monomers comprises an Fc domain monomer, and wherein the association of the two Fc partial fragment monomers forms an Fc domain, 3. (c) an Fc domain, wherein said Fc domain comprises two associated Fc domain monomers, and wherein the association of the two Fc domain monomers forms an Fc domain, 4. (d) a serial stradomer, wherein said serial stradomer comprises two or more associated stradomer monomers, wherein each of said stradomer monomers comprises two or more Fc domain monomers, and wherein the association of the two or more stradomer monomers forms two or more Fc domains, and 5. (e) a cluster stradomer, wherein said cluster stradomer comprises two or more multimerized cluster stradomer units, wherein each of said cluster stradomer units comprises a multimerizing region and at least one Fc domain, wherein each of said cluster stradomer units comprises two associated cluster stradomer unit monomers, wherein each of said cluster stradomer unit monomers comprises a multimerizing region monomer and at least one Fc domain monomer, wherein the association of the two cluster stradomer unit monomers forms a multimerizing region and at least one Fc domain, and wherein the multimerizing regions of the two or more cluster stradomer units multimerize to form the cluster stradomer, and wherein the core stradomer specifically binds to a first Fey receptor through a first of the two or more core stradomer units and to a second Fey receptor through a second of the two or more core stradomer units.

[0024] Preferably in this fourth embodiment, the core moiety is selected from the group consisting of an immunoglobulin J chain, albumin, liposome, bead, peptide and polyethylene glycol.

[0025] In preferred embodiments directed to core stradomers the two or more core stradomer units are each independently an Fc fragment. Alternatively, the two or more core stradomer units are each independently a serial stradomer.

[0026] In a further preferred embodiment directed to core stradomers the core stradomer comprises two core stradomer units, wherein each of the two core stradomer units is each independently a serial stradomer, wherein the serial stradomer comprises two associated stradomer monomers, wherein both of said stradomer monomers comprises two Fc domain monomers, and wherein the association of the two stradomer monomers forms two Fc domains. In a first particular example of this embodiment, at least one of the Fc domains of the two or more core stradomer units comprises an lgG1 hinge or an lgG3 hinge, an lgG1 CFI2 domain or an lgG3 CFI2 domain, and an lgG1 CFI3 domain or an lgG3 CH3 domain. In a second particular example at least one of the Fc domains of the two or more two core stradomer units comprises an lgG1 hinge or an lgG3 hinge, and an lgG1 CFI2 domain. In a third particular example each of the Fc domains of the two or more two core stradomer units independently comprises an lgG1 hinge, an lgG1 CFI2 domain, and an lgG1 CH3 domain. In a fourth particular example at least one of the Fc domains of the two or more two core stradomer units comprises an IgG hinge and an IgG CFI2 domain. In a fifth particular example each of the Fc domains of the two or more two core stradomer units independently comprises an IgG hinge and an IgG CH2 domain. In a sixth particular example each of the Fc domains of the two or more two core stradomer units independently comprises an lgG3 hinge, an lgG3 CFI2 domain, and an lgG3 CFB domain. In a seventh particular example each of the Fc domains of the two or more two core stradomer units independently comprises an lgG1 hinge, an lgG1 CFI2 domain, and an lgG3 CH3 domain.

[0027] In this embodiment, the first and second Fey receptors are each independently an Fey receptor I, an Fey receptor II, an Fey receptor III or an Fey receptor IV. Preferably, the first and second Fey receptors are each Fey receptor Ilia.

[0028] In a fifth embodiment the present disclosure provides cluster stradomers comprising two or more multimerized cluster stradomer units, wherein each of the cluster stradomer units comprises a multimerizing region and at least one Fc domain, wherein each of the cluster stradomer units comprises two associated cluster stradomer unit monomers, wherein each of the cluster stradomer unit monomers comprises a multimerizing region monomer and at least one Fc domain monomer, wherein the association of the two cluster stradomer unit monomers forms a multimerizing region and at least one Fc domain, wherein the multimerizing regions of the two or more cluster stradomer units multimerize to form the cluster stradomer, and wherein the cluster stradomer specifically binds to a first Fey receptor through a first Fc domain and to a second Fey receptor through a second Fc domain.

[0029] In preferred embodiments, the multimerizing region is selected from the group consisting of an lgG2 hinge, an IgE CH2 domain, a leucine, an isoleucine zipper and a zinc finger.

[0030] In further preferred embodiment, the cluster stradomers comprising two, three, four or five multimerized cluster stradomer units.

[0031] In a first particular example of this fifth embodiment at least one of the Fc domains comprises an lgG1 hinge or an lgG3 hinge, an lgG1 CH2 domain or an lgG3 CH2 domain, and an lgG1 CH3 domain or an lgG3 CH3 domain. In a second particular example each of the Fc domains independently comprises an lgG1 hinge, an lgG1 CH2 domain, and an lgG1 CH3 domain. In a third particular example at least one of the Fc domains comprises an IgG hinge and an IgG CH2 domain. In a fourth particular example each of the Fc domains independently comprises an IgG hinge and an IgG CH2 domain. In a fifth particular example each of the Fc domains independently comprises an lgG3 hinge, an lgG3 CH2 domain, and an lgG3 CH3 domain. In a sixth particular example each of the Fc domains independently comprises an lgG1 hinge, an lgG1 CH2 domain, and an lgG3 CH3 domain. In a seventh particular example each of the Fc domains independently comprises an IgG hinge, an IgG CH2 domain and an IgG CH3 domain. In an eighth particular example at least one of the cluster stradomer units comprises two or more Fc domains. In a ninth particular example each of the cluster stradomer units comprises two or more Fc domains.

[0032] In this embodiment, the first and second Fey receptors are each independently an Fey receptor I, an Fey receptor II, an Fey receptor III or an Fey receptor IV. Preferably, the first and second Fey receptors are each Fey receptor Ilia.

[0033] In a sixth embodiment the present disclosure provides stradobodies comprising two or more associated stradomer monomers and an Fab domain, wherein each of the stradomer monomers comprises an Fab fragment heavy chain and two or more Fc domain monomers, wherein the Fab fragment heavy chain is in a position amino terminal or carboxy terminal to the two or more Fc domain monomers, wherein the association of the two or more stradomer monomers forms two or more Fc domains, wherein an Fab fragment light chain is independently associated with the Fab fragment heavy chain of each stradomer monomer, wherein the Fab domain has antigen-binding activity, and wherein the stradobody specifically binds to a first Fey receptor through a first of the two or more Fc domains and to a second Fey receptor through a second of the two or more Fc domains.

[0034] In preferred embodiments the two or more stradomer monomers are associated through a covalent bond, a disulfide bond or chemical cross-linking.

[0035] In a further preferred embodiment, each of said stradomer monomers of the stradobodies further comprises an immunoglobulin hinge monomer, and wherein the immunoglobulin hinge monomer is in a position between the Fab fragment heavy chain and the two Fc domain monomers.

[0036] In a particular embodiment the stradobody comprises two associated stradomer monomers, wherein each of said stradomer monomers comprises an Fab fragment heavy chain and two Fc domain monomers, and wherein the association of the two stradomer monomers forms two Fc domains. In a first particular example of this embodiment, at least one of the two Fc domains comprises an IgG hinge, an IgG CH2 domain and an IgG CH3 domain. In a second particular example each of the two Fc domains independently comprises an IgG hinge, an IgG CH2 domain and an IgG CH3 domain. In a third particular example at least one of the two Fc domains comprises an IgG hinge and an IgG CH3 domain. In a fourth particular example each of the Fc two domains independently comprises an IgG hinge and an IgG CH3 domain. In a fifth particular example at least one of the two Fc domains comprises an lgG1 hinge or an lgG3 hinge, an lgG1 CH2 domain or an lgG3 CH2 domain, and an lgG1 CH3 domain or an lgG3 CH3 domain. In a sixth particular example each of the two Fc domains independently comprises an lgG1 hinge or an lgG3 hinge, an lgG1 CH2 domain or an lgG3 CH2 domain, and an lgG1 CH3 domain or an lgG3 CH3 domain. In a seventh particular example each of the two Fc domains independently comprises an lgG1 hinge, an lgG1 CH2 domain, and an lgG1 CH3 domain. In an eighth particular example each of the two Fc domains independently comprises an lgG3 hinge, an lgG3 CH2 domain, and an lgG3 CH3 domain. In a ninth particular example each of the two Fc domains independently comprises an lgG1 hinge, an lgG1 CH2 domain, and an lgG3 CH3 domain. In a tenth particular example at least one of the two Fc domains comprises an lgG1 hinge or an lgG3 hinge, and an lgG1 CH2 domain or an lgG3 CH2 domain. In an eleventh particular example at least one of the two Fc domains comprises an lgG1 hinge or an lgG3 hinge, and an lgG1 CH2 domain.

[0037] In this embodiment, the first and second Fey receptors are each independently an Fey receptor I, an Fey receptor II, an Fey receptor III or an Fey receptor IV. Preferably, the first and second Fey receptors are each Fey receptor Ilia.

[0038] In a seventh embodiment the present disclosure provides methods of altering an immune response in a subject comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a serial stradomer and a carrier or diluent. In a preferred embodiment, the pharmaceutical composition comprises a therapeutically effective amount of a heterogeneous mixture of serial stradomers and a carrier or diluent.

[0039] In an eighth embodiment the present disclosure provides methods of altering an immune response in a subject comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a core stradomer and a carrier or diluent. In a preferred embodiment, the pharmaceutical composition comprises a therapeutically effective amount of a heterogeneous mixture of core stradomers and a carrier or diluent.

[0040] In a ninth embodiment the present disclosure provides methods of altering an immune response in a subject comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a cluster stradomer and a carrier or diluent. In a preferred embodiment, the pharmaceutical composition comprises a therapeutically effective amount of a heterogeneous mixture of cluster stradomers and a carrier or diluent.

[0041] In a tenth embodiment the present disclosure provides methods of altering an immune response in a subject comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a stradobody and a carrier or diluent. In a preferred embodiment, the pharmaceutical composition comprises a therapeutically effective amount of a heterogeneous mixture of stradobodies and a carrier or diluent.

[0042] In an eleventh embodiment the present disclosure provides methods of screening an antibody for a specific activity on a cell of the immune system, comprising: (a) contacting a homogenous population of cells of the immune system with a candidate antibody, (b) measuring an activity of the population of cells of (a), (c) contacting a homogenous population of cells of the same cell type as in (a) with a serial stradomer of claim 1, (d) measuring an activity of the population of cells of (c), and (e) comparing the activity measured in (b) with the activity measured in (d), thereby screening an antibody for a specific activity on a cell of the immune system. In a preferred embodiment, the candidate antibody and the serial stradomer are species-matched and isotype-matched. In a further preferred embodiment, the comparison in (e) is a ratio of activity measured in (d) versus the activity measured in (b).

[0043] In a twelfth embodiment the present disclosure provides methods of inhibiting the activity of a monocyte-derived cell (MDC). The method involves contacting the cell with a composition containing a substrate with an Fc reagent bound to it. The contacting can be in vitro, in vivo, or ex vivo. The cell can be in an animal, e.g., an animal that has or is at risk of developing a monocyte derived cell mediated condition (MDCMC). The cell can be, for example, a dendritic cell, a macrophage, a monocyte, or an osteoclast.

[0044] In a thirteenth embodiment the present disclosure provides methods of treatment that includes administering to an animal a composition comprising a substrate having an Fc reagent bound thereto, the animal having or being at risk of developing a monocyte-derived cell mediated condition (MDCMC).

[0045] The following are embodiments common to both these two methods (the twelfth and thirteenth embodiments).

[0046] The animal can be, for example, a human.

[0047] The Fc reagent can contain or be a functional portion of a human Fc fragment, e.g., a human IgG 1 Fc fragment, a human lgG3 Fc fragment, a human lgG2, or a human lgG4 Fc fragment. Moreover it can include or be an IgG molecule. The Fc reagent can also be or include a functional portion of a non-human Fc fragment.

[0048] The substrate can be or include a synthetic polymer, e.g., nylon, teflon, dacron, polyvinyl chloride, PEU (poly (ester urethane)), PTFE (polytetrafluoroethylene), or PMMA (methyl methacrylate). The substrate can include or be a metal or a metal alloy, e.g., stainless steel, platinum, iridium, titanium, tantalum, a nickel-titanium alloy, or a cobalt-chromium alloy. The substrate can contain or be animal tissue or an animal tissue product, e.g., a tissue or organ graft, bone (e.g., osteogenic bone), or cartilage. The substrate can contain or be a protein, e.g., collagen or keratin. The substrate can also be or contain a polysaccharide, e.g., agarose. Moreover, the substrate can contain or be a tissue matrix, e.g., an acellular tissue matrix. The substrate can contain or be an animal cell (e.g., a tissue repair cell such as a fibroblasts or a mesenchymal stem cell). The substrate can contain or be a salt, e.g., calcium sulfate. Furthermore the substrate can be or contain a gel or cream. It can also contain or be silicon or silastic. It can also contain be a natural fiber, e.g., silk, cotton, or wool.

[0049] The substrate can be a hair transplant plug or an implantable medical device such as a stent (e.g., a vascular stent such as a coronary artery stent; an airway stent such as an endotracheal or nasal stent; a gastrointestinal stent such a biliary or pancreatic stent; or a urinary stent such as a ureteral stent). It can also be a surgical suture (e.g., a braid silk, chromic gut, nylon, plastic, or metal suture or a surgical clip (e.g., an aneurism clip)). In addition, the substrate the can be an artificial hip, an artificial hip joint, an artificial knee, an artificial knee joint, an artificial shoulder, an artificial shoulder joint, an artificial finger or toe joint, a bone plate, a bone dowel, a bone non-union implant, an intervertebral disk implant, bone cement, or a bone cement spacer. It can be an arterial-venous shunt, an implantable wire, a pacemaker, an artificial heart, a heart assist device, a cochlear implant, an implantable defibrillator, a spinal cord stimulator, a central nervous system stimulator, a peripheral nerve implant, a dental prosthesis, or a dental crown. Furthermore, the substrate can be a large vessel embolic filtering device or cage, a percutaneous device, a dermal or sub-mucosal patch, or an implantable drug delivery device.

[0050] The substrate can also be a large blood vessel graft, wherein the blood vessel is, for example, a carotid artery, a femoral artery, or an aorta. It can also be a sub-dermal implant, a corneal implant, an intraocular lens, or a contact lens.

[0051] The substrate can be in the form of, e.g., a sheet, a bead, a mesh, a powder particle, a thread, a bead, or a fiber. The substrate can contain or be a solid, a semi-solid, or a gelatinous substance. Thus, a substrate includes substances that are substantially insoluble in aqueous solvents, e.g., a fat-soluble lipid such as a liposome.

[0052] The MDCMC can be an inflammatory condition, an autoimmune disease, a cancer, a disorder of bone density, an acute infection, or a chronic infection.

[0053] It can be a hematoimmunological process, e.g., Idiopathic Thrombocytopenic Purpura, alloimmune/autoimmune thrombocytopenia, Acquired immune thrombocytopenia, Autoimmune neutropenia, Autoimmune hemolytic anemia, Parvovirus B19-associated red cell aplasia, Acquired antifactor VIII autoimmunity, acquired von Willebrand disease, Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance, Sepsis, Aplastic anemia, pure red cell aplasia, Diamond-Blackfan anemia, hemolytic disease of the newborn, Immune-mediated neutropenia, refractoriness to platelet transfusion, neonatal post-transfusion purpura, hemolytic uremic syndrome, systemic Vasculitis, Thrombotic thrombocytopenic purpura, or Evan's syndrome.

[0054] Alternatively, the MDCMC can be a neuroimmunological process, e.g., Guillain-Barré syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Paraproteinemic IgM demyelinating Polyneuropathy, Lambert-Eaton myasthenic syndrome, Myasthenia gravis, Multifocal Motor Neuropathy, Lower Motor Neuron Syndrome associated with anti-GM1 antibodies, Demyelination, Multiple Sclerosis and optic neuritis, Stiff Man Syndrome, Paraneoplastic cerebellar degeneration with anti-Yo antibodies, paraneoplastic encephalomyelitis, sensory neuropathy with anti-Hu antibodies, epilepsy, Encephalitis, Myelitis, Myelopathy especially associated with Human T-cell lymphotropic virus-1, Autoimmune Diabetic Neuropathy, or Acute Idiopathic Dysautonomic Neuropathy.

[0055] The MDCMC can be a Rheumatic disease process, e.g., Kawasaki's disease, Rheumatoid arthritis, Felty's syndrome, ANCA-positive Vasculitis, Spontaneous Polymyositis, Dermatomyositis, Antiphospholipid syndromes, Recurrent spontaneous abortions, Systemic Lupus Erythematosus, Juvenile idiopathic arthritis, Raynaud's, CREST syndrome, or Uveitis.

[0056] Moreover, the MDCMC can be a dermatoimmunological disease process, e.g., Epidermal Necrolysis, Gangrene, Granuloma, Autoimmune skin blistering diseases including Pemphigus vulgaris, Bullous Pemphigoid, and Pemphigus foliaceus, Vitiligo, Streptococcal toxic shock syndrome, Scleroderma, systemic sclerosis including diffuse and limited cutaneous systemic sclerosis, Atopic dermatitis, or steroid dependent Atopic dermatitis.

[0057] In addition, the MDCMC can be a musculoskeletal immunological disease, e.g., Inclusion Body Myositis, Necrotizing fasciitis, Inflammatory Myopathies, Myositis, Anti-Decorin (BJ antigen) Myopathy, Paraneoplastic Necrotic Myopathy, X-linked Vacuolated Myopathy, Penacillamine-induced Polymyositis, Atherosclerosis, Coronary Artery Disease, or Cardiomyopathy.

[0058] The MDCMC can also be a gastrointestinal immunological disease process, e.g., pernicious anemia, autoimmune chronic active hepatitis, primary biliary cirrhosis, Celiac disease, dermatitis herpetiformis, cryptogenic cirrhosis, Reactive arthritis, Crohn's disease, Whipple's disease, ulcerative colitis, or sclerosing cholangitis.

[0059] The MDCMC can be, for example, Graft Versus Host Disease, Antibody-mediated rejection of the graft, Post-bone marrow transplant rejection, Post-infectious disease inflammation, Lymphoma, Leukemia, Neoplasia, Asthma, Type 1 Diabetes mellitus with anti-beta cell antibodies, Sjogren's syndrome, Mixed Connective Tissue Disease, Addison's disease, Vogt-Koyanagi-Harada Syndrome, Membranoproliferative glomerulonephritis, Goodpasture's syndrome, Graves' disease, Hashimoto's thyroiditis, Wegener's granulomatosis, micropolyarterits, Churg-Strauss syndrome, Polyarteritis nodosa or Multisystem organ failure.

[0060] Where the MDCMC is a cancer, it can be fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic disease, heavy chain disease,neuroendocrine tumors, or Schwanoma,.

[0061] Where the MDCMC is a disorder of bone density, it can be osteoporosis, osteopenia, osteopetrosis, idiopathic hypogonadotropic hypogonadism, anorexia nervosa, non-healing fracture, post-menopausal osteoporosis, Vitamin D deficiency or excess, primary or secondary hyperparathyroidism, thyroid disease, or bisphosphonate toxicity.

[0062] Where the MDCMC is an acute infection, it can be: a fungal disorder including Candidiasis, Candidemia, or Aspergillosis; a bacterial disorder, including staphylococcus including Methicillin Resistant Staph aureus, streptococcal skin and oropharyngeal conditions, or gram negative sepsis; a mycobacterial infection including tuberculosis; a viral infection including mononucleosis, Respiratory Syntitial virus infection, or Herpes zoster infection; a parasitic infection including malaria, schistosomiasis, or trypanosomiasis.

[0063] Where the MDCMC is a chronic infection, it can be onchyomycosis; a bacterial disorder including Helicobacter pylori; a mycobacterial infection including tuberculosis; a viral infection including Epstein Barr virus infection, Human Papilloma Virus infection, or Herpes Simplex Virus infection; or a parasitic infection including malaria or schistosomiasis.

[0064] In a fourteenth embodiment the present disclosure provides a composition that contains or is an implantable or attachable medical device and an Fc reagent bound thereto.

[0065] In a fifteenth embodiment the present disclosure provides a kit that contains an implantable or attachable medical device and an Fc reagent. In both these embodiments, the implantable or attachable medical device and the Fc reagent can be any of those recited herein. The kit can further contain a suitable container.

BRIEF DESCRIPTION OF THE DRAWINGS

[0066] FIG. 1A shows in schematic form a native Fc fragment monomer structure from lgG1 having a Hinge domain linked to a CH2 domain linked to a CH3 domain; FIG. 1B shows a self-aggregated, native lgG1 Fc fragment formed from two associated Fc fragment monomers. FIG. 1C shows in schematic form a native Fc fragment monomer structure from lgG3 having a Hinge domain linked to a CH2 domain linked to a CH3 domain; FIG. 1D shows a self-aggregated, native lgG3 Fc fragment formed from two associated Fc fragment monomers. FIGS. 2Aand 2B show higher order aggregates of the native Fc fragment structure shown in FIG. I B. Fc fragments may naturally multimerize into dimers of dimer (i.e. tetramers) or even higher order multimer aggregates. FIG. 3A shows a schematic of a native lgG1 antibody having a native Fab fragment linked to the Fc fragment at the hinge of the Fc fragment; FIG. 3B shows the analogous lgG3 structure. FIG. 4A shows a stradomer monomer composed of two lgG1 Fc domain monomers in series; FIG. 4B shows an alternative stradomer monomer structure having linked in series lgG1 Fc-lgG3 Fc-lgE Fc. FIG. 5A& B show the stradomer monomers of FIGS. 4A& B autodimerizing into a serial stradomer due to the intrinsic capacity of the component Fc domain monomers. FIG. 6Ashows a stradomer monomer containing lgG1 Fc - lgG1 (hinge - CH2); FIG. 6B shows a stradomer containing lgG1 (hinge - CFI2) - lgG3 (hinge - CFI2) - IgE (hinge - CFI2) derived sequences. FIG. 7A & B show the stradomer monomers of 6A & B autodimerizing into a serial stradomer due to the intrinsic capacity of the component Fc domains. FIG. 7C shows a serial stradomer containing lgE(hinge)-lgG1 Fc-lgG1 (hinge-CFI2)-lgE (CH3). FIG. 7D shows a serial stradomer containing an lgG3Fc- IgGlFc. FIG. 8A shows a stradobody construct containing a Fab with a serial stradomer structure with each stradomer monomer containing two lgG1 CFI2-CFI3 derived Fc domain monomers; FIG. 8B shows a stradobody construct as in 8Abut with a stradomer structure containing an lgG1 Fc linked to an lgG3 Fc linked to an IgE Fc. FIG. 9Ashows an lgG1 Fc - lgG1 (hinge - CFI2) stradobody; FIG. 9B shows lgG1 (hinge - CFI2) - lgG3 (hinge - CFI2) - IgE (hinge -CH2) 3-stradobody. FIG. 10A shows an lgG1 (hinge-CFI2)- lgG3 CFI3 - IgM CFI4 stradomer monomer and a J chain protein; FIG. 10B shows a core stradomer based on a fivemer of the stradomer of FIG. 10A formed by association through the IgM CFI4 domain to a J chain. FIG. 10C shows an lgG1 Fc - lgG1 Fc - IgM CFI4 stradomer monomer and a J chain protein; FIG. 10D shows a core stradomer based on a fivemer of the stradomer of FIG. 10C formed by association through the IgM CFI4 domain to a J chain. FIG. 11A shows an lgG1 Fc - lgG1 (hinge - CFI2) stradomer monomer. FIG. 11B demonstrates how the stradomer monomer in FIG. 11Acan auto-dimerize to form a serial stradomer. FIG. 11C demonstrates how the same stradomer monomer in FIG. 11A can have monomer Fc domains align with the same or similar Fc domain monomers on another stradomer monomer but not as an autodimer, thereby forming a stradomer composed of the same stradomer monomer as the autodimer but with a zipper effect structure. FIG. 12A shows an lgG3 Fc - lgG1 Fc stradomer monomer. FIG. 12B shows that the addition of a second lgG3 Fc followed by autodimerization can form a branched structured lgG3 Fc - lgG1 Fc - lgG3 Fc stradomer. FIG. 13A shows an IgE CH2 - IgG 1 Fc - lgG1 (hinge-CH2) - IgE CH4 stradomer monomer. FIG. 13B shows the autodimer of the FIG. 13A monomer and highlights two FcyR binding sites formed. FIG. 14A shows a stradomer composed of two lgG1 Fc domains joined by a linker. FIG. 14B shows a stradomer composed of two serial stradomers (specifically in each case a 2(lgG1 Fc) stradomer) joined by a linker. FIG. 15A shows the nucleic acid (SEQ ID NO:1) and amino acid (SEQ ID NO:2) sequences of the human lgG1 Fc fragment. FIG. 15B shows the nucleic acid (SEQ ID NO:3) and amino acid (SEQ ID NO:4) sequences of the human lgG2 Fc fragment. FIG. 15C shows the nucleic acid (SEQ ID NO: 5) and amino acid (SEQ ID NO:6) sequences of the human lgG3 Fc fragment. FIG. 15D shows the nucleic acid (SEQ ID NO:7) and amino acid (SEQ ID NO:8) sequences of the human lgG4 Fc fragment. FIG. 16 shows the nucleic acid (SEQ ID NO:17) and amino acid (SEQ ID NO: 18) sequences of a construct comprising {IgK signal sequence-lgG1 Fc fragment-lgG1 Fc fragment}. The amino acid sequence of the IgK signal is in bold. The amino acid sequence of the first IgG 1 Fc fragment is single underlined. The amino acid sequence of the second lgG1 Fc fragment is double underlined. The serine and lysine marked with an asterisk are those amino acids that may be mutated to alter Fey receptor binding. FIG. 17 shows the nucleic acid (SEQ ID NO:19) and amino acid (SEQ ID NO:20) sequences of a construct comprising {Restriction Enzyme Sites-lgK signal Sequence-Restriction Enzyme Sites-lgG1(Flinge-CFI2-CH3)-Restriction Enzyme Sites-epitope tags(V5 and His)-STOP}. The amino acid sequence of the IgK signal is in bold. The amino acid sequence of the lgG1 Fc fragment is single underlined. The amino acid sequence of the V5 tag is underlined with a dashed line. The amino acid sequence of the His tag is underlined in bold. FIG. 18 shows the nucleic acid (SEQ ID NO:21) and amino acid (SEQ ID NO:22) sequences of a construct comprising {Restriction Enzyme Sites-lgK signal-Restriction Enzyme Sites-lgG1(Hinge-CH2-CH3)-Xbal site-lgG1(Hinge-CH2-CH3)-STOP}. The amino acid sequence of the IgK signal is in bold. The amino acid sequence of the first lgG1 Fc fragment is single underlined. The amino acid sequence of the second lgG1 Fc fragment is double underlined. FIG. 19 shows the nucleic acid (SEQ ID NO:23) and amino acid (SEQ ID NO:24) sequences of a construct comprising {Restriction Enzyme Sites-lgK signal-Restriction Enzyme Sites-lgG1(Hinge-CH2-CH3)-Xbal site-lgG1(Hnge-CH2-CH3)-Restriction Enzyme

Sites-epitope tags(V5 and His)-STOP}. The amino acid sequence of the IgK signal is in bold. The amino acid sequence of the first lgG1 Fc fragment is single underlined. The amino acid sequence of the second lgG1 Fc fragment is double underlined. The amino acid sequence of the V5 tag is underlined with a dashed line. The amino acid sequence of the His tag is underlined in bold. FIG. 20A shows the nucleic acid (SEQ ID NO:31) and amino acid (SEQ ID NO:32) sequences of the N-terminal signal sequence of FcRgammallla with the phenylalanine (F) polymorphism shown in bold and underlined. The variable nucleic acid is also in bold and underlined. Figure 20B shows the nucleic acid (SEQ ID NO:33) and amino acid (SEQ ID NO:34) sequences of the N-terminal signal sequence of FcRgammallla with valine (V) polymorphism shown in bold and underlined. The variable nucleic acid is also in bold and underlined. Both constructs contain a C-terminal hexaHis tag for purification. FIG. 21 shows the nucleic acid (SEQ ID NO:25) and amino acid (SEQ ID NO:26) sequences of a construct comprising {Restriction Enzyme Sites-lgK signal-EcoRV Site-lgG3(Hinge-CH2-CH3)-lgG1(Hinge-CH2-CH3)-Restriction Enzyme Sites-epitope tags(V5 and His) -STOP}. The amino acid sequence of the IgK signal is in bold. The amino acid sequence of the lgG3 Fc fragment is single underlined. The amino acid sequence of the IgG 1 Fc fragment is double underlined. The amino acid sequence of the V5 tag is underlined with a dashed line. The amino acid sequence of the His tag is underlined in bold. FIG. 22 shows the nucleic acid (SEQ ID NO:27) and amino acid (SEQ ID NO:28) sequences of a construct comprising {Restriction Enzyme Sites-lgK signal-EcoRV Site-lgE(CH2)-lgG1(Hinge-CH2-CH3)-lgG1(Finge-CH2)-lgE(CH4)-STOP}. The amino acid sequence of the IgK signal is in bold. The amino acid sequence of the lgE(CH2) domain is single underlined. The amino acid sequence of the lgG1(Hinge-CH2-CH3) domain is double underlined. The amino acid sequence of the lgG1(Finge-CH2) domain is underlined with a dashed line. The amino acid sequence of the IgE (CH4) domain is underlined with a wavy line. FIG. 23Ashows an Fc fragment and demonstrates that such Fc fragment is composed of two Fc fragment monomers, and further comprises an Fc domain (dashed circle) and Fc partial domains (hinge, CH2 and CH3 as indicated). FIG. 23B shows the composition of a serial stradomer, composed of two stradomer monomers which are connected by an inter-stradomer monomer linkage. The serial stradomer comprises at least two Fc domains (indicated as dashed circles) and may optionally comprise a domain linkage region. FIG. 23C shows the composition of a core stradomer comprising a core moiety to which are bound core stradomer units that contain at least one Fc domain each. The core stradomer units may be an Fc fragment, a serial stradomer or a cluster stradomer unit. FIG. 23D shows the composition of a cluster stradomer comprising multimerized cluster stradomer units, each of which has a multimerizing region and a region containing at least one Fc domain. The cluster stradomer unit may be an Fc fragment or a serial stradomer. The multimerizing region, once multimerized, forms the head of a cluster stradomer. The legs of the cluster stradomer are formed by the Fc domain regions of the cluster stradomer units that are spatially less constrained than the multimerized head of the cluster stradomer. FIG. 24 shows the amino acid sequences of the stradomer set forth in Table 3. FIG. 25 shows the amino acid sequences for the Fc partial domains monomers (hinge, CH2 and CH3) of human lgG1, lgG2, lgG3 and lgG4 (Kabat, EA, Wu, TT, Perry, HM, Gottesman, KS, and Foeller, C. 1991. Sequences of proteins of immunological interest 5th Ed. US Public Health Services, NIH, Bethesda).

DETAILED DESCRIPTION OF THE INVENTION

[0067] As noted, the invention itself is as defined in the claims.

[0068] The approach to rational molecular design for hIVIG replacement compounds described herein includes recombinant and/or biochemical creation of immunologically active biomimetic(s). In preferred methods, these replacement compounds are screened in vitro to assess each replacement compound's efficiency at binding to Fey receptor and modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. The replacement compounds have utility for treating, for example, autoimmune diseases, inflammatory diseases, osteoporosis, and cancer. Each phase is described in detail below along with specific exemplary embodiments.

[0069] As used herein, the use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one." [0070] As used herein, the terms "biomimetic", "biomimetic molecule", "biomimetic compound", and related terms, refer to a human made compound that imitates the function of another compound, such as pooled hIVIG, a monoclonal antibody or the Fc fragment of an antibody. “Biologically active” biomimetics arc compounds which possess biological activities that arc the same as or substantially similar to their naturally occurring counterparts. "Immunologically active" biomimetics arc biomimetics which exhibit immunological activity the same as or substantially similar to naturally occurring immunologically active molecules, such as antibodies, cytokines, interleukins and other immunological molecules known in the art. In preferred embodiments, the biomimetics of the disclosure are stradomers and stradobodies, as defined herein.

[0071] The immunologically active biomimetics are designed to possess one or more immune modulating activities of the IgG Fc domain and have at least (i) a first Fc domain capable of binding an FcyR, including FcyRI, FcyRII, FcyRIII and FcyRIV, and (ii) a second Fc domain capable of binding an FcyR, including FcyRI, FcyRII, FcyRIII and FcyRIV.

[0072] The following paragraphs define the building blocks of the biomimetics, both structurally and functionally, and then define biomimetics themselves. However, it is first helpful to note that, as indicated above, each of the biomimetics has at least two Fc domains. At a minimum, an Fc domain is a dimeric polypeptide (or a dimeric region of a larger polypeptide) that comprises two peptide chains or arms (monomers) that associate to form a functional Fey receptor binding site. Therefore, the functional form of the individual fragments and domains discussed herein generally exist in a dimeric (or multimeric) form. The monomers of the individual fragments and domains discussed herein are the single chains or arms that must associate with a second chain or arm to form a functional dimeric structure.

Fc Fragment [0073] "Fc fragment" is a term of art that is used to describe the protein region or protein folded structure that is routinely found at the carboxy terminus of immunoglobulins (see Figure 3A-3B). The Fc fragment can be isolated from the Fab fragment of a monoclonal antibody through the use of papain digestion, which is an incomplete and imperfect process (see Mihaesco C and Seligmann M. Papain Digestion Fragments Of Human IgM Globulins. Journal of Experimental Medicine, Vol 127, 431-453 (1968)). In conjunction with the Fab fragment (containing the antibody binding domain) the Fc fragment constitutes the holo-antibody, meaning here the complete antibody. The Fc fragment consists of the carboxy terminal portions of the antibody heavy chains. Each of the chains in an Fc fragment is between about 220-265 amino acids in length and the chains are often linked via a disulfide bond. The Fc fragment often contains one or more independent structural folds or functional subdomains. In particular, the Fc fragment encompasses an Fc domain, defined herein as the minimum structure that binds an Fey receptor (see, e.g., Figures 1B and 1D). An isolated Fc fragment is comprised of two Fc fragment monomers (e.g., the two carboxy terminal portions of the antibody heavy chains; further defined herein) that are dimerized. When two Fc fragment monomers associate, the resulting Fc fragment has Fey receptor binding activity.

Fc Partial Fragment [0074] An "Fc partial fragment" is a domain comprising less than the entire Fc fragment of an antibody, yet which retains sufficient structure to have the same activity as the Fc fragment, including Fey receptor binding activity. An Fc partial fragment may therefore lack part or all of a hinge region, part or all of a CH2 domain, part or all of a CH3 domain, and/or part or all of a CH4 domain, depending on the isotype of the antibody from which the Fc partial domain is derived. An example of a Fc partial fragment includes a molecule comprising the upper, core and lower hinge regions plus the CH2 domain of lgG3 (Tan, LK, Shopes, RJ, Oi, VT and Morrison, SL, Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins, Proc Natl Acad Sci U SA. 1990 January; 87(1): 162-166). Thus, in this example the Fc partial fragment lacks the CH3 domain present in the Fc fragment of lgG3. Fc partial fragments are comprised of two Fc partial fragment monomers. As further defined herein, when two such Fc partial fragment monomers associate, the resulting Fc partial fragment has Fey receptor binding activity.

Fc Domain [0075] As used herein, "Fc domain" describes the minimum region (in the context of a larger polypeptide) or smallest protein folded structure (in the context of an isolated protein) that can bind to or be bound by an Fey receptor. In both an Fc fragment and an Fc partial fragment, the Fc domain is the minimum binding region that allows binding of the molecule to an Fey receptor. While an Fc domain can be limited to a discrete polypeptide that is bound by an Fey receptor, it will also be clear that an Fc domain can be a part or all of an Fc fragment, as well as part or all of an Fc partial fragment. When the term "Fc domains" is used in this disclosure it will be recognized by a skilled artisan as meaning more than one Fc domain. An Fc domain is comprised of two Fc domain monomers. As further defined herein, when two such Fc domain monomers associate, the resulting Fc domain has Fey receptor binding activity. Thus an Fc domain is a dimeric structure that functionally can bind an Fey receptor.

Fc Partial Domain [0076] As used herein, "Fc partial domain" describes a portion of an Fc domain. Fc partial domains include the individual heavy chain constant region domains (e.g., CH1, CFI2, CFI3 and CH4 domains) and hinge regions of the different immunoglobulin classes and subclasses. Thus, Fc partial domains include the CH1 domains of lgG1, lgG2, lgG3, lgG4, IgM, lgA1, lgA2, IgD and IgE, the CFI2 domains of lgG1, lgG2, lgG3, lgG4, IgM, lgA1, lgA2, IgD and IgE, the CFI3 domains of IgG 1, lgG2, lgG3, lgG4, IgM, lgA1, lgA2, IgD and IgE, the CFI4 domains of IgM and IgE, and the hinge regions of lgG1, lgG2, lgG3, lgG4, IgM, lgA1, lgA2, IgD and IgE. The Fc partial domain may further comprise a combination of more than one more of these domains and hinges. However, the individual Fc partial domains and combinations thereof lack the ability to bind an FcyR. Therefore, the Fc partial domains and combinations thereof comprise less than an Fc domain. Fc partial domains may be linked together to form a peptide that has Fey receptor binding activity, thus forming an Fc domain. Fc partial domains are used with Fc domains as the building blocks to create the biomimetics as defined herein. Each Fc partial domain is comprised of two Fc partial domain monomers. When two such Fc partial domain monomers associate, an Fc partial domain is formed.

[0077] As indicated above, each of Fc fragments, Fc partial fragments, Fc domains and Fc partial domains are dimeric proteins or domains. Thus, each of these molecules is comprised of two monomers that associate to form the dimeric protein or domain. While the characteristics and activity of the dimeric forms was discussed above the monomeric peptides are discussed as follows.

Fc Fragment Monomer [0078] As used herein, an "Fc fragment monomer" is a single chain protein that, when associated with another Fc fragment monomer, comprises an Fc fragment. The Fc fragment monomer is thus the carboxy terminal portion of one of the antibody heavy chains that make up the Fc fragment of a holo-antibody (e.g., the contiguous portion of the heavy chain that includes the hinge region, CH2 domain and CH3 domain of IgG) (see Figure 1Aand Figure 1C)). In one embodiment, the Fc fragment monomer comprises, at a minimum, one chain of a hinge region (a hinge monomer), one chain of a CH2 domain (a CH2 domain monomer) and one chain of a CH3 domain (a CH3 domain monomer), contiguously linked to form a peptide. In another embodiment, the Fc fragment monomer comprises at least one chain of a hinge region, one chain of a CH2 domain, one chain of a CH3 domain, and one chain of a CH4 domain (a CH4 domain monomer) contiguously linked to form a peptide.

Fc Domain Monomer [0079] As used herein, "Fc domain monomer" describes the single chain protein that, when associated with another Fc domain monomer, comprises an Fc domain that can bind to an Fey receptor. The association of two Fc domain monomers creates one Fc domain. An Fc domain monomer alone, comprising only one side of an Fc domain, cannot bind an Fey receptor.

Fc Partial Domain Monomer [0080] As used herein, "Fc partial domain monomer" describes the single chain protein that, when associated with another Fc partial domain monomer, comprises an Fc partial domain. The amino acid sequences of the Fc partial domain hinge, CH2 and CH3 monomers for lgG1, lgG2, lgG3 and lgG4 are shown in Figure 25. The association of two Fc partial domain monomers creates one Fc partial domain.

Stradomers [0081] In particular embodiments, the biomimetics include stradomers. Stradomers are biomimetic compounds capable of binding two or more Fey receptors (see, e.g., Figure 13B). In a preferred embodiment, the stradomers of are used to bind Fey receptors on effector cells such as NK cells and immature dendritic cells and other monocyte-derived cells. In one embodiment, the Fey receptors are low affinity Fey receptors. A stradomer can have four different physical conformations: serial, cluster, core or Fc fragment, each of which is discussed in the following paragraphs. As will be evident, the Fc fragments, Fc partial fragments, Fc domains and Fc partial domains discussed above are used in the construction of the various stradomer conformations. Further, it is the individual Fc domain monomers and Fc partial domain monomers, also discussed above, that arc first produced, and that then self-associate to form the dimeric structures that are the stradomers.

Serial Stradomer [0082] A "serial stradomer" is dimeric polypeptide comprised of two linear stradomer monomers that, when associated, form two or more Fc domains. The Fc domains of the stradomer are only functional when the two peptide chains (stradomer monomers) arc associated (i.e., non-functional in the monomeric state). Thus a serial stradomer is a biomimetic compound capable of binding two or more Fey receptors. In different embodiments, serial stradomer may have two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or more Fc domains, as well as Fc partial domains. The Fc domains, and Fc partial domains, within a serial stradomer may be linked by domain linkages, as further defined herein.

[0083] As used herein, a "stradomer dimer" is a specific form of a stradomer, composed of only two stradomers. In one embodiment, the stradomer dimers are molecules formed by self-aggregation of relevant stradomer monomers. In another embodiment, stradomer monomers in the stradomer dimers are physically linked through an inter-stradomer monomer linkage, as defined herein. A "multimeric stradomer" is comprised of three or more stradomers, formed by self-aggregation of stradomer monomers, or through an inter-stradomer monomer linkage, as defined herein in.

Stradomer Monomer [0084] As used herein, the term "stradomer monomer" refers to a single, contiguous peptide molecule that, when associated with at least a second stradomer monomer, forms a polypeptide comprising at least two Fc domains (see, e.g., Figures 6A-6B, Figure 12A). While in preferred embodiments serial stradomer are comprised of two associated stradomer monomers (see, for example, Figures 5A, 5B, 7A, 7B, 7C, 7D), a serial stradomer may also contain three (see Figure 11C) or more stradomer monomers. Stradomer monomers may be associated to form stradomers by inter-stradomer monomer linkages or they may form stradomers through self-aggregation.

[0085] A stradomer monomer may have an amino acid sequence that will form one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or more Fc domains when associated with another stradomer monomer to form a stradomer. A stradomer monomer may further have an amino acid sequence that will form one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or more Fc partial domains when associated with another stradomer monomer to form a stradomer.

[0086] The regions of stradomer monomers that will form Fc domains and Fc partial domains in the context of a stradomer may simply be arranged from carboxy terminal to amino terminal of successive regions of the stradomer monomer molecule (see, e.g., Figure 4A-4B). Alternatively, the successive regions of the stradomer monomers may be linked through a peptide sequence termed a "domain linkage" herein. The arrangement of the particular Fc domain monomers and Fc partial domain monomers comprising a stradomer monomer is not critical. Flowever, the arrangement must permit formation of two functional Fc domains upon association of two stradomer monomers.

[0087] In one embodiment of the stradomers, stradomer monomers are produced that contain at the N-terminus of the peptide an Fc domain monomer or Fc partial domain monomer that binds strongly to itself, such as a single or two terminal IgE CH2 domain monomers or a partial lgG3 hinge domain monomer, to create an Fc domain or an Fc partial domain, respectively. Each of these stradomer monomers has the requisite complement of Fc domain monomers and/or partial Fc domain monomers to bind to two Fc gamma receptors upon formation of a stradomer. Stradomers that result from association of such stradomer monomers are biomimetics capable of binding two or more Fc gamma receptors. In a preferred embodiment the N-terminal Fc domain or Fc partial domain contains an additional glycosylation site such as that which exists on the IgE CFI2 domain.

[0088] As a clarifying example, the skilled artisan will understand that the stradomer molecules may be constructed by preparing a polynucleotide molecule that encodes various combinations of Fc domain monomers and Fc partial domain monomers, but with a combination that will form a minimum of two Fc domain monomers. Such a polynucleotide molecule may be inserted into an expression vector, which can be used to transform a population of bacteria. Stradomer monomers can then produced by culturing the transformed bacteria under appropriate culture conditions. Stradomer monomers can then form functional stradomcrs upon either self-aggregation of the stradomer monomers or association of stradomer monomers using inter-stradomer monomer linkages. The present invention encompasses both stradomcrs formed through the association of stradomer monomers having identical amino acid sequences, stradomer monomers having substantially similar amino acid sequences, or stradomer monomers having dissimilar sequences. In the latter embodiment the amino acid sequence of the stradomer monomers comprising a stradomer need only be of such similarity that two or more functional Fey receptor binding sites are formed.

[0089] As indicated above, an Fc domain can be functionally defined by its ability to bind an Fey receptor. As a result, the particular amino acid sequence of an Fc domain will vary based on the Fc partial domains that comprise the Fc domain. However, in one embodiment the Fc domain comprises the hinge region and a CH2 domain of an immunoglobulin molecule. In a further embodiment the Fc domain comprises the hinge region, a CH2 domain and CH3 domain of an immunoglobulin molecule. In a further embodiment, the Fc domain comprises the hinge region, a CH2 domain, CH3 domain and CH4 domain of an immunoglobulin molecule. In yet another embodiment, the Fc domain comprises the hinge region, a CH2 domain and CH4 domain of an immunoglobulin molecule.

Domain Linkage [0090] As indicated above, a "domain linkage" is a peptide linkage between Fc domain monomers and/or Fc partial domain monomers that comprise each of the individual stradomer monomers of the serial stradomers or stradobodies . The domain linkage may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acids. Adomain linkage does not occur between Fc partial domain monomers that are in their natural sequence. That is, where linked naturally contiguous portions of Fc domain monomers arc used, such as the hinge region, CH2 domain and CH3 domain of IgG, these Fc partial domain monomers comprise a contiguous sequence and no domain linkage between these elements is required. In contrast, for example, when two or more Fc domain monomers or partial Fc domain monomers are linked in a manner that is not naturally occurring to form an individual stradomer monomer, domain linkages may be used. An example would be the linkage between two hinge/CH2/CH3 peptides, creating an individual stradomer monomer of a stradomer comprising: hinge/CH2/CH3/L/hinge/CH2/CH3, where "L" is the domain linkage (see, e.g., Figure 4A where the domain linkage (not shown) occurs between the IgG 1 CH3 domain and the lgG1 hinge). In the various cases described, the domain linkage may be one of the naturally occurring portions of the heavy chain that joins the hinge and CH domains in the Fc domain monomer of an antibody. Alternatively, the domain linkage may be any other amino acid sequence that provides needed spacing and flexibility between the Fc domain monomers and partial Fc domain monomers of an individual stradomer monomer and that allows the individual stradomer monomers to pair with other each other to form the stradomers.

[0091] The skilled artisan will understand that the identity of the domain linkage is not particularly important as long as it permits two or more individual stradomer monomers to form the biomimetic compounds, and that the resulting compounds have the ability to cross-link more than one FcyR. It is envisioned that each immunologically active biomimetic compound will preferably contain at least one domain linkage in each stradomer monomer of the serial stradomer or stradobody which will function to maintain the Fc domains of the immunologically active biomimetic within a restricted spatial region and which will facilitate FcyR activation activity, for example, by aggregating FcyRs through co-binding to the Fc domains within the immunologically active biomimetic. Preferably, the domain linkages will allow the same or a greater degree of conformational variability as is provided by the hinge domain of IgG molecules. All the above linkages are well-known in the art.

Inter-Stradomer Monomer Linkage [0092] A separate linkage found in the biomimetic compounds is the "inter-stradomer monomer linkage" that occurs between two or more individual stradomer monomers that comprise the stradomers and stradobodies. While the domain linkages are short amino acid sequences that serve to link the Fc domain monomers and partial Fc domain monomers that comprise individual stradomer monomers of the biomimetic compounds to each other, the inter-stradomer monomer linkages serve to join two or more individual stradomer monomers that comprise the biomimetic compounds. The inter-stradomer monomer linkage may be any linkage capable of stably associating the individual stradomer monomers. In some embodiments, the inter-stradomer monomer linkage may be a covalent link between the stradomer monomers. Alternatively, the inter-stradomer monomer linkage between stradomer monomers may be by direct chemical crosslinking. In preferred embodiments, the stradomer monomer structures take advantage of the natural self-aggregation properties between Fc domain monomers to create self-aggregating stradomers. In such embodiments, disulfide bonds form between the individual stradomer monomers to form the stradomers (see, e.g., Figure 5A, where inter-stradomer monomer linkages (not shown) serve to join the two individual stradomer monomers of the stradomer).

The disulfide bonds form between cysteine residues of the Fc domain monomers that comprise the biomimetic molecules, using either cysteine residues occurring in the natural Fc domain monomer sequence or cysteine residues incorporated into an Fc domain monomer by site-directed mutagenesis. Such natural self-aggregation properties can also be used to form the inter-stradomer monomer linkages between individual stradomer monomers in stradomer multimers. Alternative embodiments include inter-stradomer monomer linkages where disulfide bonds form between cysteine residues introduced through site-directed mutagenesis into the amino acid sequence comprising the individual stradomer monomers.

[0093] As discussed above, in a preferred embodiment, the inter-stradomer monomer linkage that forms a stradomer is a linkage that results from self-aggregation of stradomer monomers. In one embodiment, the two stradomer monomers that comprise the stradomer are identical peptides, such that the two individual stradomer monomers that comprise the stradomer are identical in sequence. However, the skilled artisan will understand that other embodiments include stradomers where the stradomer monomers differ from each other in amino acid sequence.

[0094] Two stradomer monomers can form a stradomer by, for example, aligning in parallel such that pairing takes place between identical Fc partial domain monomers in the stradomer monomers (see, e.g., Figures 5A-B). However, the present disclosure also includes embodiments winere pairing occurs between non-identical Fc partial domain monomers, and embodiments (see Figure 11C) where pairing occurs between identical Fc partial domain monomers in the stradomer monomers but where the alignment of the two stradomer monomers is offset.

[0095] In order to control the production and self dimerization of a stradomer monomer, "capping regions" may be used. For example, a stradomer monomer sequence may comprise the following Fc partial domains: IgE CH2 /lgG1 hinge/lgG1 CH2/lgG1 CH3/lgG1 hinge/lgG1 CH2/lgE CH4, (see Figure 13A) where the IgE domains serve as a cap to prevent a "zippering effect." A zippering effect can occur when a stradomer monomer (see Figure 11 A) can auto-dimerize (see Figure 11B) or can align itself not as an auto-dimer but as alternating monomers in parallel (see Figure 11C). One of ordinary skill in the art wll understand that a variety of Fc partial domains, such as the hinge of any immunoglobulin or the CH4 domain of IgM or IgE, may be used alone or in combination to direct the stradomer to auto-dimerize and to prohibit the zippering effect when desired. Other non-series structures may contain branched molecules (see Figure 12B), two or more stradomers lined up in parallel joined by linkers such as a simple covalent bond, peptide linkers, or non-peptide linkers (see Figures 14Aand 14B).

Core Stradomer [0096] A "core stradomer" is comprised of a core moiety to which are bound two or more core stradomer units, wherein each core stradomer unit comprises at least one Fc domain, thereby creating a biomimetic compound capable of binding two or more Fey receptors. An Fc fragment, Fc partial fragment, serial stradomer or cluster stradomer unit can each independently serve as one or both (if they comprise two Fc domains) of the core stradomer units in a core stradomer because each of these molecules contains at least one Fc domain. Thus, a core stradomer may comprise a core moiety to which is bound at least one serial stradomer.

[0097] As used herein, the core moiety of a core stradomer is any physical structure to which the core stradomer units may be linked or covalently bound. Preferred polypeptides that may serve as the core moiety include keyhole limpet hemocyanin, bovine serum albumin and ovalbumin. Chemical crosslinking between such core moieties and core stradomer units (e.g., Fc fragment, Fc partial fragment, Fc domain, serial stradomer and cluster stradomer unit) may be achieved by means of numerous chemicals using well known techniques. Exemplary chemicals generally suitable for use in the crosslinking include glutaraldehyde, carbodiimide, succinimide esters (e.g. MBS, SMCC), benzidine, periodate, isothiocyanate; PEO (polyethylene)/PEG (polyethylene glycol) spacers such as Bis(NHS)PEOs, DFDNB (1,5-Difluoro-2,4-dinitrobenzene); and Amine Reactive homobifunctional cross-linking reagents including Aldehyde-Activated Dextran, Bis(Sulfosuccinimidyl)suberate, Bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone, Dimethyl adipimidate*2 HCI, Dimethyl pimelimidate*2 HCI, Dimethyl Suberimidate*2 HCI, Disuccinimidyl glutarate, Dithiobis(succinimidyl) propionate, Disuccinimidyl suberate, Disuccinimidyl tartrate, Dimethyl 3,3'-dithiobispropionimidate*2 HCI, 3,3'-Dithiobis(sulfosuccinimidylpropionate), Ethylene glycol bis[succinimidylsuccinate], Ethylene glycol bis[sulfosuccinimidylsuccinate], B-[Tris(hydroxymethyl) phosphino] propionic acid and Tris-succinimidyl aminotriacetate. One of skill in the art will be able to select the appropriate crosslinking chemical and conditions based upon the particular core moiety selected and the sequence of the Fc domain-contaiing polypeptides being combined to form an immunologically active biomimetic. See, e.g., Wong, Shan S. Chemistry of protein conjugation and cross-linking. Boca Raton: CRC Press, c1991 (ISBN 0849358868).

[0098] In another preferred embodiment, a joining (J) chain polypeptide may be used as the core moiety. When a J chain is used as the core moiety, cysteine bridges may be used to connect individual core stradomer units to form a core stradomer (See Fig. 10A-10D). In an embodiment of a core stradomer, serial stradomers (serving as the core stradomer units) containing a terminal IgM CH4 domain are associated with a J chain to form a core stradomer. The inclusion of the IgM CH4 domain results in the selfaggregation of stradomers comprising this Fc partial domain with a J chain to form a biomimetic capable of binding multiple Fc gamma receptors. Another exemplary core stradomer is one comprising Fc domains (serving as the core stradomer units) where the Fc domains have the structure lgG3 hinge / lgG3 CFI2 / lgG3 CFI3 / IgM CFI4. The component Fc domains of this molecule cannot individually bind more than one Fc gamma receptor, but the entire structure can bind five Fc gamma receptors when the component Fc domains associate with a J chain.

[0099] In another embodiment, the core moiety may be a non-polypeptide entity. A variety of suitable compositions may be physically associated with the core stradomer units to produce an immunologically active biomimetic. Non-toxic beads, hyperbranched polymers and dendrimers, nanoparticles, and various compounds that are classified by the FDA as Generally Regarded As Safe (e.g. propylene glycol, sorbitol, liposomes and silicate calcium) may be used. See, e.g., Nanoparticulates as Drug Carriers by Vladimir P. Torchilin (Editor), Imperial College Press (Sept. 2006) ISBN: 1860946305/ISBN-13:9781860946301.

[0100] Preferred core moieties include a bead, albumin, a liposome, a peptide and polyethylene glycol.

Cluster Stradomer [0101] A "cluster stradomer" is a biomimetic that has an octopus-like form with a central moiety "head" and two or more "legs", wherein each leg comprises one or more Fc domain that is capable of binding at least one Fc gamma receptor, thus creating a biomimetic capable of binding two or more Fc gamma receptors. Each cluster stradomer is comprised of more than one dimeric protein, each called a "cluster stradomer unit." Each cluster stradomer unit is comprised of a region that multimerizes and a "leg" region that comprises at least one functional Fc domain. The multimerizing region creates a cluster stradomer "head" once multimerized with the multimerizing region of another cluster stradomer unit. The leg region is capable of binding as many Fey receptors as there are Fc domains in each leg region. Thus a cluster stradomer is a biomimetic compound capable of binding two or more Fey receptors.

[0102] The multimerizing region may be a peptide sequence that causes dimeric proteins to further multimerize or alternatively the multimerizing region may be a glycosylation that enhances the multimerization of dimeric proteins. Examples of peptide multimerizing regions include lgG2 hinge, IgE CH2 domain, isoleucine zipper, and zinc fingers. The influence of glycosylation on peptide multimerization is well described in the art (e.g., Role of Carbohydrate in Multimeric Structure of Factor Vlll/V on Willebrand Factor Protein. Harvey R. Gralnick, Sybil B. Williams and Margaret E. Rick. Proceedings of the National Academy of Sciences of the United States of America, Vol. 80, No. 9, [Part 1: Biological Sciences] (May 1, 1983), pp. 2771-2774; Multimerization and collagen binding of vitronectin is modulated by its glycosylation. Kimie Asanuma, FumioArisaka and Haruko Ogawa. International Congress Series Volume 1223, December 2001, Pages 97-101).

[0103] A trained artisan will recognize that a cluster stradomer unit may itself comprise a serial stradomer (containing two or more Fc domains) along with a multimerizing region. Thus the "legs" of a cluster stradomer may be comprised of any of the types of serial stradomers discussed herein and/or one or more of an IgG 1 Fc fragment and/or an lgG3 Fc fragment and/or a single Fc domain. One trained in the art will recognize that each of the IgG 1 Fc fragments and lgG3 Fc fragment in such biomimetics may be modified to comprise partial Fc fragments from any immunoglobulin. The monomers that comprise the cluster stradomer unit (which, as indicated above, exists as a dimeric association of two peptides) are "cluster stradomer unit monomers." An exemplary cluster stradomer that has been made whose cluster stradomer unit would not bind more than one low affinity Fc gamma receptor prior to multimerization is: IgE CH2 / lgG1 hinge / lgG1 CH2 / lgG1 CH3.

[0104] One trained in the art will recognize that when a serial stradomer is used as the "leg" of a cluster stradomer, each "leg" will be capable of binding more than one Fc gamma receptor (as at least two Fc domains are present in a serial stradomer), thus creating a biomimetic capable of binding more than one Fc gamma receptor. Fc partial domains, other immunoglobulin sequences, and non-immunoglobulin sequences may be placed at the termini of individual cluster stradomer unit monomers comprising the legs to create a cluster stradomer wherein each leg has preferred spatial proximity to increase their availability to bind one or more than one Fc gamma receptor.

[0105] The multimerizing region may be a peptide sequence that causes peptides to dimerize or multimerize and includes the lgG2 hinge, the IgE CH2 domain, an isoleucine zipper and a zinc finger. As is known in the art, the hinge region of human lgG2 can form covalent dimers (Yoo, E.M. et al. J. Immunol. 170, 3134-3138 (2003); Salfeld Nature Biotech. 25, 1369-1372 (2007)).

The dimer formation of lgG2 is potentially mediated through the lgG2 hinge structure by C-C bonds (Yoo et al 2003), suggesting that the hinge structure alone can mediate dimer formation. Thus, serial stradomers having an lgG2 hinge (and thus serving as cluster stradomer units) will form a cluster stradomer that may comprise two serial stradomers or even three serial stradomers.

[0106] The amino acid sequence of the human lgG2 hinge monomer is as follows: ERKCCVECPPCP (SEQ ID NO: 36). The core structure of the hinge is the C-X-X-C portion of the hinge monomer. Thus, stradomer monomers of the present invention may comprise either the complete 12 amino acid sequence of the lgG2 hinge monomer, or the four amino acid core, along with Fc domain monomers. While the X-Xof the core structure can be any amino acid, in a preferred embodiment the X-X sequence is V-E or P-P. The skilled artisan will understand that the lgG2 hinge monomer may be comprised of any portion of the hinge sequence in addition to the core four amino acid structure, including all of the lgG2 hinge sequence and some or all of the lgG2 CH2 and CH3 domain monomer sequences. Specific examples of possible lgG2 hinge-lgG1 Fc domain serial stradomer constructs are as follows:

[0107] These are only a few of many examples. Any of the lgG1 Fc domains can, for example, be replaced with an lgG3 Fc domain. Additional proteins with lgG2 dimerization domains includes lgG2-lgG1 chimeric proteins with the addition of N and/or C terminal sequences comprising IgM or IgE domain monomer sequences. These N and C terminal sequences can be hinge regions, constant domains, or both.

[0108] As indicated above, leucine and isoleucine zippers may also be used as the multimerizing region. Leucine and isoleucine zippers (coiled-coil domains) are known to facilitate formation of protein dimers, trimers and tetramers (Flarbury et al. Science 262:1401-1407 (1993); O'Shea et al. Science 243 :538 (1989)). By taking advantage of the natural tendency of an isoleucine zipper to form a trimer, cluster stradomers may be produced using serial stradomers comprising an isoleucine zipper. Association of three or more serial stradomers (as cluster stradomer units) having isoleucine zippers results in the formation of cluster stradomers having at least six Fc gamma receptor binding regions.

[0109] While the skilled artisan will understand that different types of leucine and isoleucine zippers may be used, in a preferred embodiment the isoleucine zipper from the GCN4 transcriptional regulator modified as described (Morris et al., Mol. Immunol. 44:3112-3121 (2007) ; Harbury et al. Science 262:1401-1407 (1993)) is used: YTQKSLSLSPGKELLGGGSIKQIEDKIEEILSKIYHIENEIARIKKLIGERGHGGGSNS QVSHRYPRFQSIKVQFTEYKKEKGFILTS (SEQ ID NO:37) This isoleucine zipper sequence is only one of several possible sequences that can be used for multimerization of Fc domain monomers. While the entire sequence shown in SEQ ID NO:37 may be used, the underlined portion of the sequence represents the core sequence of the isoleucine zipper that may be used in the cluster stradomers. Thus, stradomer monomers may comprise either the complete 88 amino acid sequence of the isoleucine zipper (ILZ), or the 28 amino acid core, along with one or more Fc domain monomers. The skilled artisan will also understand that the isoleucine zipper may be comprised of any portion of the zipper in addition to the core 28 amino acid structure, and thus may be comprised of more than 28 amino acids, but less than 88 amino acids of the isoleucine zipper. Specific examples of possible ILZ-lgG1 Fc domain constructs are shown as follows.

Table 2

[0110] These arc only a few of many examples. Any of the IgG 1 domains can, for example, be replaced with lgG3 domains. Additional proteins with ILZ domains include IgG 1 chimeric proteins with the addition of N and/or C terminal sequences from other Ig molecules like IgM or IgE. These N and C terminal sequences can be hinge regions, constant domains or both.

Fc Fragment Stradomer [0111] An "Fc fragment stradomer" is comprised of more than one Fc fragment. Under certain circumstances attributable to post-translational modification of the Fc fragment, the Fc fragment binds with sufficient strength to another Fc fragment to permit the formation of a molecule that binds to more than one Fey receptor. The post-translational modification that permits such binding includes glycosylation and methylation. The identity of the cell line in which the recombinant Fc fragments are produced, and conditions under which they are produced, govern whether Fc fragments will form Fc fragment stradomers. For example, a recombinant Fc fragment produced in a FreestyleMax CHO transient transfection cell forms multimers that are visible on western blots, binds according to a bivalent fit on plasmon resonance binding assay, and demonstrates biological activity in a dendritic cell assay comparable to MG. In contrast, the same recombinant Fc fragment produced in a stable CHO cell line does not form multimers of the Fc fragment on western blots, binds according to a univalent fit on Plasmon resonance binding assay, and does not demonstrate comparable biological activity. Thus an Fc fragment stradomer is a biomimetic compound capable of binding two or more Fey receptors.

[0112] As also used herein, the term "Fc dimer" is a dimer of Fc fragments (see Figure 2A), the term "Fc trimer" is a trimer of Fc fragments, and the term "Fc multimer" is a multimer of Fc fragments (see Figure 2B).

Stradobodv [0113] The present disclosure also provides stradobodies. As used herein, "stradobody" refers to a molecule comprising two or more Fc domains, preferably in the context of a stradomer (including serial stradomers, core stradomers, cluster stradomers and Fc fragment stradomers), to which one or more Fab domains is attached (see, e.g., Figure 8A-B and 9A-B). Thus, by virtue of such Fab domains, stradobodies have both antigen binding capacity, as well as stradomer Fey receptor binding activity. In some embodiments, the Fey receptor binding activity may be due to an ability to bind and cross-link FcyR equal to or greater than the Fc portion of a native structure holo-antibody. Preferably the Fab portion of the stradobody comprises both a heavy and a light chain. The variable heavy chain and the light chain may be independently from any compatible immunoglobulin such as lgA1, lgA2, IgM, IgD, IgE, lgG1, lgG2, lgG3, or lgG4, and may be from the same or different Ig isotype, but preferably are from the same Ig isotype. The light chains kappa or lambda may also be from different Ig isotypes. Stradobodies, like stradomers, can bind two or more FCyRs and modulate immune function.

[0114] In one embodiment, the stradomers may have a Fab of an immunoglobulin linked to an Fc hinge (H) domain of a stradomer to generate a stradobody (e.g. Figure 8A& B). In another embodiment, the stradobody may be comprised of lgG1 Fc -lgG1 (hinge - CH2) (e.g., Fig. 9A). In other embodiments, the stradobody may be comprised of an lgG1 domain and hinge, an lgG3 domain and hinge and an IgGE domain and hinge (e.g., Figure 9B). The Fab comprises both a heavy and a light chain as found in native immunoglobulin structures (Figure 3A-B).

[0115] Stradobodies will possess the antigen binding properties of the Fab portion and the above described stradomer properties. Such a combination will serve to bind, cross-link, and activate Fey receptors on effector cells at a higher rate than can be accomplished by an Fc backbone of a holo-antibody, particularly in the environment of low epitope expression (e.g. the 90% of breast cancer patients whose tumors are not classified as her/2-neu high expressors), inducing ADCC in a higher percentage of patients. As indicated above, one or more antigen-binding Fab fragments can be added to the stradomers to form stradobodies. Preferably, polypeptides (other than the linkages described herein) added to stradomers are not all or parts of nonimmunoglobulin polypeptides.

[0116] The Fab may be a chimeric structure comprised of human constant regions and non-human variable regions such as the variable region from a mouse, rat, rabbit, monkey, or goat antibody. One of ordinary skill in the art would be able to make a variety of Fab chimeric structures for incorporation into stradobodies using methodologies currently available and described in the scientific literature for such constructions. Thus, "humanized" stradobodies may be designed analogous to "humanized monoclonal antibodies.

Variants and Homologs [0117] The skilled artisan will understand that the stradomers and other biomimetics can be designed to include specific immunoglobulin Fc domains, such as two Fc domains from lgG1 (i.e., lgG1 hinge/lgG1 CH2/lgG1 CH3/lgG1 hinge/lgG1 CH2/lgG1 CH3). Such a stradomer could be constructed by first preparing a polynucleotide encoding two IgG 1 Fc domain monomers (i.e., lgG1 hinge monomer/lgG1 CH2 monomer/lgG1 CH3 monomer/lgG1 hinge monomer/lgG1 CH2 monomer/lgG1 CH3 monomer), and then expressing stradomer monomers there from. Upon association of two such stradomer monomers a serial stradomer having two lgG1 Fc domains would be produced.

[0118] The stradomers and other biomimetics can also be designed based on the identity of specific immunoglobulin Fc partial domains that comprise the Fc domains. For example, a serial stradomer could be produced having two Fc domains, where the first Fc domain comprises lgG1 hinge/lgG3 CH2/lgG1 CH3 and the second Fc domain comprises lgG3 hinge/IgG 1 GH2/lgG3 CH3.

[0119] It is understood that the stradomers and other biomimetic molecules disclosed herein can be derived from any of a variety of species. Indeed, Fc domains, or Fc partial domains, in any one biomimetic molecules can be derived from immunoglobulin from more than one (e.g., from two, three, four, five, or more) species. However, they will more commonly be derived from a single species. In addition, it will be appreciated that any of the methods disclosed herein (e.g., methods of treatment) can be applied to any species. Generally, the components of a biomimetic applied to a species of interest will all be derived from that species. However, biomimetics in which all the components are of a different species or are from more than one species (including or not including the species to which the relevant method is applied) can also be used.

[0120] The specific CH1, CH2, CH3 and CH4 domains and hinge regions that comprise the Fc domains and Fc partial domains of the stradomers and other biomimetics may be independently selected, both in terms of the immunoglobulin subclass, as well as in the organism, from which they are derived. Accordingly, the stradomers and other biomimetics disclosed herein may comprise Fc domains and partial Fc domains that independently come from various immunoglobulin types such as lgG1, lgG2, lgG3, lgG4, lgA1, lgA2, IgD, IgE, and IgM. Similarly each Fc domain and partial Fc domain may be derived from various species, preferably a mammalian species, including non-human primates (e.g., monkeys, baboons, and chimpanzees), humans, murine, rattus, bovine, equine, feline, canine, porcine, rabbits, goats, deer, sheep, ferrets, gerbils, guinea pigs, hamsters, bats, birds (e.g., chickens, turkeys, and ducks), fish and reptiles to produce species-specific or chimeric stradomer molecules.

[0121] The individual Fc domains and partial Fc domains may also be humanized. One of skill in the art will realize that different Fc domains and partial Fc domains will provide different types of functionalities. For example, FcyRs bind specifically to IgG immunoglobulins and not other classes of immunoglobulins. Thus, one of skill in the art, intending to design a stradomer with multiple Fey receptor binding capacity, would design stradomer Fc domains that at least incorporate the well characterized Fey receptor binding sequences of IgG, including those in the IgG hinge region and the IgG CH2 & CH3 domains. One of ordinary skill in the art will also understand various deleterious consequences can be associated with the use of particular Ig domains, such as the anaphylaxis associated with IgA infusions. The biomimetics disclosed herein should generally be designed to avoid such effects, although in particular circumstances such effects may be desirable.

[0122] The present disclosure also provides stradomers comprising Fc domains and Fc partial domains having amino acids that differ from the naturally-occurring amino acid sequence of the Fc domain or Fc partial domain. Preferred Fc domains for inclusion in the biomimetic compounds have a measurable specific binding affinity to cither a holo-Fcy receptor or a soluble extracellular domain portion of an FcyR. Primary amino acid sequences and X-ray crystallography structures of numerous Fc domains and Fc domain monomers are available in the art. See, e.g., Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol. 2004 Feb;4(2):89-99. Representative Fc domains with Fey receptor binding capacity include the Fc domains from human immunoglobulin G isotypes 1-4 (hlgG-1-4) (SEQ ID NOS: 1, 3, 5 and 7 respectively; see also

Figure 15A-D). (See Fig. 2 of Robert L. Shields, et al. High Resolution Mapping of the Binding Site on Human lgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of lgG1 Variants with Improved Binding to the FcyR. J. Biol. Chem., Feb 2001; 276: 6591 -6604). These native sequences have been subjected to extensive structure-function analysis including site directed mutagenesis mapping of functional sequences14. Based on these prior structure-function studies and the available crystallography data, one of skill in the art may design functional Fc domain sequence variants (e.g., of SEQ ID NOS: 1,3, 5 and 7) while preserving the Fc domain's Fey receptor binding capacity.

[0123] The amino acid changes may be found throughout the sequence of the Fc domain, or be isolated to particular Fc partial domains that comprise the Fc domain. The functional variants of the Fc domain used in the stradomers and other biomimetics will have at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a native Fc domain. Similarly, the functional variants of the Fc partial domains used in the stradomers and other biomimetics will have at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a native Fc partial domain.

[0124] The present disclosure further provides the use of functional variants of Fc domain monomers in the construction of Fc fragment monomers, Fc partial fragment monomers, stradomer monomers and the other monomers. The functional variants of the Fc domain monomers will have at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a native Fc domain monomer sequence.

[0125] Similarly, the present disclosure provides the use of functional variants of Fc partial domain monomers in the construction of Fc fragment monomers, Fc partial fragment monomers, Fc domains monomers, stradomer monomers and the other monomers. The functional variants of the Fc partial domain monomers will have at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a native Fc partial domain monomer sequence.

[0126] The amino acid changes may decrease, increase, or leave unaltered the binding affinity of the stradomer to the Fey receptor. Preferably such amino acid changes will be conservative amino acid substitutions, however, such changes include deletions, additions and other substitutions. Conservative amino acid substitutions typically include changes within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine, glutamine, serine and threonine; lysine, histidine and arginine; and phenylalanine and tyrosine.

[0127] The term "functional variant" as used herein refers to a sequence related by homology to a reference sequence which is capable of mediating the same biological effects as the reference sequence (when a polypeptide), or which encodes a polypeptide that is capable of mediating the same biological effects as a polypeptide encoded by the reference sequence (when a polynucleotide). For example, a functional variant of any of the biomimetics herein described would have a specified homology or identity and would be capable of immune modulation of DCs. Functional sequence variants include both polynucleotides and polypeptides. Sequence identity is assessed generally using BLAST 2.0 (Basic Local Alignment Search Tool), operating with the default parameters: Filter-On, Scoring Matrix- BLOSUM62, Word Size -3, E value - 10, Gap Costs - 11,1 and Alignments -50.

[0128] From the above, it will be appreciated that stradomers include stradomers having: (a) only naturally occurring Fc domains; (b) a mixture of naturally occurring Fc domains and Fc domains with altered amino acid sequences; and (c) only Fc domains with altered amino acid sequences. All that is required is that stradomers containing altered amino acid sequences have at least 25%; 30%; 40%; 50%; 60%; 70%; 80%; 90%; 95%; 96%; 97%; 98%; 99%; 99.5%; or 100% or even more of the ability of a corresponding stradomer comprising Fc domains with naturally-occurring sequences to bind to two or more Fey receptors.

[0129] The aforementioned Fcy receptor binding sites occurring in the stradomers and stradobodies may be altered in sequence through genetic engineering to predictably derive binding sites with altered binding capabilities and affinities relative to a native sequence. For example, specific residues may be altered that reduce Fc domain binding of the biomimetic compounds to FcyRII while increasing binding to FcYRIIIa. An example of an extensive mutagenesis based structure-function analysis for hlgG Fcy receptor binding sequences is Robert L. Shields, et al. High Resolution Mapping of the Binding Site on Human lgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of lgG1 Variants with Improved Binding to the FcyR. J. Biol. Chem., Feb 2001; 276: 6591 -6604. Similar studies have been performed on murine IgG Fc (mlgG Fc). Based on the structural and primary sequence homologies of native IgG Fc domains across species, one of skill in the art may translate the extensive structure-function knowledge of hlgG Fc and mlgG Fc to rational mutagenesis of all native Fcy receptor binding site sequences in the biomimetic compounds to design binding sites with particular Fcy receptor specificities and binding affinities.

[0130] In addition to the amino acid sequence composition of native Fc domains, the carbohydrate content of the Fc domain is known to play an important role on Fc domain structure and binding interactions with FcyR. See, e.g., Robert L. Shields, et al. Lack of Fucose on Human IgG 1 N-Linked Oligosaccharide Improves Binding to Human Fc Rill and Antibody-dependent Cellular

Toxicity. J. Biol. Chem., Jul 2002; 277: 26733 - 26740 (doi: 10.1074/jbc.M202069200); Ann Wright and Sherie L. Morrison. Effect of C2-Associated Carbohydrate Structure on Ig Effector Function: Studies with Chimeric Mouse-Human IgG 1 Antibodies in Glycosylation Mutants of Chinese Hamster Ovary Cells. J. Immunol., Apr 1998; 160: 3393 - 3402. Carbohydrate content may be controlled using, for example, particular protein expression systems including particular cell lines or in vitro enzymatic modification. Thus, the present disclosure provides stradomers and stradobodies comprising Fc domains with the native carbohydrate content of holo-antibody from which the domains were obtained, as well as those biomimetic compounds have an altered carbohydrate content.

[0131] The addition to the polypeptide chain of an Fc partial domain, a multimerization region, or glycosylation changes may create a conformational change in the Fc domain permitting enhanced binding of the Fc domain to an Fey receptor. Thus, seemingly minor changes to the polypeptide may also create a stradomer capable of binding multiple Fey receptors.

Partial Domains and Partial Fragments [0132] The skilled artisan will further recognize that the Fc domains and Fc partial domains need not be full-length versions. That is, the present disclosure provides the use of Fc domain monomers and Fc partial domain monomers lacking amino acids from the amino terminus, carboxy terminus or middle of the particular Fc domain monomers and Fc partial domain monomers that comprise the stradomers and other biomimetics.

[0133] For example, the binding site on human IgG immunoglobulins for Fey receptors has been described (e.g. Radaev, S., Sun, P., 2001. Recognition of Immunoglobulins by Fey Receptors. Molecular Immunology 38, 1073 - 1083; Shields, R.L. et. al., 2001. High Resolution Mapping of the Binding Site on Human lgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of lgG1 Variants with Improved Binding to the FcyR. J. Biol. Chem. 276 (9), 6591-6604). Based on that knowledge, one may remove amino acids from the Fc domain of these immunoglobulins and determine the effects on the binding interaction between the Fc domain and the receptor. Thus, the present disclosure may employ IgG Fc domains having at least about 90% of the amino acids encompasses positions 233 through 338 of the lower hinge and CH2 as defined in Radaev, S., Sun, P., 2001 [0134] Fc partial domains of IgG immunoglobulins include all or part of the hinge region, all or part of the CH2 domain, and all or part of the CH3 domain.

[0135] The IgG Fc partial domains having only a part of the hinge region, part of the CH2 domain or part of the CH3 domain are constructed from Fc partial domain monomers. Thus, the present disclosure provides IgG hinge region monomers derived from the N-terminus of the hinge region or the C-terminus of the hinge region. They can thus contain, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20,21,22,23,24,25, 26, 27, 28, 29, 30,31,32,33,34,35, 36, 37, 38, 39,40,41,42,43,44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, or 62 (up to 15 for lgG1, up to 12 for lgG2, up to 62 for lgG3, up to 12 for lgG4) amino acids of the hinge region.

[0136] The present disclosure also provides IgG CH2 domain monomers derived from the N-terminus of the CH2 domain or the C-terminus of the CH2 domain. They can thus contain, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, or 110 (up to 110 for lgG1 and lgG3, up to 109 for lgG2 and lgG4) amino acids of the CH2 domain.

[0137] The present disclosure further provides IgG CH3 domain monomers derived from the N-terminus of the CH3 domain or the C-terminus of the CH3 domain. They can thus contain, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56, 57, 58, 59, 60, 61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, or 107 (up to 106 for lgG1 and lgG3, up to 107 for lgG2 and lgG4) amino acids of the CH3 domain.

[0138] Fc partial domains of IgA1, lgA2 and IgD immunoglobulins include all or part of the hinge region, all or part of the CH2 domain, and all or part of the CH3 domain. Moreover all or part of the CH1 domain of the lgA1, lgA2, or IgD immunoglobulin can be used as Fc partial domains.

[0139] The lgA1, lgA2 and IgD partial domains having only a part of the hinge region, part of the CH1 domain, part of the CH2 domain or part of the CH3 domain are constructed from Fc partial domain monomers. Thus, the present disclosure may employ hinge region monomers derived from the N-terminus of the hinge region or the C-terminus of the hinge region of lgA1, lgA2 or IgD. They can thus contain, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61,62, 63, or 64 (up to 26 for lgA1, up to 13 for lgA2, up to 64 for IgD) amino acids of the hinge region.

[0140] The present disclosure provides CH2 domain monomers derived from the N-terminus of the CH2 domain or the C- terminus of the CH2 domains of lgA1, lgA2 or IgD. They can thus contain, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, or 107 (up to 102 for lgA1, up to 96 for lgA2, up to 107 for IgD) amino acids of the CH2 domain.

[0141] The present disclosure provides CH3 domains derived from the N-terminus of the CH3 domain or the C-terminus of the CH3 domains of lgA1, lgA2 or IgD. They can thus contain, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56, 57, 58, 59, 60, 61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, or 131 (up to 113 for lgA1, up to 131 for lgA2, up to 110 for IgD) amino acids of the CH3 domain.

[0142] Fc partial domains of IgM and IgE immunoglobulins include all or part of the hinge / CH2 domain, all or part of the CH3 domain, and all or part of the CH4 domain of these molecules. Moreover all or part of the CH1 domain of the IgM and IgE immunoglobulins can be used as Fc partial domains.

[0143] The IgM and IgE partial domains having only a part of the hinge / CH2 domain, part of the CH3 domain, or part of the CH4 domain are constructed from Fc partial domain monomers. Thus, the present disclosure provides hinge / CH2 domain monomers derived from the N-terminus of the hinge / CH2 domain or the C-terminus of the hinge / CH2 domain of IgM or IgE. They can thus contain, for example, 5, 6, 7, 8, 9,10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51,52, 53, 54, 55, 56, 57, 58, 59, 60, 61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, or 112 (up to 112 for IgM, up to 109 for IgE) amino acids of the hinge / CH2 domain.

[0144] The present disclosure provides IgM and IgE CH3 domain monomers derived from the N-terminus of the CH3 domain or the C-terminus of the CH3 domain of IgM or IgE. They can thus contain, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, or 106 (up to 106 for IgM, up to 105 for IgE) amino acids of the CH3 domain.

[0145] The present disclosure provides IgM and IgE CH4 domain monomers derived from the N-terminus of the CH4 domain or the C-terminus of the CH4 domain of IgM or IgE. They can thus contain, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61,62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 86, 87,88,89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, or 130 (up to 130 for IgM, up to 105 for IgE) amino acids of the CH4 domain. However, parts of the CH4 domain of IgM or IgE that include the C-terminal end of the CH4 domain will preferably be more than 18 amino acids in length, and more preferably will be more than 30 amino acids in length, and most preferably will be more than 50 amino acids in length.

[0146] From the above, it will be appreciated that different embodiments include stradomers containing: (a) full-length Fc domains; (b) a mixture of full-length Fc domains and Fc partial domains; and (c) Fc partial domains. In each of these embodiments, the stradomers may further comprise CH1 domains. As discussed herein, in each embodiment of the stradomers of the present invention, the stradomers have the ability to bind two or more Fey receptors.

Preferred Embodiments of Stradomers and Stradomer Monomers [0147] The following are examples of stradomer monomers: 1. 1. lgG1 hinge - IgG 1 CH2 - IgG 1 CH3 - IgG 1 hinge - IgG 1 CH2 - IgG 1 CH3 2. 2. IgG 1 hinge - lgG3 CH2 - lgG1 CH3 - lgG1 hinge-lgG1 CH2 - lgG1 CH3 3. 3. IgG 1 hinge - lgG1 CH2 - lgG3 CH3 - IgG 1 hinge - IgG 1 CH2 - lgG1 CH3 4. 4. lgG1 hinge - lgG1 CH2 - lgG1 CH3 - lgG3 hinge - lgG1 CH2 - lgG1 CH3 5. 5. lgG1 hinge - lgG1 CH2 - lgG1 CH3 - lgG1 hinge - lgG3 CH2 - lgG1 CH3 6. 6. lgG1 hinge - lgG1 CH2 - lgG1 CH3 - lgG1 hinge - IgG 1 CH2 lgG3 CH3 7. 7. lgG1 hinge - lgG3 CH2 - lgG1 CH3 - lgG3 hinge - IgG 1 CH2 - lgG1 CH3 8. 8. lgG3 hinge - lgG1 CH2 - lgG1 CH3 - lgG1 hinge - lgG1 CH2 - lgG1 CH3 9. 9. lgG3 hinge - lgG1 CH2 - lgG1 CH3 - lgG3 hinge - lgG1 CH2 - lgG1 CH3 10. 10. lgG3 hinge - lgG1 CH2 - lgG1 CH3 - IgG 1 hinge - lgG1 CH2 - lgG3 CH3 -lgG1 hinge - lgG3 CH2 - lgG3 CH3 11. 11. IgG 1 hinge - lgG1 CH2 - lgG1 CH3 - lgG3 hinge - lgG3 CH2 - lgG3 CH3- lgG1 hinge - lgG1 CH2 - lgG1 CH3 12. 12. IgG 1 hinge - lgG1 CH2 - lgG1 CH3 - lgG3 hinge - lgG1 hinge - lgG3 CH2 - lgG3 CH3 - lgG1 hinge - lgG1 CH2 - lgG1 CH3 13. 13. IgG 1 hinge - lgG1 CH2 - lgG1 CH3 - lgG3 hinge - lgG3 CH2 - lgG3 CH3 - lgG1 hinge -lgG2 CH2 - lgG3 CH3. 14. 14. IgG 1 hinge - lgG1 CH2 - lgG1 CH3 - lgG4 hinge - lgG4 CH2 - lgG4 CH3 - lgG1 hinge - lgG1 CH2 - lgG1 CH3 [0148] In each of these embodiments, and the other embodiments presented herein, it will be understood that domain linkages may be used to link the individual Fc partial domain monomers that make up the stradomer monomers. In one embodiment, the Fc partial domain monomers shown for each of the stradomer monomers set forth above are human Fc partial domain monomers.

[0149] The present invention includes stradomers comprising two or more of the stradomer monomers listed above. In preferred embodiments, the present invention includes serial stradomers comprising two identical stradomer monomers provided above.

[0150] As indicated above, the stradomer functionality of binding more than one Fey receptor can also be achieved by incorporating a J chain as a core moiety in a core stradomer, similar to a natural IgM or IgA molecule. In native IgA and IgM immunoglobulins the joining (J) chain is a 15 kDa peptide that joins the heavy and light chains of IgA and IgM antibodies through disulfide bridges with an 18 amino acid "secretory tailpiece" of the Fc portions of the antibodies. Braathen, R., et al., The Carboxyl-terminal Domains of IgA and IgM Direct Isotype-specific Polymerization and Interaction with the Polymeric Immunoglobulin Receptor, J. Bio. Chem. 277(45), 42755-42762 (2002).

[0151] Such core stradomers may be comprised of stradomer monomers containing a naturally occurring CH4 Fc domain, preferably from IgM immunoglobulins, thereby permitting association of the stradomers comprising such stradomer monomers to a J chain (see Figures 10A-10D). The following are examples of stradomer monomers which can self-dimerize to form a stradomer and then be associated with a J chain to form a core stradomer composed of a plurality (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, fifteen, eighteen, twenty, or more) of stradomers: 1.1. lgG1 hinge - lgG1 CFI2 - lgG1 CH3 - lgG1 hinge - lgG1 CH2 - lgG1 CH3 - IgM CH4 (see Figures 10C-10D) 2. 2. lgG1 hinge - lgG3 CH2 - lgG1 CH3 - lgG1 hinge - lgG1 CH2 - lgG1 CH3 - IgM CH4 3. 3. lgG1 hinge - lgG1 CFI2 - lgG3 CH3 - lgG1 hinge - lgG1 CH2 - lgG1 CH3 - IgM CH4 (see Figures 10A-10B) 4. 4. lgG1 hinge - lgG1 CH2 - lgG1 CH3 - lgG3 hinge - lgG1 CH2 - lgG1 CH3 - IgM CH4 5. 5. lgG1 hinge - lgG1 CH2 - lgG1 CH3 - lgG1 hinge - lgG3 CH2 - lgG1 CH3 - IgM CH4 6. 6. lgG1 hinge - lgG1 CH2 - lgG1 CH3 - lgG1 hinge - lgG1 CH2 - lgG1 CH3 - IgM CH4 7. 7. lgG1 hinge - lgG1 CH2 - lgG1 CH3 - lgG1 hinge - lgG1 CH2 - lgG3 CH3 - IgM CH4 8. 8. lgG1 hinge - lgG3 CH2 - lgG1 CH3 - lgG3 hinge - lgG1 CH2 - lgG1 CH3 - IgM CH4 9. 9. lgG3 hinge - lgG1 CH2 - lgG1 CH3 - lgG1 hinge - lgG1 CH2 - lgG1 CH3 - IgM CH4 10. 10. lgG3 hinge - lgG1 CH2 - lgG1 CH3 - lgG3 hinge - lgG1 CH2 - lgG1 CH3 - IgM CH4 11. 11. lgG3 hinge - lgG1 CH2 - lgG1 CFI3 - lgG1 hinge - lgG1 CH2 - lgG1 hinge - lgG3 CH2 - lgG3 CH3 - IgM CH4 [0152] In each of these embodiments, and the other embodiments presented herein, it will be understood that domain linkages may be used to link the individual Fc partial domain monomers that make up the stradomer monomers. In one embodiment, the Fc partial domain monomers shown for each of the stradomer monomers set forth above are human Fc partial domain monomers.

[0153] Core stradomers based on a J chain may be also be comprised of Fc fragments, Fc partial fragments and/or Fc domains that have a CH4 Fc domain. In this example, each of the Fc fragments, Fc partial fragments and Fc domains having a CFI4 Fc domain linked to the core moiety may contain only one Fey receptor binding site but in the context of such a core stradomer, forms a biologically active biomimetic containing more than one Fey receptor binding site. A skilled artisan will recognize that the Fc partial domains from different native immunoglobulins can be used to generate the functional Fc fragments, Fc partial fragments and Fc domains of such a core stradomer. The following are examples of monomers of Fc fragments, Fc partial fragments and Fc domains which can self-dimerize and then be associated with a J chain to form a core stradomer: 1. 1. lgG1 hinge - lgG1 CH2 - lgG1 CH3 - IgM CH4 2. 2. lgG3 hinge - lgG1 CH2 - lgG1 CH3 - IgM CH4 3. 3. lgG1 hinge - lgG3 CH2 - lgG1 CH3 - IgM CH4 4. 4. lgG1 hinge - lgG1 CH2 - lgG3 CH3 - IgM CH4 5. 5. lgG1 hinge - lgG3 CH2 - lgG3 CH3 - IgM CH4 6. 6. lgG3 hinge - lgG3 CH2 - lgG1 CH3 - IgM CH4 7. 7. lgG3 hinge - lgG3 CH2 - lgG1 CH3 - IgM CH4 8. 8. lgG1 hinge - lgG3 CH2 - lgG2 CH3 - IgM CH4 9. 9. lgG1 hinge - lgG3 hinge - lgG3 CFI2 - lgG2 CH3 - IgM CFI4 10. 10. IgG 1 hinge - lgG1 CH2 - lgG1 CH3 - IgE CH4 - IgM CH4 [0154] In each of these embodiments, and the other embodiments presented herein, it will be understood that domain linkages may be used to link the individual Fc partial domain monomers that make up the stradomer monomers. In one embodiment, the Fc partial domain monomers shown for each of the stradomer monomers set forth above are human Fc partial domain monomers.

[0155] It is clear from the above examples that stradomer monomers can be of differing lengths and compositions to accomplish the goal, when associated through self-aggregation or inter-stradomer monomer linkages to a second stradomer monomer and associated with a J chain, producing a core stradomer containing more than one Fey receptor binding site. The examples are in no way limiting and one skilled in the art will appreciate that multiple other stradomer configurations in stradomers are possible.

Fcv Receptors [0156] The terms "FcyR" and "Fey receptor" as used herein includes each member of the Fc gamma receptor family of proteins expressed on immune cell surfaces as described in Nimmerjahn F and Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006 Jan; 24(1):19-28, or as may later be defined. It is intended that the term "FcyR" herein described encompasses all members of the Fc gamma RI, Rll, and Rill families. Fey receptor includes low affinity and high affinity Fey receptors, including but not limited to FcyRI (CD64); FcyRII (CD32) and its isotypes and allotypes FcyRIla LR, FcyRIla HR, FcyRIIb, and FcyRIIc; FcyRIII (CD16) and its isotypes FcyRIIIa and FcyRIIIb. A skilled artisan will recognize that the present invention, which includes compounds that bind to FcyR, will apply to future FcyRs and associated isotypes and allotypes that may not yet have been discovered.

[0157] It has been described that MG binds to and fully saturates the neonatal Fc receptor ("FcRn") and that such competitive inhibition of FcRn may play an important role in the biological activity of IVIG (e.g. Mechanisms of Intravenous Immunoglobulin Action in Immune Thrombocytopenic Purpura. F. Jin, J. Balthasar. Human Immunology, 2005, Volume 66, Issue 4, Pages 403-410.) Since immunoglobulins that bind strongly to Fey receptors also bind at least to some degree to FcRn, a skilled artisan will recognize that stradomers which are capable of binding to more than one Fey receptor vull also bind to and may fully saturate the FcRn.

[0158] "Immunological activity of aggregated native IgG" refers to the properties of multimerized IgG which impact the functioning of an immune system upon exposure of the immune system to the IgG aggregates. Specific properties of native multimerized IgG includes altered specific binding to FcyRs, cross-linking of FcyRs on the surfaces of immune cells, or an effector functionality of multimerized IgG such as antibody dependent cell-mediated cytotoxicity (ADCC), phagocytosis (ADCP), or complement fixation (See, e.g., Nimmerjahn F, Ravetch JV. The anti-inflammatory activity of IgG: the intravenous IgG paradox J Exp Med. 2007; 204:11-15; Augener W, Friedman B, Brittinger G. Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)? Blut. 1985;50:249-252; Arase N, Arase H, Park SY, Ohno H, Ra C, Saito T. Association with FcRgamma is essential for activation signal through NKR-P1 (CD161) in natural killer (NK) cells and NK1.1+ T cells. J Exp Med. 1997;186:1957-1963; Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood. 2001;98:1095-1099; Anderson CF, Mosser DM. Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. J Immunol. 2002;168:3697-3701; Jefferis R, Lund J. Interaction sites on human IgG-Fc for Fc[gamma]R: current models. Immunology Letters. 2002;82:57; Banki Z, Kacani L, Mullauer B, et al. Cross-Linking of CD32 Induces Maturation of Human Monocyte-Derived Dendritic Cells Via NF-{kappa}B Signaling Pathway. J Immunol. 2003; 170:3963-3970; Siragam V, Brine D, CrowAR, Song S, Freedman J, Lazarus AH. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest. 2005; 115:155-160). These properties are generally evaluated by comparison to the properties of monomeric IgG.

[0159] "Comparable to or superior to an Fey receptor cross-linking or an effector functionality of a plurality of naturally-occurring, aggregated IgG immunoglobulins" as used herein means the stradomer generates an assay value of about 70% or more of the value achieved using MG. In some embodiments, the assay value is at least within the standard error range of the assay values achieved using MG. In other embodiments, the assay value is 110% or higher than that of IVIG. Assays for FcyR cross-linking are well known to those of ordinary skill in the art (see e.g., Falk Nimmerjahn and Jeffrey Ravetch. Fey receptors as regulators of immune responses. Nature Reviews Immunology, advanced published on line December 7, 2007).

[0160] "Immune modulating activities," "modulating immune response," "modulating the immune system," and "immune modulation" mean altering immune systems by changing the activities, capacities, and relative numbers of one or more immune cells, including maturation of a cell type within its cell type or into other cell types. For example, immune modulation of immature monocytes may lead to greater populations of more mature monocytes, dendritic cells, macrophages, or osteoclasts, all of which are derived from immature monocytes. For example, immune cell receptors may be bound by immunologically active biomimetics and activate intracellular signaling to induce various immune cell changes, referred to separately as “activating immune modulation." Blockading immune cell receptors to prevent receptor activation is also encompassed within "immune modulation" and may be separately referred to as "inhibitory immune modulation." [0161] Modulation of maturation of a monocyte refers to the differentiation of a monocyte into a mature DC, a macrophage, or an osteoclast. Differentiation may be modulated to accelerate the rate of maturation and/or to increase the number of monocytes undergoing differentiation. Alternatively, differentiation may be reduced in terms of rate of differentiation and/or number of cells undergoing differentiation.

[0162] The term "isolated" polypeptide or peptide as used herein refers to a polypeptide or a peptide which either has no naturally-occurring counterpart or has been separated or purified from components which naturally accompany it, e.g., in tissues such as pancreas, liver, spleen, ovary, testis, muscle, joint tissue, neural tissue, gastrointestinal tissue, or breast tissue or tumor tissue (e.g., breast cancer tissue), or body fluids such as blood, serum, or urine. Typically, the polypeptide or peptide is considered "isolated" when it is at least 70%, by dry weight, free from the proteins and other naturally-occurring organic molecules with which it is naturally associated. Preferably, a preparation of a polypeptide (or peptide) of the invention is at least 80%, more preferably at least 90%, and most preferably at least 99%, by dry weight, the polypeptide (peptide), respectively, of the invention. Since a polypeptide or peptide that is chemically synthesized is, by its nature, separated from the components that naturally accompany it, the synthetic polypeptide or peptide is "isolated." [0163] An isolated polypeptide (or peptide) can be obtained, for example, by extraction from a natural source (e.g., from tissues or bodily fluids); by expression of a recombinant nucleic acid encoding the polypeptide or peptide; or by chemical synthesis. A polypeptide or peptide that is produced in a cellular system different from the source from which it naturally originates is "isolated," because it will necessarily be free of components which naturally accompany it. The degree of isolation or purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

Pharmaceutical Compositions [0164] Administration of the immunologically active biomimetic compositions described herein will be via any common route, orally, parenterally, or topically. Exemplary routes include, but are not limited to oral, nasal, buccal, rectal, vaginal, ophthalmic, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intratumoral, spinal, intrathecal, intra-articular, intraarterial, sub-arachnoid, sublingual, oral mucosal, bronchial, lymphatic, intra-uterine, subcutaneous, intratumor, integrated on an implantable device, intradural, intracortical, or dermal. Such compositions would normally be administered as pharmaceutically acceptable compositions as described herein. In a preferred embodiment the isolated immunologically active biomimetic is administered intravenously.

[0165] The term "pharmaceutically acceptable carrier" as used herein includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the vectors or cells, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.

[0166] The immunologically active biomimetic compositions may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.

[0167] Sterile injectable solutions are prepared by incorporating the immunologically active biomimetic in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0168] Further, one embodiment is an immunologically active biomimetic composition suitable for oral administration is provided in a pharmaceutically acceptable carrier with or without an inert diluent. The carrier should be assimmable or edible and includes liquid, semi-solid, i.e., pastes, or solid carriers. Except insofar as any conventional media, agent, diluent or carrier is detrimental to the recipient or to the therapeutic effectiveness of an immunologically active biomimetic preparation contained therein, its use in an orally administrable an immunologically active biomimetic composition for use in practicing the methods is appropriate. Examples of carriers or diluents include fats, oils, water, saline solutions, lipids, liposomes, resins, binders, fillers and the like, or combinations thereof. The term "oral administration" as used herein includes oral, buccal, enteral or intragastric administration.

[0169] In one embodiment, the composition is combined with the carrier in any convenient and practical manner, i.e., by solution, suspension, emulsification, admixture, encapsulation, microencapsulation, absorption and the like. Such procedures are routine for those skilled in the art.

[0170] In a specific embodiment, the immunologically active biomimetic composition in powder form is combined or mixed thoroughly with a semi-solid or solid carrier. The mixing can be carried out in any convenient manner such as grinding. Stabilizing agents can be also added in the mixing process in order to protect the composition from loss of therapeutic activity through, i.e., denaturation in the stomach. Examples of stabilizers for use in an orally administrable composition include buffers, antagonists to the secretion of stomach acids, amino acids such as glycine and lysine, carbohydrates such as dextrose, mannose, galactose, fructose, lactose, sucrose, maltose, sorbitol, mannitol, etc., proteolytic enzyme inhibitors, and the like. More preferably, for an orally administered composition, the stabilizer can also include antagonists to the secretion of stomach acids.

[0171] Further, the immunologically active biomimetic composition for oral administration vtfiich is combined with a semi-solid or solid carrier can be further formulated into hard or soft shell gelatin capsules, tablets, or pills. More preferably, gelatin capsules, tablets, or pills are enterically coated. Enteric coatings prevent denaturation of the composition in the stomach or upper bowel where the pH is acidic. See, i.e., U.S. Pat. No. 5,629,001. Upon reaching the small intestines, the basic pH therein dissolves the coating and permits the composition to be released to interact with intestinal cells, e.g., Peyer's patch M cells.

[0172] In another embodiment, the immunologically active biomimetic composition in powder form is combined or mixed thoroughly with materials that create a nanoparticle encapsulating the immunologically active biomimetic or to which the immunologically active biomimetic is attached. Each nanoparticle will have a size of less than or equal to 100 microns. The nanoparticle may have mucoadhesive properties that allow for gastrointestinal absorption of an immunologically active biomimetic that would otherwise not be orally bioavailable.

[0173] In another embodiment, a powdered composition is combined with a liquid carrier such as, i.e., water or a saline solution, with or without a stabilizing agent.

[0174] A specific immunologically active biomimetic formulation that may be used is a solution of immunologically active biomimetic protein in a hypotonic phosphate based buffer that is free of potassium where the composition of the buffer is as follows: 6 mM sodium phosphate monobasic monohydrate, 9 mM sodium phosphate dibasic heptahydrate, 50 mM sodium chloride, pH 7.0.+/- 0.1. The concentration of immunologically active biomimetic protein in a hypotonic buffer may range from 10 microgram/ml to 100 milligram/ml. This formulation may be administered via any route of administration, for example, but not limited to intravenous administration.

[0175] Further, an immunologically active biomimetic composition for topical administration which is combined with a semi-solid carrier can be further formulated into a cream or gel ointment. A preferred carrier for the formation of a gel ointment is a gel polymer. Preferred polymers that are used to manufacture a gel composition include, but are not limited to carbopol, carboxymethyl-cellulose, and pluronic polymers. Specifically, a powdered Fc multimer composition is combined with an aqueous gel containing an polymerization agent such as Carbopol 980 at strengths between 0.5% and 5% wt/volume for application to the skin for treatment of disease on or beneath the skin. The term "topical administration" as used herein includes application to a dermal, epidermal, subcutaneous or mucosal surface.

[0176] Upon formulation, solutions are administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective to result in an improvement or remediation of the symptoms. The formulations are easily administered in a variety of dosage forms such as ingestible solutions, drug release capsules and the like. Some variation in dosage can occur depending on the condition of the subject being treated. The person responsible for administration can, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations meet sterility, general safety and purity standards as required by FDA Office of Biologies standards.

[0177] The route of administration will vary, naturally, with the location and nature of the disease being treated, and may include, for example intradermal, transdermal, parenteral, intravenous, intramuscular, intranasal, subcutaneous, percutaneous, intratracheal, intraperitoneal, intratumoral, perfusion, lavage, direct injection, and oral administration.

[0178] The term "parenteral administration" as used herein includes any form of administration in which the compound is absorbed into the subject without involving absorption via the intestines. Exemplary parenteral administrations that are used in the present invention include, but are not limited to intramuscular, intravenous, intraperitoneal, intratumoral, intraocular, or intraarticular administration.

[0179] Below are specific examples of various pharmaceutical formulation categories and preferred routes of administration, as indicated, for specific exemplary diseases: [0180] Buccal or sub-lingual dissolvable tablet: angina, polyarteritis nodosa.

[0181] Intravenous: Idiopathic Thrombocytopenic Purpura, Inclusion Body Myositis, Paraproteinemic IgM demyelinating Polyneuropathy, Necrotizing fasciitis, Pemphigus, Gangrene, Dermatomyositis, Granuloma, Lymphoma, Sepsis, Aplastic anemia, Multisystem organ failure, Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Inflammatory Myopathies, Thrombotic thrombocytopenic purpura, Myositis, Anemia, Neoplasia, Hemolytic anemia, Encephalitis, Myelitis, Myelopathy especially associated with Human T-cell lymphotropic virus-1, Leukemia, Multiple sclerosis and optic neuritis, Asthma, Epidermal necrolysis, Lambert-Eaton myasthenic syndrome, Myasthenia gravis, Neuropathy, Uveitis, Guillain-Barre syndrome, Graft Versus Host Disease, Stiff Man Syndrome, Paraneoplastic cerebellar degeneration with anti-Yo antibodies, paraneoplastic encephalomyelitis and sensory neuropathy with anti-Hu antibodies, systemic vasculitis, Systemic Lupus Erythematosus, autoimmune diabetic neuropathy, acute idiopathic dysautonomic neuropathy, Vogt-Koyanagi-Harada Syndrome, Multifocal Motor Neuropathy, Lower Motor Neuron Syndrome associated with anti-/GM1, Demyelination, Membranoproliferative glomerulonephritis, Cardiomyopathy, Kawasaki's disease, Rheumatoid arthritis, and Evan's syndrome IM - ITP, CIDP, MS, dermatomyositis, mysasthenia gravis, muscular dystrophy. The term "intravenous administration" as used herein includes all techniques to deliver a compound or composition of the present invention to the systemic circulation via an intravenous injection or infusion.

[0182] Dermal gel, lotion, cream or patch: vitiligo, Herpes zoster, acne, chelitis.

[0183] Rectal suppository, gel, or infusion: ulcerative colitis, hemorrhoidal inflammation.

[0184] Oral as pill, troche, encapsulated, or with enteric coating: Crohn's disease, celiac sprue, irritable bowel syndrome, inflammatory liver disease, Barrett's esophagus.

[0185] Intra-cortical: epilepsy, Alzheimer's, multiple sclerosis, Parkinson's Disease, Huntingdon's Disease.

[0186] Intra-abdominal infusion or implant: endometriosis.

[0187] Intra-vaginal gel or suppository: bacterial, trichomonal, or fungal vaginitis.

[0188] Medical devices: coated on coronary artery stent, prosthetic joints.

[0189] The immunologically active biomimetics described herein may be administered in dosages from about 0.01 mg per kg to about 300 mg per kg body weight, and especially from 0.01 mg per kg body weight to about 300 mg per kg body weight, and may be administered at least once daily, weekly, biweekly or monthly. A biphasic dosage regimen may be used wherein the first dosage phase comprises about 0.1% to about 10% of the second dosage phase.

Therapeutic Applications of Stradomers and Stradobodies [0190] Based on rational design and in vitro and in vivo validations, the immunologically active biomimetics will serve as important biopharmaceuticals for treating autoimmune diseases and for modulating immune function in a variety of other contexts such as bioimmunotherapy for cancer and inflammatory diseases. Medical conditions suitable for treatment with the immunologically active biomimetics described herein include those currently routinely treated with hMG or in which hMG has been found to be clinically useful such as autoimmune cytopenias, Guillain-Barre' syndrome, myasthenia gravis, anti-Factor VIII autoimmune disease, dermatomyositis, vasculitis, and uveitis (See, F. G. van der Meche, P. I. Schmitz, N. Engl. J. Med. 326, 1123 (1992 ); P. Gajdos et al., Lancet i, 406 (1984); Y. Sultan, M. D. Kazatchkine, P. Maisonneuve, U. E. Nydegger, Lancet ii, 765 (1984 ); M. C. Dalakas et al., N. Engl. J. Med. 329, 1993 (1993); D. R. Jayne, M. J. Davies, C. J. Fox, C. M. Black, C. M. Lockwood, Lancet 337, 1137 (1991); P. LeHoang, N. Cassoux, F. George, N. Kullmann, M. D. Kazatchkine, Ocul. Immunol. Inflamm. 8, 49 (2000 )) and those cancers or inflammatory disease conditions in which a monoclonal antibody may be used or is already in clinical use. Conditions included among those that may be effectively treated by the compounds that are the subject of this invention include an inflammatory disease with an imbalance in cytokine networks, an autoimmune disorder mediated by pathogenic autoantibodies or autoaggressive T cells, or an acute or chronic phase of a chronic relapsing autoimmune, inflammatory, or infectious disease or process.

[0191] In addition, other medical conditions having an inflammatory component will benefit from treatment with immunologically active biomimetics such as Amyotrophic Lateral Sclerosis, Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, Myocardial Infarction, Stroke, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus associated inflammation, adrenoleukodystrophy, and epileptic disorders especially those believed to be associated with postviral encephalitis including Rasmussen Syndrome, West Syndrome, and Lennox-Gastaut Syndrome.

[0192] The general approach to therapy using the isolated immunologically active biomimetics described herein is to administer to a subject having a disease or condition, a therapeutically effective amount of the isolated immunologically active biomimetic to effect a treatment. In some embodiments, diseases or conditions may be broadly categorized as inflammatory diseases with an imbalance in cytokine networks, an autoimmune disorder mediated by pathogenic autoantibodies or autoaggressive T cells, or an acute or chronic phase of a chronic relapsing disease or process.

[0193] The term "treating" and "treatment" as used herein refers to administering to a subject a therapeutically effective amount of a biomimetic so that the subject has an improvement in a disease or condition, or a symptom of the disease or condition. The improvement is any improvement or remediation of the disease or condition, or symptom of the disease or condition. The improvement is an observable or measurable improvement, or may be an improvement in the general feeling of well-being of the subject. Thus, one of skill in the art realizes that a treatment may improve the disease condition, but may not be a complete cure for the disease. Specifically, improvements in subjects may include one or more of: decreased inflammation; decreased inflammatory laboratory markers such as C-reactive protein; decreased autoimmunity as evidenced by one or more of: improvements in autoimmune markers such as autoantibodies or in platelet count, white cell count, or red cell count, decreased rash or purpura, decrease in weakness, numbness, or tingling, increased glucose levels in patients with hyperglycemia, decreased joint pain, inflammation, swelling, or degradation, decrease in cramping and diarrhea frequency and volume, decreased angina, decreased tissue inflammation, or decrease in seizure frequency; decreases in cancer tumor burden, increased time to tumor progression, decreased cancer pain, increased survival or improvements in the quality of life; or delay of progression or improvement of osteoporosis. 28 [0194] The term "therapeutically effective amount" as used herein refers to an amount that results in an improvement or remediation of the symptoms of the disease or condition.

[0195] As used herein, "prophylaxis" can mean complete prevention of the symptoms of a disease, a delay in onset of the symptoms of a disease, or a lessening in the severity of subsequently developed disease symptoms.

[0196] The term "subject" as used herein, is taken to mean any mammalian subject to which biomimetics are administered according to the methods described herein. In a specific embodiment, the methods of the present disclosure are employed to treat a human subject. The methods of the present disclosure may also be employed to treat non-human primates (e.g., monkeys, baboons, and chimpanzees), mice, rats, bovines, horses, cats, dogs, pigs, rabbits, goats, deer, sheep, ferrets, gerbils, guinea pigs, hamsters, bats, birds (e g., chickens, turkeys, and ducks), fish and reptiles to produce species-specific or chimeric stradomer molecules.

[0197] In particular, the biomimetics may be used to treat conditions including but not limited to congestive heart failure (CHF), vasculitis, rosecea, acne, eczema, myocarditis and other conditions of the myocardium, systemic lupus erythematosus, diabetes, spondylopathies, synovial fibroblasts, and bone marrow stroma; bone loss; Paget's disease, osteoclastoma; multiple myeloma; breast cancer; disuse osteopenia; malnutrition, periodontal disease, Gaucher's disease, Langerhans' cell histiocytosis, spinal cord injury, acute septic arthritis, osteomalacia, Cushing's syndrome, monoostotic fibrous dysplasia, polyostotic fibrous dysplasia, periodontal reconstruction, and bone fractures; sarcoidosis; osteolytic bone cancers, lung cancer, kidney cancer and rectal cancer; bone metastasis, bone pain management, and humoral malignant hypercalcemia, ankylosing spondylitisa and other spondyloarthropathies; transplantation rejection, viral infections, hematologic neoplasisas and neoplastic-like conditions for example, Hodgkin's lymphoma; non-Hodgkin's lymphomas (Burkitt's lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, mycosis fungoides, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, hairy cell leukemia and lymphoplasmacytic leukemia), tumors of lymphocyte precursor cells, including B-cell acute lymphoblastic leukemia/lymphoma, and T-cell acute lymphoblastic leukemia/lymphoma, thymoma, tumors of the mature T and NK cells, including peripheral T-cell leukemias, adult T-cell leukemia/T-cell lymphomas and large granular lymphocytic leukemia, Langerhans cell histocytosis, myeloid neoplasias such as acute myelogenous leukemias, including AML with maturation, AML without differentiation, acute promyelocytic leukemia, acute myelomonocytic leukemia, and acute monocytic leukemias, myelodysplastic syndromes, and chronic myeloproliferative disorders, including chronic myelogenous leukemia, tumors of the central nervous system, e.g., brain tumors (glioma, neuroblastoma, astrocytoma, medulloblastoma, ependymoma, and retinoblastoma), solid tumors (nasopharyngeal cancer, basal cell carcinoma, pancreatic cancer, cancer of the bile duct, Kaposi's sarcoma, testicular cancer, uterine, vaginal or cervical cancers, ovarian cancer, primary liver cancer or endometrial cancer, tumors of the vascular system (angiosarcoma and hemagiopericytoma)) or other cancer.

[0198] "Cancer" herein refers to or describes the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to carcinoma, lymphoma, blastoma, sarcoma (including liposarcoma, osteogenic sarcoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, leiomyosarcoma, rhabdomyosarcoma, fibrosarcoma, myxosarcoma, chondrosarcoma), neuroendocrine tumors, mesothelioma, chordoma, synovioma, schwanoma, meningioma, adenocarcinoma, melanoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g. epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, small cell lung carcinoma, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophageal cancer, tumors of the biliary tract, Ewing's tumor, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, testicular tumor, lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pincaloma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic disease, heavy chain disease, neuroendocrine tumors, Schwanoma, and other carcinomas, as well as head and neck cancer.

[0199] The biomimetics may be used to treat autoimmune diseases. The term “autoimmune disease” as used herein refers to a varied group of more than 80 diseases and conditions. In all of these diseases and conditions, the underlying problem is that the body's immune system attacks the body itself. Autoimmune diseases affect all major body systems including connective tissue, nerves, muscles, the endocrine system, skin, blood, and the respiratory and gastrointestinal systems. Autoimmune diseases he disease or condition treatable using the compositions and methods may be a hematoimmunological process, Dut not limited to Idiopathic Thrombocytopenic Purpura, alloimmune/autoimmune thrombocytopenia, Acquired immune 'topenia, Autoimmune neutropenia, Autoimmune hemolytic anemia, Parvovirus B19-associated red cell aplasia, antifactor VIII autoimmunity, acquired von Willebrand disease, Multiple Myeloma and Monoclonal Gammopathy of Significance, Sepsis, Aplastic anemia, pure red cell aplasia, Diamond-Blackfan anemia, hemolytic disease of the Immune-mediated neutropenia, refractoriness to platelet transfusion, neonatal, post-transfusion purpura, hemolytic idrome, systemic Vasculitis, Thrombotic thrombocytopenic purpura, or Evan's syndrome. le disease or condition may also be a neuroimmunological process, including but not limited to Guillain-Barré syndrome, flammatory Demyelinating Polyradiculoneuropathy, Paraproteinemic IgM demyelinating Polyneuropathy, Lambert-Eaton c syndrome, Myasthenia gravis, Multifocal Motor Neuropathy, Lower Motor Neuron Syndrome associated with anti-nyelination, Multiple Sclerosis and optic neuritis, Stiff Man Syndrome, Paraneoplastic cerebellar degeneration with anit-dies, paraneoplastic encephalomyelitis, sensory neuropathy with anti-Hu antibodies, epilepsy, Encephalitis, Myelitis, y especially associated with Human T-cell lymphotropic virus-1, Autoimmune Diabetic Neuropathy, or Acute Idiopathic )mic Neuropathy. he disease or condition may also be a Rheumatic disease process, including but not limited to Kawasaki's disease, id arthritis, Felty's syndrome, ANCA-positive Vasculitis, Spontaneous Polymyositis, Dermatomyositis, Antiphospholipid 3, Recurrent spontaneous abortions, Systemic Lupus Erythematosus, Juvenile idiopathic arthritis, Raynaud's, CREST or Uveitis. he disease or condition may also be a dermatoimmunological disease process, including but not limited to Toxic Necrolysis, Gangrene, Granuloma, Autoimmune skin blistering diseases including Pemphigus vulgaris, Bullous id, and Pemphigus foliaceus, Vitiligo, Streptococcal toxic shock syndrome, Scleroderma, systemic sclerosis including i limited cutaneous systemic sclerosis, or Atopic dermatitis (especially steroid dependent). he disease or condition may also be a musculoskeletal immunological disease process, including but not limited to Body Myositis, Necrotizing fasciitis, Inflammatory Myopathies, Myositis, Anti-Decorin (BJ antigen) Myopathy, astic Necrotic Myopathy, X-linked Vacuolated Myopathy, Penacillamine-induced Polymyositis, Atherosclerosis, Coronary 3ase, or Cardiomyopathy. he disease or condition may also be a gastrointestinal immunological disease process, including but not limited to anemia, autoimmune chronic active hepatitis, primary biliary cirrhosis, Celiac disease, dermatitis herpetiformis, ic cirrhosis, Reactive arthritis, Crohn's disease, Whipple's disease, ulcerative colitis, or sclerosing cholangitis. ie disease or condition may also be Graft Versus Host Disease, Antibody-mediated rejection of the graft, Post-bone ansplant rejection, Post-infectious disease inflammation, Lymphoma, Leukemia, Neoplasia, Asthma, Type 1 Diabetes th anti-beta cell antibodies, Sjogren's syndrome, Mixed Connective Tissue Disease, Addison's disease, Vogt-Koyanagi-'ndrome, Membranoproliferative glomerulonephritis, Goodpasture's syndrome, Graves' disease, Hashimoto's thyroiditis, s granulomatosis, micropolyarterits, Churg-Strauss syndrome, Polyarteritis nodosa or Multisystem organ failure. another embodiment, the stradomers herein described could be utilized in a priming system wherein blood is drawn ient and transiently contacted with the stradomer(s) for a period of time from about one half hour to about three hours eing introduced back into the patient. In this form of cell therapy, the patient's own effector cells are exposed to that is fixed on a matrix ex vim in order to modulate the effector cells through exposure of the effector cells to . The blood including the modulated effector cells are then infused back into the patient. Such a priming system could erous clinical and therapeutic applications. itic Stradobodv Applications in Oncology addition to having clinical utility for treating immunological disorders, stradobodies have therapeutic use in cancer and >ry disease treatment. The stradobodies may be used essentially following known protocols for any corresponding c antibody. The stradobodies will generally be designed to enhance the effect demonstrated on an effector cell by a 30 monoclonal antibody, such as ADCC in cancer or decreased monocyte and DC maturation with decreased cytokine release in autoimmune disease, and thereby potentiate the immune response against the cancer relative to that which would occur using, for example, a source monoclonal antibody for the Fab portion of the stradobody.

[0209] Exemplary monoclonal antibody Fab domains from which a stradobody may be designed includes cetuximab, rituximab, muromonab-CD3, abciximab, daclizumab, basiliximab, palivizumab, infliximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, omalizumab, tositumomab, 1-131 tositumomab, efalizumab, bevacizumab, panitumumab, pertuzumab, natalizumab, etanercept, IGN101, volociximab, Anti-CD80 mAb, Anti-CD23 mAb, CAT-3888, CDP-791, eraptuzumab, MDX-010, MDX-060, MDX-070, matuzumab, CP-675,206, CAL, SGN-30, zanolimumab, adecatumumab, oregovomab, nimotuzumab, ABT-874, denosumab, AM 108, AMG 714, fontolizumab, daclizumab, golimumab, CNTO 1275, ocrelizumab, FluMax-CD20, belimumab, epratuzumab, MLN1202, visilizumab, tocilizumab, ocrerlizumab, certolizumab pegol, eculizumab, pexelizumab, abciximab, ranibizimumab, mepolizumab, and TNX-355, MYO-029.

[0210] The stradomers and stradobodies, collectively immunologically active biomimetics, disclosed herein have a number of further applications and uses.

Altering Immune Responses [0211] The immunologically active biomimetics disclosed herein may also be readily applied to alter immune system responses in a variety of contexts to affect specific changes in immune response profiles. Altering or modulating an immune response in a subject refers to increasing, decreasing or changing the ratio or components of an immune response. For example, cytokine production or secretion levels may be increased or decreased as desired by targeting the appropriate combination of FcRs with a stradomer designed to interact with those receptors. Antibody production may also be increased or decreased; the ratio of two or more cytokines or immune cell receptors may be changed; or additional types of cytokines or antibodies may be caused to be produced. The immune response may also be an effector function of an immune cell expressing a FcyR, including increased or decreased phagocytic potential of monocyte macrophage derived cells, increased or decreased osteoclast function, increased or decreased antigen presentation by antigen-presenting cells (e.g. DCs), increased or decreased NK cell function, increased or decreased B-cell function, as compared to an immune response which is not modulated by an immunologically active biomimetic disclosed herein.

[0212] In a preferred embodiment, a subject with cancer or an autoimmune or inflammatory disease has their immune response altered comprising the step of administering a therapeutically effective amount of an immunologically active biomimetic described herein to a subject, wherein the therapeutically effective amount of the immunologically active biomimetic alters the immune response in the subject. Ideally this intervention treats the disease or condition in the subject. The altered immune response may be an increased or a decreased response and may involve altered cytokine levels including the levels of any of IL-6, IL-10, IL-8, IL-23, IL-7, IL-4, IL-12, IL-13, IL-17, TNF-alpha and IFN-alpha. The invention is however not limited by any particular mechanism of action of the described biomimetics. The altered immune response may be an altered autoantibody level in the subject. The altered immune response may be an altered autoaggressive T-cell level in the subject.

[0213] For example, reducing the amount of TNF-alpha production in autoimmune diseases can have therapeutic effects. A practical application of this is anti-TNF-alpha antibody therapy (e.g. REMICADE®) which is clinically proven to treat Plaque Psoriasis, Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis and Ankylosing Spondylitis. These autoimmune diseases have distinct etiologies but share key immunological components of the disease processes related to inflammation and immune cell activity. A stradomer designed to reduce TNF-alpha production will likewise be effective in these and may other autoimmune diseases. The altered immune response profile may also be direct or indirect modulation to effect a reduction in antibody production, for example autoantibodies targeting a subjects own tissues, or altered autoaggressive T-cell levels in the subject. For example, Multiple Sclerosis is an autoimmune disorder involving autoreactive T-cells which may be treated by interferon beta therapy. See, e.g., Zafranskaya M, et al., Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis, Immunology 2007 May;121(1):29-39-Epub 2006 Dec 18. A stradomer design to reduce autoreactive T-cell levels will likewise be effective in Multiple Sclerosis and may other autoimmune diseases involving autoreactive T-cells.

Applications in Immunological Assays [0214] The immunologically active biomimetics disclosed herein may be used to perform immunological assays for testing the negation and cross linking parameters are postulated to be met through Fab binding to an antigen specific target with it interaction between the Fc region and low affinity FcyRs on the surface of responding cells. In this context, antibodies potential to evoke cellular responses through two distinct pathways: 1. Fab interaction/blocking with/of an epitope rget and 2. Fc interactions with FcRs. Despite this knowledge, current controls for the majority of therapeutic studies loclonal antibodies employed in vivo do not adequately address the potential of Fc: Fey receptor interactions as rs to observed functional effects. Multiple strategies are currently employed to eliminate Fc:FcR interactions as ig variables. For example, some studies employ Scv (single chain variable regions) or Fab fragments, which retain lecificity but lack the Fc region. These approaches are limited by the short half life of these reagents and their limited o induce signaling. Other studies employ fusion proteins composed of a receptor or ligand fused to an Fc fragment. >e types of approaches help to differentiate Fab specific effects from those observed wth receptor ligand interactions, ot effectively control for Fc mediated effects. Evaluations of antibody based therapeutics in animal models may also stype control antibodies with an irrelevant Fab binding site. The rationale for this choice is based on presumed similarity between antibodies of the same isotype regardless of their Fab binding specificity or affinity. However, this use nt isotype controls has several fundamental flaws: the Fab fragments of these antibodies cannot bind a ligand or antigenic epitope, it is likely that the Fc fragments will stimulate signaling through low affinity FcR interactions because of the absence of Fey receptor cross-linking, refore, observed functional differences between experimental and control antibodies cannot be correctly attributed to interaction with an epitope specific target lacking a means to cross-link the FcyR. : these isotypes are produced in cells which yield different glycoforms or different relative percentages of individual oforms than the parent antibody, binding to both low and high affinity FcRs will be altered, even if Fab affinity is itical. hile there is no perfect control to overcome this problem, one option is the use of isotype specific stradomers produced ie cells as the parent antibodies and given at a dose proportional to the expression levels of the epitope targeted by the tal antibody. For example, the appropriate control for an epitope-specific antibody produced in rat would be a rat ecific stradomer capable of aggregating Fey receptor on the surface of effector cells. enerally, an immune cell is exposed to an effective amount of an immunologically active biomimetic to modulate an an immune cell in a known way and this immune modulation is compared to a test compound or molecule to determine if impound has similar immune modulating activity. another embodiment, heat aggregated stradomers, and aggregated immunoglobulins may be used as reagents for controls in various immunological assays herein described and known to those of ordinary skill in the art. munological assays may be in vitro assays or in vivo assays and may involve human or non-human immune cells using -matched or species-unmatched immunologically active biomimetic. In one embodiment an immunological assay is by using an effective amount of the immunologically active biomimetic to modulate an activity of an immune cell and the modulation with a modulation of an immune cell by a test compound. The stradomer or stradobody may serve the F a positive control reagent in assays involving the testing of other compounds for immunological effect. The assay may he effect of the subject monoclonal antibody in comparison to the stradomer for effector cell Fey receptor binding and response as measured by changes in receptor expression level, cytokine release, and function such as by using a iphocyte Reaction. In this manner, if a stradomer (which lacks the Fab) generates a response which is in part similar to :lonal antibody then the monoclonal antibody's effect is, in some part, not due to specificity of its Fab but to the general inding and cross-linking more than one Fey receptor on the effector cell. The stradobody which contains both this same and the Fab from this same monoclonal antibody can further help distinguish the specificity of the monoclonal antibody he general effect of binding and cross-linking more than one Fey receptor on the effector cell. the biological activity of a species-specific and isotype-specific antibody is replicated in part or in whole by a species-id isotype-specific stradomer then it is clear that Fc - Fey receptor activity accounts for the portion of observed activity attributable to the species-specific and isotype-specific stradomer. Thus species-specific and isotype-specific s are useful in assessing potential therapeutic antibodies to determine whether and to what degree the observed activity is attributable either to the Fab portion of the test antibody or to a non-specific effect of the Fc portion of the 32 molecule binding to and cross-linking more than one Fey receptor.

[0221] In one embodiment an isolated immunologically active biomimetic comprises at least one stradomer which comprises at least two Fc domains, or partial domains thereof, from the same immunoglobulin Fc class, where the immunoglobulin Fc class is selected from the group consisting of lgG1, lgG2, lgG3, lgG4 and combinations thereof. Such biomimetics are further capable of specifically binding to a first FcyRx·], wherein x-| is I, II, III, or IV and to a second FcyRxg, wherein X2 is I, II, III, or IV. These biomimetics can be further characterized as having an immunological activity comprising an Fey receptor cross-linking or effector functionality comparable to or superior to an Fey receptor cross-linking or an effector functionality of a plurality of naturally-occurring, aggregated IgG immunoglobulins.

[0222] In another embodiment the present disclosure provides an isolated immunologically active biomimetic that comprises at least one stradomer comprising at least two Fc domains from different immunoglobulin classes, or partial domains thereof, wherein the biomimetic binds specifically to a first FcyRx-|, wherein x-| is I, II, III, or IV and to a second FcyRx2, wherein X2 is I, II, III, or IV. This biomimetic can be further characterized as having an immunological activity comprising an Fey receptor cross-linking or effector functionality comparable to or superior to an Fey receptor cross-linking or an effector functionality of a plurality of naturally-occurring, aggregated IgG immunoglobulins to FcyRs.

[0223] In a further embodiment the present disclosure provides an isolated immunologically active biomimetic that comprises one or more stradomers that each independently comprises three or more Fc domains, wherein the three or more Fc domains comprise: a) a first Fc domain, wherein the first Fc domain comprises a Fc hinge (FI) of a first immunoglobulin, b) a second Fc domain, wherein the second Fc domain comprises a constant region 2 (CFH2) of a second immunoglobulin, wherein the second Fc domain is capable of binding specifically to a FcyRx-ι, wherein x-| is I, II, III, or IV; c) a third Fc domain, wherein the third Fc domain comprises a constant region 3 (CFB) of a third immunoglobulin, wherein the third Fc domain is capable of binding specifically to an FcyRx2, wherein X2 is I, II, III, or IV. These biomimetics may optionally comprise a fourth Fc domain, wherein the fourth Fc domain comprises of a constant region 4 (CFI4) of a fourth immunoglobulin IgM. With this molecule the Fc hinge may contain at least one cysteine.

[0224] In yet another embodiment the present disclosure provides an isolated immunologically active biomimetic that comprises: a) a first Fc domain or Fc partial domain thereof, wherein the first Fc domain comprises a Fc hinge (FI) domain from a first immunoglobulin, wherein the Fc hinge domain comprises at least one cysteine, wherein the first Fc domain contributes to binding specificity to a FcyRx, wherein x is I, II, III, or IV; and at least one of: i) a second Fc domain or partial domain thereof, wherein the second Fc domain comprises a constant region 2 (CFI2) from a second immunoglobulin which may or may not be the same as the first immunoglobulin, wherein the second Fc domain contributes to binding specificity to a FcyFtx, wherein x is I, II, or III, IV; and, optionally, and ii) a third Fc domain or partial domain thereof, wherein the third Fc domain comprises a constant region 3 (CFI3) from a third immunoglobulin, wherein the third Fc domain contributes to binding specificity to an FcyFtx, wherein x is I, II, III, or IV; and b), optionally, a fourth Fc domain or partial domain thereof, wherein the fourth Fc domain specificity a constant region 4 (CFI4) from an IgM immunoglobulin.

[0225] In another embodiment, the isolated immunologically active biomimetic is a stradomer wherein the immunoglobulin source of the Fc domains are the same or different and include IgA isotypes, IgG isotypes, IgD, IgE, and IgM. Another stradomer embodiment is an isolated immunologically active biomimetic comprising a secretory signal sequence.

[0226] In one preferred embodiment the therapeutically effective amount of the isolated immunologically active biomimetics is an amount sufficient to permit binding of the biomimetics to two or more FcyRx, wherein x is I, II, III, or IV, on the surface of an immune cell, thereby causing the FcyRx to aggregate. The immune cell may be any immune effector cell such as a monocyte, a dendritic cell, a macrophage, an osteoclast, or an NK cell. The immune effector cell's maturation may be modulated by the immunologically active biomimetic. The ratio of FcyR lla to FcyRIIb may also become altered on the immune cell. The immune cell may be located in the plasma, bone marrow, gut, bone, lymphoid tissue, thymus, brain, a site of infection or a tumor. The functional activity of a macrophage, dendritic cell, osteoclast, or NK cell may be modulated.

[0227] The therapeutically effective amount of the isolated immunologically active biomimetic described herein above may be administered ex vivo to an immune cell to generate a treated immune cell followed by the step of infusing the treated immune cell into the subject. The treated immune cell may be a dendritic cell, macrophage, osteoclast or a monocyte.

[0228] Additional immunotherapy may be given together with any of the isolated immunologically active biomimetics described herein in a therapeutically effective amount to the subject. The additional immunotherapy may include, for example, one or more of a co-stimulatory molecule, a monoclonal antibody, a polyclonal antibody, a fusion protein, a biospecific antibody, a cytokine, an immunologically recognized antigen, a small molecule anti-cancer agent or anti-proliferative agent. The additional immunotherapy may be administered concurrently with or separately from the administration of the immunologically active biomimetic.

[0229] Cytokine (including those listed above) levels can be altered by for, example, administering one or more cytokines of interest, one or more other cytokines that modulate the level of the one or more cytokines of interest, and/or antibodies (of any of the types and classes recited herein) specific for one or more of any of the above two categories of cytokines.

[0230] The immunologically active biomimetics described herein may be used to modulate expression of co-stimulatory molecules from an immune cell, including a dendritic cell, a macrophage, an osteoclast, a monocyte, or an NK cell or to inhibit in these same immune cells differentiation, maturation, or cytokine secretion, including interleukin-12 (IL-12), or of increasing cytokine secretion, including interleukin-10 (IL-10), or interleukin-6 (IL-6). A skilled artisan may also validate the efficacy of an immunologically active biomimetic by exposing an immune cell to the immunologically active biomimetic and measuring modulation of the immune cell function, wherein the immune cell is a dendritic cell, a macrophage, an osteoclast, or a monocyte. In one embodiment the immune cell is exposed to the immunologically active biomimetic in vitro and further comprising the step of determining an amount of a cell surface receptor or of a cytokine production, wherein a change in the amount of the cell surface receptor or the cytokine production indicates a modulation of the immune cell function. In another embodiment the immune cell is exposed to the immunologically active biomimetic in vivo in a model animal for an autoimmune disease further comprising a step of assessing a degree of improvement in the autoimmune disease.

[0231] "Capable of specifically binding to a FcyRx" as used herein refers to binding to an FcyR, such as FcyRIII. Specific binding is generally defined as the amount of labeled ligand which is displaceable by a subsequent excess of unlabeled ligand in a binding assay. However, this does not exclude other means of assessing specific binding which are well established in the art (e.g., Mendel CM, Mendel DB, 'Non-specific' binding. The problem, and a solution. Biochem J. 1985 May 15;228(1):269-72). Specific binding may be measured in a variety of ways well known in the art such as surface plasmon resonance (SPR) technology (commercially available through BIACORE®) to characterize both association and dissociation constants of the immunologically active biomimetics (Aslan K, Lakowicz JR, Geddes C. Plasmon light scattering in biology and medicine: new sensing approaches, visions and perspectives. Current Opinion in Chemical Biology 2005, 9:538-544).

Methods Employing Fixed Fc [0232] In order to understand the role of Fc: Fc gamma receptor (FcyR, the Fc receptor for IgG Fc) interactions and the importance to MG function of its Fc being biologically immobilized within an immunoglobulin, we compared the effects of MG with both a fixed form of a recombinant lgG1 Fc fragment (rFCF) and a soluble form of a recombinant lgG1 Fc fragment (sFc) containing the hinge-CH2-CH3 domains on the function of monocytes during the process of differentiation from monocytes to immature dendritic cells (iDC).

[0233] Exposure of monocytes cultured in granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4), to immobilized rFCF and to immobilized MIG, but not low dose soluble IVIG, enhanced CD86 expression, delayed the expression of CD11c, and suppressed the expression of CD1a on the cells. Furthermore, these changes are likely not secondary to nonspecific protein immobilization of the rFCF on plastic, as soluble heat aggregated (sHA) MIG, sHA rFCF or high dose MIG (recognized to contain multimeric Fes), induced changes similar to those observed with immobilized rFCF.

[0234] Taken in concert, our data indicate that exposure of iDC to MIG immobilized on the surface of a solid, semi-solid, or gelatinous substrate results in a unique population of DC's (high CD86, low CD1a), capable of orchestrating immune tolerance, and that immobilized molecules that include the functional portion of immunoglobulin G (IgG) Fc fragments can be useful as mimetics of MIG for the treatment of local and systemic inflammation, as well as a wide variety of other pathological conditions that are, directly or indirectly, mediated by monocyte derived cells (MDC) such as iDC. Moreover, immobilizing the functional portion of IgG Fc on devices, described herein as "coating devices", that are implanted into the bodies or attached to the bodies of animals (e.g., human patients) with molecules containing the functional portion of IgG Fc fragment can lessen, if not prevent, inflammatory responses to such devices.

[0235] The disclosure provides a method of inhibiting the activity of a monocyte-derived cell (MDC). The method includes contacting the cell with a composition comprising a substrate with an Fc reagent bound thereto. The contacting can be in vitro, in vivo, or ex vivo. Alternatively, the cell can be in an animal. The animal can be one that has, or is at risk of developing, a monocyte derived cell mediated condition (MDCMC). The MDC can be, for example, a dendritic cell, a macrophage, a monocyte, or an osteoclast. 3 used herein, the term "monocyte-derived cell mediated condition (MDCMC)" refers to a pathologic condition that is indirectly, partially or wholly, due to the activity of, or factors produced by, monocyte-derived cells. Monocyte-derived de, but are not limited to, monocytes, macrophages, interdigitating dendritic cells (generally referred to herein as cells" comprising dendritic-like cells and follicular dendritic-like cells) (mature and immature), osteoclasts, microglia-like nocyte derived insulin-producing islet-like cells, monocyte-derived immature mast cells and monocyte-derived ;les. ith respect to methods using fixed Fc, the term "Fc reagent" refers to any molecule, or molecular complex, that includes re (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 20, or more) functional portions of an immunoglobulin Ig (IgG) Fc fragment, jgment of IgG consists of the C-terminal portions of the two IgG heavy chains of an IgG molecule linked together and f the hinge regions, the CFI2 domains, and the CFI3 domains of both heavy chains linked together. The "functional the IgG Fc fragment" consists of the hinge regions, the CH2 domains, and optionally, all or some (e.g., 1, 2, 3, 4, 5, 6, , 11, 12, 13, 14, 15, 16, 17, 18, 19,20,21,22,23,24,25, 26, 27, 28, 29,30,31,32,33,34, 35, 36, 37, 38, 39, 40,41, i, 45, 46, 47, 48, or 49) of the first 50 (from the N-terminus) amino acids of the CFI3 domains, of both heavy chains 3ther. In humans, (a) the lgG1 hinge region contains 15 amino acids, the CFI2 domain contains 110 amino acids, and lomain contains 106 amino acids; (b) the lgG2 hinge region contains 12 amino acids, the CFI2 domain contains 109 Is, and the CH3 domain contains 107 amino acids; (c) the lgG3 hinge region contains 62 amino acids, the CFI2 domain 04 amino acids, and the CH3 domain contains 106 amino acids; and (d) the lgG4 hinge region contains 12 amino acids, omain contains 109 amino acids, and the CH3 domain contains 107 amino acids. s in wild-type IgG molecules, in the above-described Fc reagents the two polypeptide chains derived from IgG heavy : generally, but not necessarily, identical. Thus, an Fc reagent can be, without limitation, a whole IgG molecule, a whole ule linked to a non-immunoglobulin derived polypeptide, an IgG Fc fragment, an IgG Fc fragment linked to a non->bulin derived polypeptide, a functional portion of an IgG Fc fragment, a functional portion of an IgG Fc fragment linked mmunoglobulin derived polypeptide or multimers (e.g., dimers, trimers, tetramers, pentamers, hexamers, heptamers, nonamers, or decamers) of any of these. Fc reagents can also be the above-described stradomers and stradobodies hat they fall within the definition of a Fc reagent above. the fixed Fc, immunoglobulin heavy chain components of the Fc reagents can have wild-type amino acid sequences or ie wild-type amino acid sequences but with not more than 20 (e.g., not more than: 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, i, 5, 4, 3, 2, or 1) amino acid substitutions. Such substitutions arc preferably, but not necessarily, conservative ns. Conservative changes typically include changes within the following groups: glycine and alanine; valine, isoleucine, le; aspartic acid and glutamic acid; asparagine, glutamine, serine and threonine; lysine, histidine and arginine; and nine and tyrosine. i "Fc reagent" has least 25% (e.g., at least: 30%; 40%; 50%; 60%; 70%; 80%; 90%; 95%; 98%; 99%; 99.5%; or 100% or ϊ) of the ability of the IgG molecule from which the IgG heavy chain components of the Fc reagent were derived (the IgG molecule) to bind to an Fc receptor of interest. Where an "Fc reagent" has heavy chain components derived from one type of IgG molecule, the reference IgG molecule is the one that binds with the greatest avidity to the relevant Fc f interest. ! used herein "fixed Fc" refers to an Fc reagent that is bound to a "substrate" as defined below. The terms "fixed Fc," and "stabilized Fc" are synonymous terms. Fixed Fc is comprised of the functional portion of Fc (including but not any polypeptide that includes the functional portion of Fc) attached to a substrate. Fixed Fc includes, for example, direct ; well as indirect binding through polymers of Fc to substrate; incorporation of the full IgG Fc in isolation; incorporation i functional domains of IgG Fc; or incorporation of the full IgG Fc or functional domains of IgG Fc as part of a larger e such as an antibody, a stradomer, or a stradobody. s applied to fixed Fc, the term "substrate" refers to a solid, semi-solid, or gelatinous object. The substrate can be in, or attached (or adhered) to the surface of, the body of an animal. The substrates can include, for example, liquid or components but at least a portion of the substrate is solid, semi-solid, or gelatinous. Thus, a substrate can be a that is substantially insoluble in an aqueous solvent but soluble in a non-aqueous solvent. Such substances include , phospholipids), fatty acids, and other fat-soluble, aqueous solvent-insoluble compounds. From this, it will be clear that 35 substrates include liposomes. The substrate may be porous or non-porous. In certain embodiments, the substrate is inert to the surface and/or body to which it is implanted, attached, or adhered..

[0244] The substrate can contain or be made of a synthetic polymer, e.g., nylon, teflon, dacron, polyvinyl chloride, PEU (poly (ester urethane)), PTFE (polytetrafluoroethylene), PMMA (methyl methacrylate) PEEK, thermoplastic elastomers, radiopaque polymers, polyethersulfone, silicons, polycarbonates, polyurethanes, polyisobutylene and its copolymers, polyesters, polyolefins, polyisobutylene, ethylene-alphaolefin copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers such as polyvinyl chloride, polyvinyl ethers, polyvinyl methyl ether, polyvinylidene halides, polyvinylidene fluoride, polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics, polystyrene, polyvinyl esters, polyvinyl acetate, copolymers of vinyl monomers, copolymers of vinyl monomers and olefins, ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, ethylenevinyl acetate copolymers, polyamides, Nylon 66, polycaprolactone, alkyd resins, polyoxyethylenes, polyimides, polyethers, epoxy resins, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, carboxymethyl cellulose, collagens, chitins, polylactic acid, polyglycolic acid, polylactic acid-polyethylene oxide copolymers, polysiloxanes, substituted polysiloxanes, ethylene vinyl acetate copolymers, polyolefin elastomers, and EPDM rubbers, and combinations thereof.

[0245] The substrate can also contain or be made of a metal or a metal alloy, e.g., stainless steel, platinum, iridium, titanium, tantalum, nickel-titanium alloy, or cobalt-chromium alloy. Moreover, the substrate can include or be an animal tissue or an animal tissue product, e.g., a tissue or organ graft. The animal tissue can be, for example, bone [0246] (e.g., osteogenic bone) or cartilage. Furthermore, the substrate can contain a protein, e.g., collagen or keratin. The substrate can also be or contain a tissue matrix, e.g., an acellular tissue matrix Particulate and non-particulate acellular matrices are described in detail in, for example, U.S. Patent Nos. 5,336,616 and 6,933,326.

[0247] The substrate can also be or include an animal cell (e.g., tissue repair cells such as fibroblasts; mesenchymal stem cells) and it can be, for example, a hair transplant plug. The substrate can contain or be a polysaccharide, e.g., agarose. It can also contain or be a salt, preferably a relatively insoluble salt, e.g., calcium sulfate. The substrate can be a gel or cream. Moreover, it can contain silicon or silastic. Substrates can also contain a natural fiber, e.g., silk, cotton, or wool.

[0248] In addition, the substrate can be an implantable medical device. It can be, for example, a stent (e.g., a vascular stent such as a coronary artery stent; an airway stent such as an endotracheal or nasal stent; a gastrointestinal stent such a biliary or pancreatic stent; or a urinary stent such as a ureteral stent) or a surgical suture (e.g., a braid silk, chromic gut, nylon, plastic, or metal suture) or a surgical clip (e.g., an aneurism clip). The substrate can be, for example, an artificial hip, an artificial hip joint, an artificial knee, an artificial knee joint, an artificial shoulder, an artificial shoulder joint, an artificial finger or toe joint, a bone plate, a bone dowel, a bone non-union implant, an intervertebral disk implant, bone cement, or a bone cement spacer. It can also be an arterial-venous shunt, an implantable wire, a pacemaker, an artificial heart, a heart assist device, a cochlear implant, an implantable defibrillator, a spinal cord stimulator, a central nervous system stimulator, or a peripheral nerve implant. Other substrates are dental prostheses or dental crowns.

[0249] In other embodiments, the substrate can be a large vessel embolic filtering device or cage, a percutaneous device, a dermal or sub-mucosal patch, or an implantable drug delivery device. The substrate can also be a large blood vessel graft, wherein the blood vessel is, for example, a carotid artery, a femoral artery, or an aorta. Moreover, the substrate can be a sub-dermal implant, a corneal implant, an intraocular lens, or a contact lens.

[0250] The substrate can be in the form of a sheet, a bead, a mesh, a powder particle, a thread, a bead, or a fiber. It can also include or be a solid, a semi-solid or a gelatinous substance.

[0251] Polymers are preferably those that are biostable, biocompatible, particularly during insertion or implantation of the device into the body, and avoid irritation to body tissue.

[0252] Fc reagents can be coated (i.e., fixed or stabilized) onto substrates in any of a variety of manners. For example, they can be coated directly on the surface of substrates where they remain attached by, for example, hydrophobic interactions. Below are described a few other methodologies ((a) - (e)) involving the use of polymers: 1. (a) The Fc reagent is mixed with a miscible polymer blend which is then layered on to the surface of the implantable synthetic material, thereby stabilizing the Fc reagent. Monomers routinely used in the art to make polymer blends include PLMA[poly(lauryl methacrylate)]; PEG [polyethylene glycol], PEO [polyethylene oxide]; the alkyl functionalized methacrylate polymers PMMA, ΡΕΜΑ. PPMA, and PBMA; itaconates; fumarates; and styrenics. 2. (b) A polymeric undercoat layer or a nanometer dimension film is adhered to the substrate surface and then the Fc reagent is adhered to the polymeric undercoat layer or nanometer dimension film, thereby stabilizing the F reagent. 3. (c) A thin film of a polymer monomer is applied to the implantable substrate surface and the monomer is then caused to polymerize Such monomers include, for example, Methane, Tetrafluorethylene, Benzene, Methanol, Ethylene oxide, Tetraglyme, Acrylic acid, Allylamine, Hydroxyethyl methacrylate, N-vinyl pyrrolidone, and mercaptoethanol. The Fc reagent is then attached to the resulting monomer. 4. (d) The substrate is coated with a protein such as protein A or albumin which attaches to the Fc reagent, thereby stabilizing Fc to the surface of the substrate. 5. (e) The Fc reagent can be tagged with a chain of hydrophobic amino acids that bind to implantable synthetic materials and cause the stabilized Fc to orient uniformly.

[0253] The methods can be applied to any animal species and the IgG molecules from which the IgG-derived portions of Fc reagents are made can be from any animal species. Naturally, relevant animal species are those in which IgG or IgG-like molecules occur. Generally the species to which the methods are applied and the species from which the IgG-derived portions of the Fc reagents used in the methods are the same. However, they are not necessarily the same. Relevant animal species are preferably mammals and these include, without limitation, humans, non-human primates [0254] (e.g., monkeys, baboons, and chimpanzees), horses, bovine animals (e.g., bulls, cows, or oxen), pigs, goats, sheep, dogs, cats, rabbits, gerbils, hamsters, rats, and mice. Non-mammalian species include, for example, birds (e.g., chickens, turkeys, and ducks) and fish.

[0255] The terms "treating", "treatment", and "prophylaxis" have the same meaning using fixed Fc as described above for stradomers and stradobodies.

[0256] Where the fixed Fc are implantable devices coated with Fc reagents, they can be implanted in, attached to, or adhered to relevant internal organs or tissue or body surfaces of relevant subjects using methods well known in the art. Where they are formulated as, for example, suspensions, powders, they can be formulated and administered as described above for stradomers and stradobodies.

[0257] The fixed Fc reagents may be used to treat or prevent conditions including but not limited to cancer, congestive heart failure (CHF), vasculitis, rosecea, acne, eczema, myocarditis and other conditions of the myocardium, systemic lupus erythematosus, diabetes, spondylopathies, synovial fibroblasts, and bone marrow stroma; bone loss; Paget's disease, hypertrophic bone formation;; disuse osteopenia; malnutrition, periodontal disease, Gaucher's disease, Langerhans' cell histiocytosis, spinal cord injury, acute septic arthritis, osteomalacia, Cushing's syndrome, monoostotic fibrous dysplasia, polyostotic fibrous dysplasia, periodontal reconstruction, and bone fractures, bone pain management, and humoral malignant hypercalcemia, ankylosing spondylitis and other spondyloarthropathies; transplantation rejection, and viral infections.

[0258] All autoimmune diseases may be in part or in whole an MDCMD. The term "autoimmune disease" as used herein refers to a varied group of more than 80 chronic illnesses. In all of these diseases, the underlying problem is that the body's immune system attacks the body itself. Autoimmune diseases affect all major body systems including connective tissue, nerves, muscles, the endocrine system, skin, blood, and the respiratory and gastrointestinal systems.

[0259] The autoimmune disease or condition may be a hematoimmunological process, including but not limited to Idiopathic Thrombocytopenic Purpura, alloimmune/autoimmune thrombocytopenia, Acquired immune thrombocytopenia, Autoimmune neutropenia, Autoimmune hemolytic anemia, Parvovirus B19-associated red cell aplasia, Acquired antifactor VIII autoimmunity, acquired von Willebrand disease, Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance, Sepsis, Aplastic anemia, pure red cell aplasia, Diamond-Blackfan anemia, hemolytic disease of the newtoorn, Immune-mediated neutropenia, refractoriness to platelet transfusion, neonatal, post-transfusion purpura, hemolytic uremic syndrome, systemic Vasculitis, Thrombotic thrombocytopenic purpura, or Evan's syndrome.

[0260] The autoimmune disease or condition may be a neuroimmunological process, including but not limited to Guillain-Barré syndrome, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Paraproteinemic IgM demyelinating Polyneuropathy, Lambert-Eaton myasthenic syndrome, Myasthenia gravis, Multifocal Motor Neuropathy, Lower Motor Neuron Syndrome associated with anti-/GM1, Demyelination, Multiple Sclerosis and optic neuritis, Stiff Man Syndrome, Paraneoplastic cerebellar degeneration with anti-Yo antibodies, paraneoplastic encephalomyelitis, sensory neuropathy wth anti-Hu antibodies, epilepsy, Encephalitis, Myelitis, Myelopathy especially associated with Human T-cell lymphotropic virus-1, Autoimmune Diabetic Neuropathy, or Acute Idiopathic Dysautonomic Neuropathy.

[0261] The autoimmune disease or condition may be a Rheumatic disease process, including but not limited to Kawasaki's disease, Rheumatoid arthritis, Felty's syndrome, ANCA-positive Vasculitis, Spontaneous Polymyositis, Dermatomyositis, Antiphospholipid syndromes, Recurrent spontaneous abortions, Systemic Lupus Erythematosus, Juvenile idiopathic arthritis, Raynaud's, CREST syndrome, or Uveitis.

[0262] The autoimmune disease or condition may be a dermatoimmunological disease process, including but not limited to Toxic Epidermal Necrolysis, Gangrene, Granuloma, Autoimmune skin blistering diseases including Pemphigus vulgaris, Bullous Pemphigoid, and Pemphigus foliaceus, Vitiligo, Streptococcal toxic shock syndrome, Scleroderma, systemic sclerosis including diffuse and limited cutaneous systemic sclerosis, or Atopic dermatitis (especially steroid dependent).

[0263] The autoimmune disease or condition may be a musculoskeletal immunological disease process, including but not limited to Inclusion Body Myositis, Necrotizing fasciitis, Inflammatory Myopathies, Myositis, Anti-Decorin (BJ antigen) Myopathy, Paraneoplastic Necrotic Myopathy, X-linked Vacuolated Myopathy, Penacillamine-induced Polymyositis, Atherosclerosis, Coronary Artery Disease, or Cardiomyopathy.

[0264] The autoimmune disease or condition may be a gastrointestinal immunological disease process, including but not limited to pernicious anemia, autoimmune chronic active hepatitis, primary biliary cirrhosis, Celiac disease, dermatitis herpetiformis, cryptogenic cirrhosis, Reactive arthritis, Crohn's disease, Whipple's disease, ulcerative colitis, or sclerosing cholangitis.

[0265] The autoimmune disease or condition may be Graft Versus Host Disease, Antibody-mediated rejection of the graft, Postbone marrow transplant rejection, Post-infectious disease inflammation, Lymphoma, Leukemia, Neoplasia, Asthma, Type 1 Diabetes mellitus with anti-beta cell antibodies, Sjogren's syndrome, Mixed Connective Tissue Disease, Addison's disease, Vogt-Koyanagi-Harada Syndrome, Membranoproliferative glomerulonephritis, Goodpasture's syndrome, Graves' disease, Hashimoto's thyroiditis, Wegener's granulomatosis, micropolyarterits, Churg-Strauss syndrome, Polyarteritis nodosa or Multisystem organ failure.

[0266] "Cancer" herein refers to or describes the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to carcinoma, lymphoma, blastoma, sarcoma (including liposarcoma, osteogenic sarcoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, leiomyosarcoma, rhabdomyosarcoma, fibrosarcoma, myxosarcoma, chondrosarcoma,), osteoclastoma, neuroendocrine tumors, mesothelioma, chordoma, synovioma, schwanoma, meningioma, adenocarcinoma, melanoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g. epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, small cell lung carcinoma, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophageal cancer, tumors of the biliary tract, Ewing's tumor, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, testicular tumor, lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic disease, heavy chain disease, neuroendocrine tumors, Schwanoma, and other carcinomas, head and neck cancer, myeloid neoplasias such as acute myelogenous leukemias, including AML with maturation, AML without differentiation, acute promyelocytic leukemia, acute myelomonocytic leukemia, and acute monocytic leukemias, myelodysplastic syndromes, and chronic myeloproliferative disorders, including chronic myelogenous leukemia, tumors of the central nervous system, e.g., brain tumors (glioma, neuroblastoma, astrocytoma, medulloblastoma, ependymoma, and retinoblastoma), solid tumors (nasopharyngeal cancer, basal cell carcinoma, pancreatic cancer, cancer of the bile duct, Kaposi's sarcoma, testicular cancer, uterine, vaginal or cervical cancers, ovarian cancer, primary liver cancer or endometrial cancer, tumors of the vascular system (angiosarcoma and hemagiopericytoma), hematologic neoplasias and neoplastic-like conditions for example, Hodgkin's lymphoma; non-Hodgkin's lymphomas (Burkitt's lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, mycosis fungoides, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, hairy cell leukemia and lymphoplasmacytic leukemia), tumors of lymphocyte precursor cells, including B-cell acute lymphoblastic leukemia/lymphoma, and T-cell acute lymphoblastic leukemia/lymphoma, thymoma, tumors of the mature T and NK cells, including peripheral T-cell leukemias, adult T-cell leukemia/T-cell lymphomas and large granular lymphocytic leukemia, osteolytic bone cancers, and bone metastasis.

[0267] As used herein, a subject "at risk of developing a monocyte-derived cell mediated disease (MDCMD)" is a subject that has a predisposition to develop the MDCMD, i.e., a genetic predisposition to develop the MDCMD or has been exposed to conditions that can result in MDCMD. A subject "suspected of having a MDCMD" is one having one or more symptoms of a MDCMD. From the above it will be clear that neither subjects "at risk of developing a MDCMD" nor subjects "suspected of having a MDCMD" are all individuals within a species of interest.

[0268] In any of the above methods, the MDCMC can be one caused by the substrate and the Fc reagent serves to prevent or ameliorate the MDCMC.

Example 1 - Construct Design of Immunoloaicallv Active Biomimetics [0269] A sequence encoding a Fc fragment monomer from human IgG q (SEQ ID NO: 1) has been cloned into an expression vector (pCDNA 3.1D/V5 Flis TOPO Invitrogen) comprising selected restriction enzyme cleavage sites, an IgK signal (further defined below) and epitope tags to create the lgG1 monomer sequence (RestEnzSites-lgKsignal-RestEnzSites-lgG1 (Hnge-CH2-CH3)-RestEnzSites-epitope tags (V5 and His)-STOP}, shown in Figure 17 (SEQ ID NO: 19). The construct was transfected into CFIO cells (CHO-002) for protein production. Additionally, we have designed several stradomer constructs with the general structures: 1. a) (RestEnzSites-lgK signal-RestEnzSites-lgG1(Hinge-CH2-CFB)-Xbal site-lgG1(Flinge-CFI2-CH3)- STOP} (SEQ ID NO: 21) (see also Figure 4A and Figure 18); 2. b) {RestEnzSites-lgK signal-RestEnzSites-lgG1(Hinge-CH2-CH3)-Xbal site-lgG1(Flinge-CH2-CH3)-RestEnzSites-epitope tags (V5 and Plis)-STOP} (SEQ ID NO: 23) (see also Figure 19); 3. c) (RestEnzSites-lgK signal-EcoRV Site-lgG3(Hinge-CFI2-CFI3)-lgG1(Hinge-CH2-CFI3)-RestEnzSites-epitope tags(V5 and His)-STOP} (SEQ ID NO.: 25) (see also Figure 21); and 4. d) (RestEnzSites-lgK signal-EcoRV Site-lgE(CH2)-lgG1(Hinge-CH2-CH3)-lgG1(Hinge-CH2)-lgE(CH4)-STOP} (SEQ ID NO.:27) (see also Figure 22).

[0270] The lgG-| stradomer construct a) (SEQ ID NO: 21; Figure 18) was engineered using PCR. Primers complementary to the hinge sequence (at the 5' end) of lgG-| (SEQ ID NO: 29) and to the C terminus of the lgG-| (at the 3' end) (SEQ ID NO: 30) were used to amplify the lgG-| Plinge-Fc region. Restriction sites were added to the primers to permit in-frame cloning of the second Fc domain in series with the first, which was cloned into a pcDNA cloning vector (pCDNA 3.1D/V5 His TOPO, Invitrogen). A stop codon was added before the restriction site of the C terminal primer to prevent read through of flanking sequences for this construct.

[0271] The stradomer construct b) (SEQ ID NO: 23; Figure 19), was similarly made and contained the lgG-| Fc - IgGq Fc as described above but also contained two epitope tags added to the C terminus of the construct. These epitope tags are used for identification or purification of the protein. In this second construct the two epitope tags, V5 and His tag, are present in frame prior to the stop codon.

[0272] Proteins that are normally secreted routinely contain a hydrophobic signal sequence at the N terminus of the protein. For the stradomer constructs, we used the IgK signal sequence METDTLLLVWLLLWVPGSTG (SEQ ID NO:35) which is removed from the protein as it is secreted by mammalian cells such as Chinese Hamster Ovary cells. The predicted cleavage site was based on algorithms for signal site cleavage prediction (SignalP 3.0).

[0273] Additional stradomer constructs, similar to a) and b) above were made that contained the lgG-| Fc - IgGq Fc structure as described above (with and without the epitope tag) but using the lgG3 Hinge domain in the construct: IgGq Fc - lgG3 hinge - IgGq (CH2-CH3).

Example 2- Design and Testing of Immunoloaicallv Active Biomimetics Coated MG and Coated Fc stimulate Similar Phenotypic Changes [0274] MG and Fc when coated onto the walls and floor of the wells of a sterile plate stimulate nearly identical changes in CD1a and CD86 levels on immature DC and delay the up regulation of CD11c. Because of the recognized critical role of DC in ITP, these data provide a rational model for evaluating the function of IVIG mimetics such as stradomers. We also conclude that the fact that the phenotypic changes induced by IVIG are completely recapitulated by recombinant Fc suggest that the effects of IVIG on DC are highly likely to be Fc mediated.

Stradomer Generation [0275] We have constructed stradomers of four different classes to mimic the effects of IVIG on immature DC. The serial stradomers, cluster stradomer units comprising cluster stradomers, core stradomer units comprising core stradomers, and Fc fragment stradomers shown below in Table 3 were each produced except where noted. To obtain the appropriate sequences for each of the human constructs shown below, cDNAwas synthesized from total RNA extracted from human PBMC. To obtain those sequences from other species RNA was purified from tissue of those species. Random priming was used to produce the cDNA. The cDNAwas used to amplify the desired fragments using PCR to synthesize, clone and subsequently characterize by sequence analysis the DNAfragments. The final constructs were produced by either sewing by overlap extension with PCR (Horton RM, Hunt HD, Ho SN, Pullen, JK and Pease LR. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68, 1989) or utilized existing compatible restriction sites to fuse the appropriate fragments.

[0276] For example, in the cloning of G-007, the lgECH4 domain was directly fused to the CH2 domain of lgG1 at the 3' end of the protein. This was accomplished by making primers that contain the overlapping sequences for lgG1CH2 (C terminus) with the N terminal amino acids for lgECH4. In one case, a hybrid primer was used to amplify 5' with lgG1 sequences and the complementary primer was used to amplify with a 3' primer from the C terminus of the lgECH4. Products from these two reactions were mixed and the flanking primers were used to amplify the fusion protein. Sequence analysis confirmed the construct.

[0277] In many cases, restriction sites were utilized that were conveniently present at the ends of the molecules to be joined. When restriction sites are in fusion there are detectable remnant restriction sequences at the ends of the linked sequences. This approach was used for most of the constructs shown below in Table 3. The amino acid sequences of the stradomers shown in Table 3 are provided in Figure 24. Some of the sequence are shown with Hs-tags, known in the art to be useful in purifying proteins.

Table 3

i i

I

I

I

I

I

I

I

I

I

I

I

Wivi—r £Ι0ϋϋ09 10

Stradomer protein expression 41 [0278] For protein expression of the stradomers, plasmid DNA encoding the stradomers described above were transfected into CHO suspension cells (FreestylejM MAX CHO expression system, Invitrogen CA). Following protein expression the expressed stradomers were purified from the culture media by affinity column chromatography using protein A or protein G affinity columns. Purified stradomers were analyzed by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) under reducing conditions followed by Coomasie Blue staining to confirm the presence of monomeric protein bands of expected size as exemplified: G-002: approximately 35KD band, G-004 approximately 70KD band, , G-010: approximately 45KD band, G-011: approximately 80KD band, G-012: approximately 85KD band, G-018 approximately 70KD band, G-019: approximately 35KD, G-028 approximately 37KD band. Plasmid DNA encoding the stradomers described can also be transfected into other mammalian cells such as HEK293, BHK cells, murine NSO, and murine SP2/0 cells.

Multimer Formation [0279] We observed that these constructs, when transfected, cultured, and purified may create proteins of the expected size in non-denatured and denatured protein analysis. In addition, we observed that certain compounds also exhibited larger bands which by size criteria are multimers of the expected dimeric protein.

[0280] Formation of higher order compounds by selected stradomers was analyzed by SDS-PAGE followed by Western blot under non-reducing conditions (A) and reducing conditions (B). SDS-PAGE analysis shows formation of high molecular weight compounds of stradomers G-002, G-010, and G-019 under non-reducing conditions as compared to reducing conditions: • G-002: an approximately 35KD band under reducing condition - bands at approximately 70KD (dimer) and 135KD (tetramer) under non-reducing conditions. • G-010: an approximately 45KD band under reducing condition - bands at approximately 90KD (dimer) and 180KD (tetramer) under non-reducing conditions. • G-019: an approximately 35KD band under reducing conditions - bands at approximately 70KD (dimer), 140 KD (tetramer) under non-reducing conditions.

[0281] We anticipate that the tetrameric and other higher order multimers of the dimerized protein will contribute significantly to the biological activity of the compound as measured by the immature Dendritic Cell assay (see below).

Stradomer Monomers. Stradomers. and Higher Order Multimers of Stradomers Maintain Recognition Sites.

[0282] Each of the proteins in Table 3 are recognized by a rabbit anti-human IgG (Fc) [Thermo Scientific 31789]. We conclude from this that each of these proteins maintains the recognition sites for this antibody.

Plasmon Resonance Imaging [0283] The ability of the stradomers in Table 3 to bind FcyRIIIa was assessed using surface plasmon resonance (SPR) technology (commercially available through Biacore®). Human FcyRIIIa was directly immobilized via amine coupling to a CM5 Biacore chip by diluting the ligand in Acetate pH5.0 to a concentration of 5ug/ml. Ligands were perfused over specified flow cell at a rate of 5ul/min until an RU of 250 was reached. The flow cells were then blocked with ethanolamine. Stradomers and MG were diluted to 1000nM in HBS-EP (0.01 M HEPES pH 7.4; 0.15M NaCI; 3mM EDTA; 0.005% Surfactant P20) and serially diluted 500nM, 250nM, 125nM and finally 62.5nM. A baseline sample containing only buffer (HBS-EP) was also included. A flow rate of 20ul/min was used for all samples. Atotal of 60uL of sample was injected, for an injection time of 3 minutes. Regeneration was achieved by perfusing running buffer over flow cells for an extended period of time of approximately 10 minutes.

[0284] At 500nM, the measured Req (equilibrium), relative to baseline for the stradomer G-010 construct was 24.9 RU when perfused over human FcyRIIIa, and the KD was 1.95e-7 using a 1:1 binding model. IMG at 500nM on human FcyRIIIa gave a Req of 63.6 RU and a KD of 1.89e-7 using a 1:1 binding model. G-010 was therefore determined to bind to FcyRIIIa. Similar binding ability has been assessed on other biomimetic compounds. Here are some further examples: 42

[0285] We conclude that these proteins have varied ability to bind to recombinant FcyRIIIa by plasmon resonance analysis and that certain compounds such as G-010 have a bivalent curve fit, consistent with that seen by bivalent antibodies and indicating that the stradomer may have multi-valent binding to FcyRIIIa.

Stradomers Mimic the Biological Effect of MG

[0286] The biological function of these stradomers was assessed. In order to determine the ability of each of the stradomers in Table 3 to mimic the functional utility of MG in individuals with ITP, we developed an in vitro assay using immature dendritic cells (iDC). The rationale for choosing iDC as target cells was based on published data demonstrating that adoptive transfer of DC from mice treated with IMG, conferred protection against the development of ITP to naive animals. (Siragam, V. et al. Intravenous immunoglobulin ameliorates ITP via activating Fc[gamma] receptors on dendritic cells. Nat Med 12, 688 (2006)). In our initial studies, we evaluated the impact of coated, meaning fixed to the plate, recombinant Fc (rFc) and IVIG on the expression of a variety of activation, maturation and costimulatory markers on human CD 14+ cells, cultured in the presence of IL-4 and GM-CSF. When compared to cells cultured in cytokines alone, cells exposed to coated IVIG or coated rFc demonstrated striking enhancement of CD86 expression and down regulation of CD1a expression as well as a delay in CD11c upregulation.

[0287] Next, we determined whether the stradomers in Table 3 mimicked the described effect of coated IVIG or coated Fc on iDC. These compounds when coated to the plate well walls and floors did mimic the effect: G-002, G-004, G-005, G-014, G-018, and G-019. These compounds when coated to the plate well walls and floors did not mimic the effect: G-010, G-011, and G-012 [0288] These compounds when soluble did mimic the effect of coated IVIG or coated Fc on iDC: G-002, G-010, G-014, G-018, and G-019. These compounds when soluble did not mimic the effect: G-004, G-005, G-011, and G-012.

[0289] Whether exposure of iDC to coated IVIG would influence subsequent responses to pro-inflammatory stimuli can be tested.

[0290] We draw the following conclusions from these data: 1. i. that select stradomers, when coated on a tissue culture plate, mimic the functional ability of coated IVIG to upregulate CD86 and suppress CD1a expression on immature DC, 2. ii. that select stradomers administered at a low dose in a soluble form mimic the functional ability of coated IVIG to up regulate CD86 and suppress CD1a expression on iDC, 3. iii. that certain stradomers can induce phenotypic change in both a soluble and coated form and that other stradomers, such as G-010, can induce phenotypic change in a soluble but not a coated form, 4. iv. that stradomers of differing structures can be biologically active as evidenced by the Fc fragment stradomer formed from G-002 and the cluster stradomer formed from G-010, 5. v. that structures larger than expected by dimerization of stradomer monomers are seen on protein analysis and that these multimeric structures may correspond with biological activity in comparison to IVIG, and 6. vi. that stradomers formed from dimerized stradomer monomers can demonstrate a bivalent fit on plasmon resonance consistent with binding of multiple Fey receptors and suggesting the presence of multimeric tertiary structures of the stradomers. 43

Example 3 - Heat Aggregated Biomimetics Are More Potent Than MG

[0291] Astradomer is a biologically active mimetic of aggregated immunoglobulin and especially of the aggregated Fc fragments of those immunoglobulin. In some instances, heat aggregation of the biomimetics described herein can increase biological activity. We conclude that heat-aggregated biomimetics as herein described can be as potent as MG.

Example 4 - Fc fragment Exhibits Several Activities [0292] The Fc fragment has been used as a positive control in experiments described above in which the protein is coated and thereby fixed to plastic thereby exhibiting biological behavior that mimics coated IVIG. The Fc fragment also can be used as a core stradomer unit such as when it is attached to core moieties such as a liposome, a bead, or albumin. Further, we have demonstrated that the Fc fragment when cultured in certain expression systems and certain cell types, such as the Invitrogen FreestyleMax transient transfection system using CHO-S cells, can form higher order multimers on protein analysis, exhibit bivalent binding pattern on plasmon resonance imaging, and exhibit profound biological activity in soluble form comparable to coated IVIG in the immature DC assay. We conclude therefore that under certain carefully controlled conditions, the Fc fragment forms a Fc fragment stradomer. This effect may be due to post-translational modifications such as glycosylation changes.

Example 5 - A Core Stradomer which is an Fc-coated bead may alter Phaaocvtic potential Relative to Uncoated Beads.

[0293] PBMCs are isolated from the buffy coat of healthy donors using Ficoll-Hypaque density gradient centrifugation. After isolation, PBMCs are washed twice with PBS. CD14+ cells are then purified using MACS separation column (Miltenyi). The purified cells are counted and resuspended to 2x10/'5/ml RPMI complete media containing 800ug/ml GM-CSF and 5ng/ml IL-4. The cells are then seeded in the wells of non-tissue culture but sterile 6-well plates. After seeding the CD 14+ cells in the non-tissue culture, polystyrene FITC microspheres (0.52um) coated with or without saturating amounts of Fc or IVIG are added to the cells at a 1:1 ratio and incubated for 6 days at 37°C, 5.0% C02 and then analyzed for phagocytosis of microspheres by FACS.

[0294] Both IVIG-coated beads and Fc-coated beads act as core stradomers and may thereby alter phagocytotic potential relative to uncoated beads.

Example 6 - Design of Immunoloaicallv Active Biomimetics With Altered FcvRIII binding affinities [0295] It has been shown that a shared set of residues of lgG1 are involved in binding to all FcyRs. It has also been demonstrated that additional residues in lgG1 molecules are involved in the binding to both FcyRII and FcyRIII. Some residues when altered inhibited binding of one or more receptors. Interestingly, the specific double mutation of S298A/K334A enhanced binding of Fcyllla and reduced binding to Fcyllb. Those residues have been noted on the stradomer construct shown in Figure 16 (using an asterisk at both amino acids). We therefore can use site directed mutagenesis to generate a stradomer molecule having the structure encoded by SEQ ID NO: 17 but with the corresponding S298A/K334A mutations.

Example 7 - Expression of Recombinant Proteins [0296] Numerous expression systems exist that are suitable for use in producing the compositions discussed above. Eukaryote-based systems in particular can be employed to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.

[0297] In a preferred embodiment, the stradomers described herein are produced using Chinese Hamster Ovary (CHO) cells which are well established for the recombinant production of immunoglobulin proteins following standardized protocols. Alternatively, for example, transgenic animals may be utilized to produce the human stradomers described herein, generally by expression into the milk of the animal using well established transgenic animal techniques. Lonberg N. Human antibodies from 44 le insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, escribed in U.S. Patent No. 5,871,986, 4,879,236, and which can be bought, for example, under the name MAXBAC® JVITROGEN® and BACPACK™ BACULOVIRUS EXPRESSION SYSTEM FROM CLONfTECH®. )ther examples of expression systems include STRATAGENE®'s COMPLETE CONTROL™ Inducible Mammalian ί System, which utilizes a synthetic ecdysone-inducible receptor. Another example of an inducible expression system is rom INVITROGEN®, which carries the T-REX™ (tetracycline-regulated expression) System, an inducible mammalian l system that uses the full-length CMV promoter. INVITROGEN® also provides a yeast expression system called the hanolica Expression System, which is designed for high-level production of recombinant proteins in the methylotrophic lia methanolica. One of skill in the art would know how to express vectors such as an expression construct described i produce its encoded nucleic acid sequence or its cognate polypeptide, protein, or peptide. See, generally, ant Gene Expression Protocols By Rocky S. Tuan, Humana Press (1997), ISBN 0896033333; Advanced Technologies armaceutical Processing By Roshni L. Dutton, Jeno M. Scharer, Blackwell Publishing (2007), ISBN 0813805171; ant Protein Production With Prokaryotic and Eukaryotic Cells By Otto-Wilhelm Merten, Contributor European Federation nology, Section on Microbial Physiology Staff, Springer (2001), ISBN 0792371372. B - Expression and Purification of Immunoloaicallv Active Biomimetics icleic acid constructs described in Examples 1 and 2 are transfected into cell lines that do not naturally express Ig. The jolypeptides are expressed as secreted proteins due to their secretory leader sequences, which generally are removed anous proteases during transport out of the cells or may be subsequently cleaved and removed by techniques well the art. These secreted immunologically active biomimetics are purified using Protein A or His tag chromatographic as well known in the art and size is verified by reducing and/or non-reducing SDS PAGE (sodium dodecyl sulfate mide gel electrophoresis). 9 - Expression and Purification of Immunoloaicallv Active Biomimetics for Large Scale Production hile various systems can be used to produce large amounts of a specific protein including bacteria, insect cells or yeast, i in mammalian cells can minimize problems due to altered glycosylation of the proteins. Mammalian cells like CHO cells i used to overproduce various proteins fused to an Ig backbone. The Fc domain in the construct becomes a tag that ibsequent purification from the cell supernatant using protein affinity column purification (Harris, CL, DM Lublin and BP fficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion )itfalls and solutions., J. Immunol. Methods 268:245-258, 2002). Many fusion proteins are directly cloned in frame with ant region of Ig, specifically the CH2 and CH3 partial Fc domain monomers. A specific example of expression of gamma receptor extracellular domain being expressed with Ig has been used to produce large amounts of the protein onal activity (Fountoulakis, M, C. Mesa, G. Schmid, R. Gentz, M. Manneberg, M. Zulauf, Z. Dembic and G. Garotta, gamma receptor extracellular domain expressed as IgG fusion protein in Chinese hamster ovary cells: Purification, al, characterization and stoichiometry of binding, J. Biol. Chem.. 270:3958-3964, 1995). 10 - Design of Immunoloaicallv Active Biomimetics With Altered Fc Glvcosvlation f a method essentially the same as that described by Shields et al. with regard to homo-antibodies, de-fucosylated Fc an be made in mutant CHO cells lacking enzymatic activity for adding fucose to protein carbohydrates. These are used > stradomers with stronger FcyRIII binding affinities relative to a fucosylated form of the same molecule. (Robert L. t al. Lack of Fucose on Human lgG1 N-Linked Oligosaccharide Improves Binding to Human Fc Rill and Antibody-t Cellular Toxicity. J. Biol. Chem., Jul 2002; 277: 26733 - 26740 (doi:10.1074/jbc.M202069200)). las been shown that changes in sialylation in the Fc N-glycan can increase biological activity. Kaneko Y, Nimmerjahn F, V. Science. 2006 Aug 4;313(5787):627-8. Thus stradomer molecule having altered sialylation can be produced using 45 similar methods.

[0304] Alternative means to altering glycosylation of stradomer Fc domains include chemoenzymatic techniques for producing polypeptides with a specific glycosylation structure. See, Li, B., Song, H., Hauser, S., and Wang, L. X 2006. A Highly Efficient Chemoenzymatic Approach Toward Glycoprotein Synthesis. Org. Lett. 8:3081-3084; See, also, International Pat. App. No. PCT/US07/70818.

Example 11 - Fusion Constructs of FcvRIIIa <176 V/F1 Polymorphism [0305] As discussed previously, the anti-inflammatory activity of MG is dependent on primary interactions between the Fc domain and FcyRIIIa. These interactions can be effectively quantitated using (SPR) technology to characterize both association and dissociation constants of the immunologically active biomimetics with the two recognized polymorphic variants of FcyRIIIa (176 V/F). In order to define the binding affinity and dissociation of our Fc domain monomeric control and stradomer constructs, FcyRIIIa HIS tag fusion proteins will be produced in CHO cells with both V (SEQ ID NO:33) and F (SEQ ID NO:31) polymorphic variants at position 176 (Figure 20). These sequences can be put into pCDNA3.1 and transfected into CHO cells. These FcyRIIIa fusion proteins are purified from the supernatants from transfected cells using affinity Ni^+ columns to purify the proteins. All FcyRIIIa fusion proteins are characterized by both cDNA sequencing and SDS PAGE.

[0306] Various other protocols in the art can be utilized to express FcyRIIIa and characterize interactions with immunologically active biomimetic. See, e.g., the materials and methods section of Robert L. Shields, et al. high Resolution Mapping of the Binding Site on Human IgG 1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of lgG1 Variants with Improved Binding to the FcyR. J. Biol.

Chem., Feb 2001; 276: 6591 - 6604 (doi:10.1074/jbc.M009483200).

Example 12 - Screening Immunologically Active Biomimetic Function In Vitro [0307] To test the function of immunologically active biomimetics such as those presented in Example 1, an in vitro assay is designed to recapitulate the mechanism by which it appears that native Fc domains reduce inflammation in vivo. It has recently been demonstrated that hIVIG inhibits the maturation of DCs and alters the secretion of IL-10, IL-12 and TNF-alpha (Bayry, J, et al., Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin, Blood 101(2):758-765(2003)). Our stradomers mediate effects on DCs similar to hIVIG. The inhibition of DC maturation and alterations in cytokine secretion in vitro can serve as an effective means to define some of the biological activities of many stradomer constructs. The stradomer constructs described above may be further validated using the following experimental parameters:

Table 4

[0308] In one preferred in vitro assay shown in Table 4, the impact on human DC phenotype of soluble, immunologically active biomimetics, having appropriate binding affinities, is measured. Soluble non-cross-linked natural sequence Fc domain constructs can serve as controls. Specific DC markers on the DC surface are evaluated including markers of activation (CD80, CD83 and CD86) as well as the FcyRs. See Prechtel AT, Turza NM, Theodoridis AA, Steinkasserer A. CD83 knockdown in monocyte-derived DCs by small interfering RNA leads to a diminished T cell stimulation. J Immunol. 2007 May 1;178(9):5454-64. In addition, multiplex analysis can be employed to evaluate the impact of our immunologically active biomimetics on DC cytokine production. Jongbloed, Sarah L., et al. Enumeration and phenotypic analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther. 2006; 8(1): R15 (Published online 2005 December 16. doi: 10.1186/ar1864). Finally, to confirm DCs interact with monocytes as expected, control DCs and DCs exposed to immunologically active biomimetics are cultured with purified monocytes and evaluated by flow cytometry for changes in the levels of activating FcyRIla receptors and other cell surface determinants related to the activation state of the monocytes.

[0309] In particular embodiments, stradomers can decrease the FcyRIla receptors present on an immune cell thereby increasing the ratio of inhibitory FcyRIIb receptors to the FcyRIla receptors which results in inhibition of immune cell functions.

Example 13 - Screening Immunoloaicallv Active Biomimetic Function In Vivo [0310] Numerous autoimmune diseases such as idiopathic thrombocytopenic purpura, multiple sclerosis, asthma, and inflammatory bowel diseases have established, art recognized animal models for in vivo testing. Wu GF, Laufer TM. The role of dendritic cells in multiple sclerosis. Curr Neurol Neurosci Rep. 2007 May;7(3):245-52; Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev. 2005 Aug;206:296-305. For example, multiple models of ITP are currently available. See, e.g., Crow AR, et al. IVIG inhibits reticuloendothelial system function and ameliorates murine passive immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol. 2001;115:679-686. Immunologically active biomimetics designed to modulate the immune system, as appropriate for each specific autoimmune disease, can be validated in such in vivo models. Importantly, in many of these models, administration of hIVIG likely results in a foreign species (e.g. mouse) anti-human antibody response which has the potential to obscure or create false positive product related anti-inflammatory effects.

[0311] We established a mouse model of Idiopathic Thrombocytopenic Purpura according to the following methodology: Platelet counts were measured in C57BL6 mice by serial tail vein nicking. 10 ul. of blood was diluted in 15 ul citrate buffer. Samples were then analyzed for absolute platelet count on a HemaVet 950 cytometer. For mice in an ITP control group, starting day 2, every afternoon platelets were depleted by giving intra peritoneal injection of 2 ug Rat Anti-Mouse CD41 (MWReg30), an anti-platelet antibody from BD Biosciences pharmingen. Mice in the IVIG pretreatment control group received 2 g/kg (40mg/mice) human IVIG by i.p. injection every morning and the same dose MWReg30 as the ITP control group. We determined that MG is highly protective of platelet count in this model of induced ITP and conclude that this model is useful for testing stradomers against IVIG for relative degree of protection from platelet count decreases. A stradomer can be assessed in this model at various concentrations to assess protection relative to IVIG as follows:

Groups in an experiment

1. 1) Control - No ITP, No IVIG 2. 2) ITP control group - 2 ug MWReg30 every evening starting day 2 3. 3) IVIG pretreatment group - 40mg IVIG every morning and 2 ug MWReg30 every evening starting day 2 4. 4) Stradomer equivalent to 10Λ12 Fc domains IV every morning 5. 5) Stradomer equivalent to 10Λ11 Fc domains IV every morning 6. 6) Stradomer equivalent to 10Λ10 Fc domains IV every morning 7. 7) Stradomer equivalent to 10^ Fc domains IV every morning 8. 8) Stradomer equivalent to 10'® Fc domains IV every morning 9. 9) Stradomer equivalent to 10Λ7 Fc domains IV every morning 10. 10) Stradomer equivalent to 10*6 Fc domains IV every morning

Example 14 - Validating Immunoloaicallv Active Biomimetic Efficacy In Vivolor Treating ITP

[0312] In another murine model of ITP, mice deficient in normal B cell function can be used. Deficiency in normal B cell function serves to eliminate the idiotype-antiidiotype effects of murine anti-human Fc fragment antibodies that would be generated by the administration of human Fc fragment or Fc partial fragment to a mouse and consequent false positive results. The deficiency in B cell function can be generated, for example, through the administration of anti-B cell antibodies or occurs in genetically engineered mice such as the m chain-knock out mouse (Jackson Labs strain B6.129S2-lgh-6tmlc9n/J) that are deficient in mature B-cells.

[0313] The immune system of immunodeficient mice is reconstituted with either unmodified or B cell depleted PBMCs from immunocompetent animals. These animals are subsequently treated with anti-platelet antibodies to mimic ITP using well defined techniques in the art. Animals are then treated with immunologically active biomimetics according to the following scheme:

Table 5. In vivo efficacy of [hlgG-| Fc domain - hlgGi Fc domain] (SEQ ID NO.: 22) immunologically active biomimetics for the treatment of ITP.

[0314] It is anticipated that groups 1 and 2 will not develop ITP upon antibody infusion as they do not have the B cells to produce anti-platelet antibodies necessary for platelet destruction. In groups 3 and 4, it is expected that both the {hlgGi Fc -hlgGi Fc} stradomer polypeptide and the hlgGi Fc monomer polypeptide effectively ameliorate ITP because endogenous murine antibodies react with hlgGi Fc domain epitopes to crosslink the hlgGi Fc monomer polypeptides. In contrast, in the absence of endogenous murine antibodies, the {hlgGi Fc - hlgGi Fc} stradomer polypeptide (group 6) is more effective than the uncross-linked IgGi Fc monomer polypeptide (group 5) in ameliorating ITP. Group 7 serves as a positive control for treatment effect.

Example 15 - Treating Patients with ITP Using Intravenous Formulations of Stradomer Proteins (SEQ ID NOs: 18 &amp; 22) [0315] Treatment protocols for ITP with the exemplary stradomer proteins encoded by SEQ. ID. NO.:17 &amp; 21 are utilized in a manner tracking standard guidelines for ITP hIVIG therapy such as the Executive Committee of the American Society of Hematology practice guideline for the diagnosis and management of primary immune thrombocytopenic purpura. See George, JN, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996 Jul 1 ;88(1 ):3-40; See also, the 2000 guidelines by Italian pediatric hematologists, the 2003 British hematologists guidelines and the 2006 Japanese pediatric hematologists guidelines. Alternatively, the stradomer IV protocols for ITP may include an initial administration phase with dosages of about 0.1 to about 0.001 times the above treatment protocol dosages. The initial low dose phase is designed to minimize any short term pro-inflammatory effects of the stradomer administration while still being sufficient to induce a long term anti-inflammatory effect, which is subsequently enhanced and maintained by the second phase standard dosing described above. The rationale for this alternative approach is that some embodiments of a stradomer may have both a short term inflammatory effect as well as a long term anti-inflammatory effect through decreasing the expression of FcyRIIa. An initial low dose (or initial low doses) can be used to stimulate the long term antiinflammatory effect while minimizing the short term inflammatory effect.

[0316] The effective stradomer dose is generally from about 0.01% to about 15% of the effective hIVIG dose, more preferably, about 0.1% to about 3% of the effective hIVIG dose. The effective hIVIG dose in ITP is generally in the range of about 100 mg/Kg to about 2 grams/Kg administered every 10-21 days.

[0317] The stradomer intravenous formulation will be substantially the same as FDA approved hIVIG formulations but may exclude the stabilizers present in some hMG formulations. See, e.g., the product insert for Gammagard S/D, distributed by Baxter Healthcare Corporation and approved for ITP therapy by the FDA.

Example 16 - Treating Patients with ITP Using Intraperitoneal Administration of a Core Stradomer [0318] Treatment protocols for ITP with exemplary stradomer proteins representing Fc fragments fixed to a core moiety such as a liposome are utilized by intraperitoneal administration with dosages of about 1% to about 0.001 % of standard intravenous MG protocol dosages. The rationale for this alternative approach is that core stradomers comprised of fixed Fc fragments delivered in a stable formulation to the intraperitoneal cavity will make available the multiple Fc domains to affect monocyte-derived effector 48 vo stradobodies have been constructed and transfected . For each stradobody, encoding cDNA was synthesized from nade from hybridoma cell lines expressing the antibody of interest. Establishing hybridoma cell lines is well known in the ication of cDNA of interest encoding the antibody heavy and light variable regions was done by BD SMART ™ RACE Dn kit (Clontech CA). Numerous other methods are available to generate cDNA encoding the heavy and light chains for jgions of antibodies (Sassano, M. et. al., 1994. Nucleic Acids Res. May 11 ;22(9): 1768-9; Jones, S.T., Bendig, M.M., technology (NY) Jan: 9(1):88-9.) To generate the stradobodies the heavy chain variable regions are fused to the constructs by either sewing by overlap extension with PCR (Hutton and Pease) or utilize existing compatible restriction se the appropriate fragments. Stradobody proteins are expressed in CHO-S cells and isolated from cell supernatants by :olumn affinity purification. Binding of the purified stradobodies to the antigen of interest is confirmed by flow cytometry jdies utilizing cell lines expressing the antigen. standard ADCC assay employing NK cells as effectors and antigen expressing tumor cells as targets at various effector-atios is employed to compare the potential of the stradobody and the monoclonal antibody (Mab) that shares the same i to induce ADCC against high and low antigen expressing tumor cell lines.. Stradobodies are selected for development nstrate similar results to the paired Mab in the NK assay against the high epitope expressing cell line but superior :he paired Mab in the NK assay against the low epitope expressing cell line. 18 - Treating Patients with Breast cancer Using Intravenous Formulations of Stradobody Containing the Sinding Domain of Trastuzumab eatment protocols for breast cancer with the exemplary stradobody containing a Fab that is or is similar to the Fab from ited product trastuzumab having activity against the her2/neu epitope are utilized in a manner tracking standard for breast cancer therapy. See Romond, EH et. al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-•east Cancer. NEJM. 2005 Oct. 20; 353:1673-1684; Seidman, AD et. al. Weekly Trastuzumab and Paclitaxel Therapy for Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification. Journal of Clinical Vol 19, Issue 10 (May), 2001: 2587-2595; Vogel, CL et. al. Journal of Clinical Oncology. Vol 20, Issue 3 (February), 726 is anticipated that the effective stradobody dose will generally range from about 1% to about 500% of the effective al antibody whose Fab is the same as the stradobody, more preferably, about 50% to about 100% of the effective al antibody dose. The effective monoclonal antibody dose in clinical cancer treatment varies. For the Her-2 neu al antibody the dose is generally in the range of about 2 mg/Kg to about 4 mg/Kg administered every 7-21 days. 19 Treating Patients with Head and Neck or Colon cancer Using Intravenous Formulations of Stradobody ig the Antiaen-Bindina Domain of Cetuximab is anticipated that treatment protocols for breast cancer with the exemplary stradobody containing a Fab that is or is the Fab from the marketed product cetuximab having activity against the EGFR epitope can be utilized in a manner andard guidelines for head and neck and colon cancer therapies. See Robert, F et. al. Phase I Study of Anti-Epidermal ictor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck >urnal of Clinical Oncology, Vol 19, Issue 13 (July), 2001: 3234-3243; Bonner, JAet. al. Cetuximab prolongs survival in ith locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy hout cetuximab. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 22, uly 15 Supplement), 2004: 5507; Shin, DM et. al. Epidermal Growth Factor Receptor-targeted Therapy with C225 and i Patients with Head and Neck Cancer. Clinical Cancer Research Vol. 7, 1204-1213, May 2001; Cunningham, D et al. i Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. NEJM. Volume 45, 2004. s anticipated that the effective EGFR / HER1 stradobody dose will generally range from about 1% to about 500% of the 49 effective monoclonal antibody whose Fab is the same as the stradobody, more preferably, about 50% to about 100% of the effective monoclonal antibody dose. The effective monoclonal antibody dose in clinical cancer treatment varies. For the EGFR monoclonal antibody the dose is generally in the range of about 250 - 400 mg/square meter which is about 5 mg/Kg - 25 mg/ Kg administered every 7-21 days.

Example 20. Increased Multimerization by Altered Glveosvlation May Increase Immunoloaicallv Active Biomimetic Activity.

[0325] The glycosylation patterns of expressed proteins are dependent on the cell line in which the protein is expressed. The Chinese Flamster Ovarian cell (CFO cell) commonly used for protein expression and purification results in a glycosylation pattern that is different from, for example, the HEK 293 cells which are of human origin and also is commonly used for protein expression of endogeneous proteins. As the binding properties of Fc fragments and cluster stradomer units can be affected by the glycosylation pattern, increased multimerization and therefore increased biological activity of the expressed peptides can be achieved by expression in cell lines other than CFIO or in cell lines including CFIO that are genetically altered to change the glycosylation pattern to an N-glycan that promotes increased aggregation between Fc fragments or Fc domain-containing peptides. Increased multimerization of Fc fragment or selected cluster stradomer units by altering glycosylation patterns may increase the ability of immunologically active biomimetics to mimic the effects of hMG.

Example 21. Does Exposure of Mature DC fmDCI to MG or rFcF /recombinant Fc fragments) Alter Their Phenotype? [0326] The rFCF fragments from human lgG1 to be used in this experiment were produced by standard recombinant protein technology. The two chains of the human rFCF each consisted of the hinge region (15 amino acids), the CFI2 domain (110 amino acids), and the CFI3 domain (106 amino acids) of human lgG1 heavy chain.

[0327] CD14+ cells can be isolated from peripheral blood mononuclear cells (PBMC) obtained from the blood of a healthy human donor using a Miltenyi MACS separation column. The cells are cultured at a final concentration of 2 x 105 /mL in GM-CSF (800 lll/mL) and IL-4 (5 ng/mL) for 5 days at 37°C. The media in all cultures is refreshed on day 3 of culture. At day 5, lipopolysaccharide (LPS; 10 pg/ml) is added to appropriate cultures to induce maturation to a mature DC. Mature DCs are known in the art not to express substantive levels of the CD16, CD32 or CD64. The cells are then cultured for an additional two days and aliquots are analyzed for CD11c, CD80, CD83, CD86, CD1a, and CD 14 expression by two dimensional fluorescence flow cytometry (FFC). The remaining cells cultured with LPS are then placed in wells with soluble or coated MG or human rFcF (all at 10 pg/mL) for 24 hours at 37°C, harvested and analyzed for expression of the markers listed above by two-dimensional FFC.

[0328] Experimental groups are as follows: 1. (1) CD14+cells; GM-CSF; IL-4; no LPS ("7d-LPS") 2. (2) CD14+ cells: GM-CSF; IL-4; LPS ("7d+LPS") 3. (3) CD14+ cells; GM-CSF; IL-4; LPS; coated MG ("cIVIG") 4. (4) CD14+ cells; GM-CSF; IL-4; LPS; soluble IVIG ("sIVIG") 5. (5) CD14+ cells; GM-CSF; IL-4; LPS; coated rFcF ("cFc") 6. (6) CD14+ cells; GM-CSF; IL-4; LPS; soluble rFcF ("sFc") 7. (7) CD14+ cells; GM-CSF; IL-4; LPS ("Control")

Example 22. Does Exposure of iDC to Coated IVIG Inhibit Phagocytosis of Opsonized Red Blood Cells? [0329] CD 14+ cells are purified from human PBMC of a healthy human donor as described in Example 21 and cultured at 37 °C for 6 days with GM-CSF and IL-4 at the concentrations indicated in the previous examples and in the presence or absence of coated or soluble IVIG. The cells are harvested and then incubated at either 37°C or 4°C for two hours with Rho-positive human red blood cells that are uncoated or coated with fluorescein isothiocyanate (FITC) conjugated anti-D antibody. After incubation with red blood cells, CD 14+ cells are stained for APC-conjugated CD1a. Phagocytosis is then evaluated by two dimensional FFC measuring side light scatter (SSC-A), forward light scatter (FSC-A), FITC fluorescence (FITC-A), andAPC fluorescence (CD1a).

Example 23. Does Exposure to Coated MG Decrease the Ability of iDC to Stimulate an Allogeneic Mixed Lymphocyte Reaction [0330] CD 14+ cells are isolated from the blood of a healthy human donor as described in the previous examples. They are then cultured at 37°C for 6 days with GM-CSF and IL-4 in the presence or absence of soluble and coated IVIG.. The concentrations of all these reagents are as described in above. The cells are then harvested and plated into the wells of 96 well microtiter tissue culture plates at various numbers (with the highest dose being 2.5 x 104 per well). CD3+ T cells are purified from the PBMC of a second human donor that was HLA incompatible with the donor from which the CD 14+ cells are isolated. The T cells are added to each of the walls of the 96 well tissue culture plates (103 T cells per well). After five days of co-culture, 1 pCi of 3H-thymidine is added to each of the culture wells. The cultures are then incubated for a further 6 hours and incorporation of the 3H-thymidine ("cpm") is measured as an indication of the degree of cell proliferation in the cultures. Three different iDC stimulator populations are tested: one generated by culture with GM-CSF and IL-4 only, one generated by culture with GM-CSF, IL-4, and coated MG, and one generated by culture with GM-CSF, IL-4, and soluble IVIG.

Example 24. Effect of Exposure of iDC to Coated and Soluble rFcF and IVIG on Cvtokine Expression bv the iDC and mDC

[0331] Cultures containing CD14+ cells, GM-CSF, and IL-4 and either rFcF (coated or soluble) or IVIG (coated or soluble) are set up under the conditions described in the previous examples. Instead of testing the cells for expression of cell surface markers, phagocytic ability, or the ability to stimulate allogeneic MLRs, the cytokines the cells produce are measured. It is expected that coated rFcF will modulate cytokine production by the cells in a manner similar to IVIG but not similar to soluble rFcF. Thus, it is expected that the level of cytokines that inhibit inflammatory responses (e.g., interleukin-4, interleukin-6, and interleukin-12) will be enhanced by exposure of the cells to coated rFcF. Moreover, it is expected that exposure of the cells to coated rFcF will result in a decrease in the level of production by the cells of cytokines that enhance inflammatory responses (e.g., interferon, interleukin-23, and tumor necrosis factor-l).

Example 25. Recombinant Mouse Fc Fragments [0332] Recombinant Fc fragments (rFcF) from mouse lgG2a were produced using standard cloning and recombinant protein expression techniques. The two chains of the mouse rFcF each consisted of the hinge region (21 amino acids), the CH2 domain (110 amino acids), and the CH3 domain (107 amino acids) of mouse lgG2a heavy chain. The mouse lgG2a was active in the human iDC assay when coated to the walls and floors of plate wells.

LIST OF REFERENCES

[0333] 1. 1. Smiley, D. &amp; MG, T. Southwestern internal medicine conference: High dose intravenous gamma globulin therapy: How does it work? Am J Med Sci 309, 295-303 (1995). 2. 2. Nimmerjahn, F. &amp; Ravetch, J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox J. Exp. Med. 204, 11-15 (2007). 3. 3. Samuelsson, A., Towers, T.L. &amp; Ravetch, J.V. Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor. Science 291,484-486 (2001). 4. 4. Follea, G. et al. Intravenous plasmin-treated gammaglobulin therapy in idiopathic thrombocytopenic purpura. Nouv Rev Fr Hematol 27, 5-10 (1985). 5. 5. Solal-Celigny, R, Bernard, J., Herrera, A. &amp; Biovin, P. Treatment of adult autoimmune thrombocytopenic purpura with high-dose intravenous plasmin-cleaved gammaglobulins. Scand J Haematol 31,39-44 (1983). 6. 6 . Debre, M. &amp; Bonnet, M.-C. Infusion of Gcgamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945-49 (1993). 7. 7. Burdach, S.E., Evers, K. &amp; Geurson, R. Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: Comparative efficacy of 7S and 5S preparations. J Pediatr 109, 770-775 (1986). 8. 8. Siragam, V. et al. Intravenous immunoglobulin ameliorates ITP via activating Fc[gamma] receptors on dendritic cells. Nat Med 12, 688 (2006). 9. 9. Clarkson, S. et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 314, 1236-1239 (1986). 10. 10. Bleeker, W.K. et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 95, 1856-1861 (2000). 11. 11. Teeling, J.L. et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 98, 1095-1099 (2001). 12. 12. Augener, W., Friedman, B. &amp; Brittinger, G. Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)? Blut 50, 249-252 (1985). 13. 13. Tankersley, D.L., Preston, M.S. &amp; Finlayson, J.S. Immunoglobulin G dimer: An idiotype-anti-idiotype complex. Molecular Immunology 25, 41 (1988). 14. 14. Robert L. Shields, Angela K. Namenuk, Kyu Ftang, Y. Gloria Meng, Julie Rae, John Briggs, Dong Xie, Jadine Lai, Andrew Stadien, Betty Li, Judith A. Fox, and Leonard G. Presta. High Resolution Mapping of the Binding Site on Human lgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of lgG1 Variants with Improved Binding to the FcyR J. Biol. Chem., Feb 2001; 276: 6591 - 6604 ; doi:10.1074/jbc.M009483200 15. 15. Sondermann, P., Huber, R., Oosthuizen, V., and Jacob, U. (2000) Nature 406, 267-273 16. 16. Robert L. Shields, Jadine Lai, Rodney Keck, Lori Y O'Connell, Kyu Hong, Y Gloria Meng, Stefanie H. A. Weikert, and Leonard G. Presta Lack of Fucose on Human lgG1 N-Linked Oligosaccharide Improves Binding to Human FcyRIII and Antibody-dependent Cellular Toxicity. J. Biol. Chem., Jul 2002; 277: 26733 - 26740 ; doi:10.1074/jbc.M202069200 17. 17. Ann Wright and Sherie L. Morrison. Effect of C2-Associated Carbohydrate Structure on Ig Effector Function: Studies with Chimeric Mouse-Human lgG1 Antibodies in Glycosylation Mutants of Chinese Hamster Ovary Cells. J. Immunol., Apr 1998; 160:3393 -3402. 18. 1 8. Crow AR, et al. Mg inhibits reticuloendothelial system function and ameliorates murine passive immune thrombocytopenia independent of antiidiotype reactivity. Br J Haematol. 2001;115:679-686. 19. 19. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin Jagadeesh Bayry, Sébastien Lacroix-Desmazes, Cedric Carbonneil, Namita Misra, Vladimira Donkova, Anastas Pashov, Alain Chevailler, Luc Mouthon, Bernard Weill, Patrick Bruneval, Michel D. Kazatchkine, and Srini V. Kaveri Blood 2003 101: 758-765. Prepublished online August 29, 2002; DO110.1182/blood-2002-05-1447 20. 20. R. Deng and J. P. Balthasar. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood, March 15, 2007; 109(6): 2470 -2476. Prepublished online as a Blood First Edition Paper on November 28, 2006; DO110.1182/blood-2006-04-018093. 21. 21. Kabat, E. A., Wu, T. T, Perry, Η. M., Gottesman, K. S., and Foeller, C. (1991) Sequences of Proteins of Immunological Interest, 5th Ed., United States Public Health Service, National Institutes of Health, Bethesda 22. 22. U.S. Published Patent Application 20060074225.

SEQUENCE LISTING

[0334]

<110> Strome, Scott E Schulze, Dan H Block, David S

<120> IMMUNOGLOBULIN CONSTANT REGION Fc RECEPTOR BINDING AGENTS <130> 70089.0021WOU1 <150> 60/941,644 <151 >2007-06-01 <150> 61/015,547 <151> 2007-12-20 <150 61/015,127 <151> 2007-12-19 <160> 98 <170> Patentln version 3.4 <210> 1 <211 > 699

<212> DNA <213> Homo sapiens <220> <221 > misc_feature <223> IgG 1 Fc domain <220> <221 > CDS <222> (1) .. (699) <400> 1 agt gag ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca 48

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 15 10 15 gca cct gaa etc ctg ggg gga ccg tea gtc ttc ctc ttc ccc cca aaa 96

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 20 " ^ 25 30 ccc aag gac acc ctc atg atc tee egg acc cct gag gtc aca tgc gtg 144

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 35 40 45 gtg gtg gac gtg age cac gaa gac cct gag gtc aag ttc aac tgg tac 192

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 50 55 60 gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg egg gag gag 240

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 65 70 75 80 cag tac aac age aeg tac egg gtg gtc age gtc ctc acc gtc ctg cac 288

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 85 90 95 cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tee aac aaa 336

Gin Asp Trp Leu Asn Giv Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 100 " 105 110 gcc ctc cca gcc ccc atc gag aaa acc atc tee aaa gcc aaa ggg cag 384

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin 115 120 125 ccc ega gaa cca cag gtg tac acc ctg ccc cca tee egg gat gag ctg 432

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 130 135 140 acc aag aac cag gtc age ctg acc tgc ctg gtc aaa ggc ttc tat ccc 480

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 145 150 155 160 age gac atc gcc gtg gag tgg gag age aat ggg cag ccg gag aac aac 528

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 165 170 175 tac aag acc aeg cct ccc gtg ctg gac tee gac ggc tee ttc ttc ctc 576

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 180 185 190 tac age aag ctc acc gtg gac aag age agg tgg cag cag ggg aac gtc 624

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 195 200 205 ttc tea tgc tee gtg atg cat gag get ctg cac aac cac tac aeg cag 672

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 210 " 215 220 aag age ctc tee ctg tct ccg ggt aaa 699

Lys Ser Leu Ser Leu Ser Pro Gly Lys 225 230 <210> 2 <211 > 233

<212> PRT <213> Homo sapiens <400>2

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 15 10 15 A.la Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 20 25 30

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 35 40 45

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 50 55 50

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 65 70 75 80

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 85 90 95

Gin A*sp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 100 105 110

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin 115 120 125

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 130 135 140

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 145 150 155 160

Ser A.sp Ile Ala Val Glu Trp Glu Ser A.sn Gly Gin Pro Glu A.sn Asn 155 170 175

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 180 185 190

Tyr Ser Lys Leu Thr Val Asp Lys Ser .Arg Trp Gin Gin Gly A.sn Val 195 200 205

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 210 215 220

Lys Ser Leu Ser Leu Ser Pro Gly Lys 225 230 <210> 3 <211 > 684

<212> DNA <213> Homo sapiens <220> <221 > misc_feature <223> lgG2 Fc domain <220> <221 > CDS <222> (1)..(684) <400>3 gag cgc aaa tgt tgt gtc gag tgc cca ccg tgc cca gca cca cct gtg 48

Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val 15 10 15 gca gga ccg tea gtc ttc etc ttc ccc cca aaa ccc aag gac ace etc 96

Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 atg ate tcc egg acc cct gag gtc aeg tgc gtg gtg gtg gac gtg age 144

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 cac gaa gac ccc gag gtc cag ttc aac tgg tac gtg gac ggc gtg gag 192

His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 gtg cat aat gcc aag aca aag cca egg gag gag cag ttc aac age aeg 240

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser Thr 65 70 75 80 ttc cgt gtg gtc age gtc etc acc gtt gtg cac cag gac tgg ctg aac 288

Phe Arg Val Val Ser Val Leu Thr Val Val His Gin Asp Trp Leu Asn 85 90 95 ggc aag gag tac aag tgc aag gtc tec aac aaa ggc etc cca gcc ccc 336

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro 100 105 110 ate gag aaa acc ate tec aaa acc aaa ggg cag ccc ega gaa cca cag 384 lie Glu Lys Thr lie Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro Gin 115 120 125 gtg tac acc ctg ccc cca tec egg gag gag atg acc aag aac cag gtc 432

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val 130 135 140 age ctg acc tgc ctg gtc aaa ggc ttc tac ccc age gac ate gcc gtg 480

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp lie Ala Val 145 150 155 160 gag tgg gag age aat ggg cag ccg gag aac aac tac aag acc aca cct 528

Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 ccc atg ctg gac tec gac ggc tec ttc ttc etc tac age aag etc acc 576

Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 " 185 " 190 gtg gac aag age agg tgg cag cag ggg aac gtc ttc tea tgc tec gtg 624

Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val 195 200 205 atg cat gag get ctg cac aac cac tac aeg cag aag age etc tec ctg 672

Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu 210 215 220 tet ccg ggt aaa 684

Ser Pro Gly Lys 225 <210> 4 <211 > 228

<212> PRT <213> Homo sapiens <400>4

Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val 15 10 15

Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 " 30

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45

His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser Thr 65 70 75 80

Phe Arg Val Val Ser Val Leu Thr Val Val His Gin Asp Trp Leu Asn 85 90 95

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala Pro 100 " 105 " 110

Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro Gin 115 120 125

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val 130 135 140

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160

Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro 155 170 175

Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190

Val .Asp Lys Ser Arg Trp Gin Gin Gly .Asn Val Phe Ser Cys Ser Val 195 200 205

Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu 210 215 220

Ser Pro Gly Lys 225 <210>5 <211 > 837

<212> DNA <213> Homo sapiens <220> <221 > misc_feature <223> lgG3 Fc domain <220> <221 > CDS <222> (1)..(837) <400> 5 gag etc aaa acc cca ett ggt gac aca act cac aca tgc cca egg tgc 48

Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys 15 10 15 cca gag ccc aaa tet tgt gac aca cct ccc ccg tgc cca egg tgc cca 96

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 20 25 30 gag ccc aaa tet tgt gac aca cct ccc cca tgc cca egg tgc cca gag 144

Glu Pro Lys Ser Cys -Asp Thr Pro Pro Pro Cys Pro -Arg Cys Pro Glu 35 40 45 ccc aaa tet tgt gac aca cct ccc cca tgc cca egg tgc cca gca cct 192

Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Ala Pro 50 55 60 gaa etc ctg gga gga ccg tea gtc ttc etc ttc ccc cca aaa ccc aag 240

Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 65 70 75 80 gat acc ett atg att tee egg acc cct gag gtc aeg tgc gtg gtg gtg 288

Asp Thr Leu Met lie Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 85 90 95 gac gtg age cac gaa gac ccc gag gtc cag ttc aag tgg tac gtg gac 336

Asp Val Ser His Glu .Asp Pro Glu Val Gin Phe Lys Trp Tyr Val Asp 100 105 110 ggc gtg gag gtg cat aat gee aag aca aag ccg egg gag gag cag ttc 384

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Phe 115 120 125 aac age aeg ttc cgt gtg gtc age gtc etc acc gtc ctg cac cag gac 432

Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp 130 135 140 tgg ctg aac ggc aag gag tac aag tgc aag gtc tee aac aaa gee etc 480

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 145 150 155 160 cca gee ccc ate gag aaa acc ate tee aaa acc aaa gga cag ccc ega 528

Pro Ala Pro lie Glu Lys Thr lie Ser Lys Thr Lys Gly Gin Pro Arg 165 170 175 gaa cca cag gtg tac acc ctg ccc cca tee egg gag gag atg acc aag 576

Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 180 185 190 aac cag gtc age ctg acc tgc ctg gtc aaa ggc ttc tac ccc age gac 624

Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 195 200 205 ate gee gtg gag tgg gag age age ggg cag ccg gag aac aac tac aac 672 lie Ala Val Glu Trp Glu Ser Ser Gly Gin Pro Glu .Asn Asn Tyr Asn 210 215 220 acc aeg cct ccc atg ctg gac tee gac ggc tee ttc ttc etc tac age 720

Thr Thr Pro Pro Met Leu Asp Ser A.sp Gly Ser Phe Phe Leu Tyr Ser 225 230 235 240 aag etc acc gtg gac aag age agg tgg cag cag ggg aac ate ttc tea 768

Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn lie Phe Ser 245 250 255 tgc tee gtg atg cat gag get ctg cac aac ege ttc aeg cag aag age 816

Cys Ser Val Met His Glu Ala Leu His .Asn Arg Phe Thr Gin Lys Ser 260 265 270 etc tee ctg tet ccg ggt aaa 837

Leu Ser Leu Ser Pro Gly Lys 275 <210> 6 <211> 279

<212> PRT <213> Homo sapiens <400>6

Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys 15 10 15

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 20 25 30

Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu 35 40 45

Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Ala Pro 50 55 50

Glu Leu Leu Gly Giv Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 65 70 75 80

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 85 90 95

Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Lys Trp Tyr Val Asp 100 105 110

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Phe 115 120 125

Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp 130 135 140

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 145 150 155 160

Pro Ala Pro Ils Glu Lys Thr Ile Ser Lys Thr Lys Gly Gin Pro Arg 155 170 175

Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 180 185 190

Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 195 200 205

Ile Ala Val Glu Trp Glu Ser Ser Gly Gin Pro Glu Asn Asn Tyr Asn 210 215 220

Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 225 230 235 " 240

Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Ile Phe Ser 245 250 255

Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr Gin Lys Ser 260 265 270

Leu Ser Leu Ser Pro Gly Lys 275 <210>7 <211 > 687

<212> DNA <213> Homo sapiens <220> <221 > misc_feature <223> lgG4 Fc domain <220> <221 > CDS <222> (1)..(687) <400>7 gag tcc aaa tat ggt ccc ccg tgc cca tea tgc cca gca cct gag ttc 48

Glu Ser Lys Tyr Gly Pro Pro Cvs Pro Ser Cys Pro Ala Pro Glu Phe 15 10 15 ctg ggg gga cca tea gtc ttc ctg ttc ccc cca aaa ccc aag gac act 96

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 etc atg ate tcc egg acc cct gag gtc aeg tgc gtg gtg gtg gac gtg 144

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 age cag gaa gac ccc gag gtc cag ttc aac tgg tac gtg gat ggc gtg 192

Ser Gin Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 gag gtg cat aat gcc aag aca aag ccg egg gag gag cag ttc aac age 240

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser 65 70 75 80 aeg tac cgt gtg gtc age gtc etc acc gtc gtg cac cag gac tgg ctg 288

Thr Tyr Arg Val Val Ser Val Leu Thr Val Val His Gin Asp Trp Leu 85 90 95 aac ggc aag gag tac aag tgc aag gtc tcc aac aaa ggc etc ccg tcc 336

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 * * * * 105 " * 110 tcc ate gag aaa acc ate tcc aaa gcc aaa ggg cag ccc ega gag cca 384

Ser lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 115 " 120 " 125 cag gtg tac acc ctg ccc cca tcc cag gag gag atg acc aag aac cag 432

Gin Val Tyr Thr Leu Pro Pro Ser Gin Glu Glu Met Thr Lys Asn Gin 130 135 140 gtc age ctg acc tgc ctg gtc aaa ggc ttc tac ccc age gac ate gcc 480

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp lie Ala 145 150 155 160 gtg gag tgg gag age aat ggg cag ccg gag aac aac tac aag acc aeg 528

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc etc tac age agg eta 576

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 " 185 190 acc gtg gac aag age agg tgg cag gag ggg aat gtc ttc tea tgc tcc 624

Thr Val Asp Lys Ser Arg Trp Gin Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 gtg atg cat gag get ctg cac aac cac tac aeg cag aag age etc tcc 672

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 210 215 220 ctg tet ctg ggt aaa 687

Leu Ser Leu Gly Lys 225 <210> 8 <211 > 229

<212> PRT <213> Homo sapiens <400>8

Leu biy biy Fro ser var Fne neu Fne Fro Fro rys Fro nys Asp inr 20 25 " 30

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45

Ser Gin Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr Val Asp Gly Val 50 55 60

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser 65 70 75 80

Thr Tyr Arg Val Val Ser Val Leu Thr Val Val His Gin Asp Trp Leu 85 90 95

Asn Giv Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110

Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 115 120 125

Gin Val Tyr Thr Leu Pro Pro Ser Gin Glu Glu Met Thr Lys Asn Gin 130 135 140

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 155 170 175

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190

Thr Val Asp Lys Ser -Arg Trp Gin Glu Gly Asn Val Phe Ser Cys Ser 195 200 205

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 210 215 220

Leu Ser Leu Gly Lys 225 <210>9 <211> 48

<212> DNA <213> Homo sapiens <220> <221 > misc_feature <223> IgG 1 hinge region <220> <221 > CDS <222> (1)..(48) <400>9 agt gag ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca 48

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 15 10 15 <210> 10 <211> 16

<212> PRT <213> Homo sapiens <400> 10

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 15 10 15 <210 11 <211> 36

<212> DNA <213> Homo sapiens <220 <221 > misc_feature <223> lgG2 hinge region <220 <221 > CDS <222> (1)..(36) <400 11 gag cgc aaa tgt tgt gtc gag tgc cca ccg tgc cca 36

Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro 1 5 10 <210> 12 <211 > 12

<212> PRT <213> Homo sapiens <400> 12

Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro 1 5 10 <210 13 <211 > 186

<212> DNA <213> Homo sapiens <220 <221 > misc_feature <223> lgG3 hinge region <220 <221 > CDS <222> (1)..(186) <400 13 gag etc aaa acc cca ctt ggt gac aca act cac aca tgc cca cgg tgc 48

Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys 15 10 15 cca gag ccc aaa tct tgt gac aca cct ccc ccg tgc cca cgg tgc cca 96

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 20 " 25 "30 gag ccc aaa tct tgt gac aca cct ccc cca tgc cca cgg tgc cca gag 144

Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu 35 40 45 ccc aaa tct tgt gac aca cct ccc cca tgc cca cgg tgc cca 186

Pro Lys Sør Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 50 55 60 <210> 14 <211 > 62

<212> PRT <213> Homo sapiens <400> 14

Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys 15 10 15

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 20 25 30

Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu 35 40 45

Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 50 55 60 <210> 15 <211> 36

<212> DNA <213> Homo sapiens <220> <221 > misc_feature <223> lgG4 hinge region <220> <221 > CDS <222> (1)..(36) <400> 15 gag tcc aaa tat ggt ccc ccg tgc cca tea tgc cca 36

Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro 1 5 10 <210> 16 <211 > 12

<212> PRT <213> Homo sapiens <400> 16

Glu Ser Lys Tyr Gly Pro Pro CVS Pro Ser Cys Pro 1 5 10

<210> 17 <211>1588 <212> DNA <213> Artificial Sequence <220> <223> lgK/lgG1 Fc/lgG1 Fc <220> <221 > CDS <222> (45)..(1550) <400> 17 gtcagttaag cttggtaccg ageteggate cagtaccctt cacc atg gag aca gac 56

Met Glu Thr Asp 1 aca ctc ctg eta tgg gta ctg ctg etc tgg gtt cca ggt tcc act ggt 104

Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly Ser Thr Gly 5 10 15 20 gac gcg gea gat atc cag cac agt ggc ggc cgc teg agt gag ccc aaa 152

Asp Ala Ala Asp Ile Gin His Ser Gly Gly Arg Ser Ser Glu Pro Lys 25 30 35 tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc 200

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 40 45 50 ctg ggg gga ccg tea gtc ttc ctc ttc ccc cca aaa ccc aag gac acc 248

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Prc Lys Asp Plir 55 60 65 etc atg ate tee egg acc cct gag gtc aca tgc gtg gtg gtg gac gtg 296

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 70 75 00 age cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg 344

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 35 90 95 100 gag gtg cat aat gcc aag aca aag ccg egg gag gag cag tac aac age 392

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 105 110 115 acq tac egg gtg gtc age gtc ctc acc gtc ctg cac caq gac tgg ctg 440

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 120 125 130 aat ggc aag gag tac aag tgc aag gtc tee aac aaa gcc ctc cca gcc 488

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 135 140 145 ccc ate gag aaa acc atc tee aaa gcc aaa ggg cag ccc ega gaa cca 536

Prc Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Prc A.rg Glu Pro 150 155 150 cag gtg tac acc ctg ccc cca tee egg gat gag ctg acc aag aac cag 584

Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin 165 170 175 _30 gtc age ctg acc tgc ctg gtc aaa ggc t.t.c tat ccc age gac atc gcc 637

Val Ser Leu Tiir Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile A_a 185 190 195 gtg gag tgg gag age aat ggg cag ccg gag aac aac tac aag acc aeg 680

Val Glu Trp Glu Ser Asn Gly G_n Pro Glu Asn Asn Tyr Lys Thr Thr 200 205 210 cct ccc gtg ctg gac tee gac ggc tee ttc tee etc tac age aag ctc 728

Prc Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 215 220 225 acc gtg gac aag age agg tgg cag cag ggg aac gtc ttc tea tgc tee 776

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 230 235 240 gtg atg can gag get ctg cac aac cac tac aeg cag aag age ctc tee 824

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 245 250 255 260 ctg tct ccg ggt aaa agt eta gac ccc aaa tct tgt gac aaa act cac 872

Leu Ser Pro Gly Ly3 Ser Leu A3p Pro Ly3 Ser Cy3 A3p Ly3 Thr Hi3 265 270 275 aca tgc cca ccg tgc cca gca cct gaa etc eng ggg gga ccg tea gtc 920

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 280 285 290 ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc 968

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 295 300 305 cct gag gtc aca tgc gtg gtg gtg gac gtg age cac gaa gac cct gag 1016

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 310 315 320 gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag 1054

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 325 " 330 " 335 340 aca aag ccg cgg gag gag cag tac aac age aeg tac cgg gtg gtc age 1112

Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser 345 350 355 gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag 1160

Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys 360 365 370 tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc 1208

Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 375 380 385 tcc aaa gcc aaa ggg cag ccc ega gaa cca cag gtg tac acc ctg ccc 1256

Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro 390 " " 395 400 cca tcc cgg gat gag ctg acc aag aac cag gtc age ctg acc tgc ctg 1304

Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu 405 410 415 420 gtc aaa ggc ttc tat ccc age gac atc gcc gtg gag tgg gag age aat 1352

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 425 430 435 ggg cag ccg gag aac aac tac aag acc aeg cct ccc gtg ctg gac tcc 1400

Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 440 445 450 gac ggc tcc ttc ttc ctc tac age aag ctc acc gtg gac aag age agg 1448

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 455 460 465 tgg cag cag ggg aac gtc ttc tea tgc tcc gtg atg cat gag get ctg 1496

Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 470 475 480 cac aac cac tac aeg cag aag age ctc tcc ctg tet ccg ggt aaa acc 1544

His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Thr 485 490 495 500 ggt tga catcatcacc atcaccattg atgagttaaa cccgctga 1588

Gly

<210> 18 <211 > 501 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 18

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Gin His Ser Gly Gly Arg Ser 20 25 30~

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 35 40 45

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 50 55 60

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 65 70 75 30

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 85 90 " 95

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 100 105 110

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 115 120 125

Gin A*sp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 130 135 140

Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin 145 150 155 160

Pro A*rg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 165 170 175

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 180 185 190

Ser A.sp lie Ala Val Glu Trp Glu Ser A.sn Gly Gin Pro Glu A.sn Asn 195 200 205

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Giv Ser Phe Phe Leu 210 215 220

Tyr Ser Lys Leu Thr Val Asp Lys Sør Arg Trp Gin Gin Gly Asn Val 225 230 235 240

Phe Sar Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 215 250 255

Lys Sar Lou Sør Lou Sør Pro Gly Lys Sor Løu Asp Pro Lys Sor Cys 260 265 270

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 275 280 285

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 290 295 300

Ile Sør Arc Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 305 310 315 320

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 325 330 335

His .Asn Ala Lys Thr Lys Pro .Arg Gin Glu Gin Tyr Asn Ser Thr Tyr 340 345 350

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 355 360 365

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 370 375 380

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 385 390 395 400

Tyr Thr Leu Pro Pro Ser Arg A3p Gin Leu Thr Ly3 A3n Gin Val Ser 405 410 415

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 420 425 430

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 435 440 445

Val Leu A3p Ser A3p Gly Ser Phe Phe Leu Tyr Ser Lv3 Leu Thr Val 450 455 460 A.sp Lvs Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 465 470 475 480

His Glu Ala Leu His .Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 485 490 495

Pro Gly Lys Thr Gly 500

<210> 19 <211> 952 <212> DNA <213> Artificial Sequence <220> <223> IgG 1 monomer sequence <220> <221 > CDS <222> (45)..(932) <400> 19 gtcagttaag cttggtaccg agctcggatc cagtaccctt cacc atg gag aca gac 56

Met Glu Thr Asp 1 aca ctc ctg eta tgg gta ctg ctg etc tgg gtt cca ggt tee act ggt 104

Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly Ser Thr Gly 5 10 15 20 gac gcg gea gat atc cag cac agt ggc ggc ege teg agt gag ccc aaa 152

Asp Ala Ala Asp Ile Gin His Ser Gly Gly Arg Ser Ser Glu Pro Lys 25 30 35 tet tgt gac aaa act cac aca tgc cca ccg tgc cca gea eet gaa etc 200

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 40 45 50 ctg ggg gga ccg tea gtc tte etc tte ccc cca aaa ccc aag gac acc 248

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 55 60 65 etc atg ate tee egg acc eet gag gtc aca tgc gtg gtg gtg gac gtg 296

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 70 75 80 age cac gaa gac eet gag gtc aag tte aac tgg tac gtg gac ggc gtg 344

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 85 90 95 100 gag gtg cat aat gcc aag aca aag ccg egg gag gag cag tac aac age 392

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 105 110 115 aeg tac egg gtg gtc age gtc etc acc gtc ctg cac cag gac tgg ctg 440

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 120 125 130 aat ggc aag gag tac aag tgc aag gtc tee aac aaa gee etc cca gcc 488

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 135 140 145 ccc ate gag aaa acc ate tee aaa gcc aaa ggg cag ccc ega gaa cca 536

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 150 155 160 cag gtg tac acc ctg ccc cca tee egg gat gag ctg acc aag aac cag 584

Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin 165 170 175 180 gtc age ctg acc tgc ctg gtc aaa ggc tte tat ccc age gac atc gcc 632

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 185 * " 190 195 gtg gag tgg gag age aat ggg cag ccg gag aac aac tac aag acc aeg 680

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 200 205 210 eet ccc gtg ctg gac tee gac ggc tee tte tte etc tac age aag etc 728

Pro Pro Val Leu Asp Ser Asp Giv Ser Phe Phe Leu Tyr Ser Lys Leu 215 220 225 acc gtg gac aag age agg tgg cag cag ggg aac gtc tte tea tgc tee 776

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 230 235 240 gtg atg cat gag get ctg cac aac cac tac aeg cag aag age etc tee 824

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 245 250 255 250 ctg tet ccg ggt aaa agt eta gag ggc ccg egg tte gaa ggt aag eet 872

Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe Glu Gly Lys Pro 265 270 275 atc eet aac eet etc etc ggt etc gat tet aeg egt acc ggt cat cat 920

Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr Gly His His 280 285 290 cac cat cac cat tgatgagtta aacccgctga 952

His His His His 295

<210> 20 <211 > 296 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 20

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Giv Ser Thr Gly Asp Ala Ala Asp Ile Gin His Ser Giv Gly Arg Ser 20 25 30

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 35 40 45 -Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 50 55 60

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 65 70 75 80

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 85 90 95

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 100 105 110

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 115 120 125

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 130 135 140

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin 145 150 155 160

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 155 170 175

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 180 185 190

Ser A-sp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 195 200 205

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 210 215 220

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 225 230 235 240

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 245 250 255

Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe 260 265 270

Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg 275 280 285

Thr Gly His His His His His His 290 295

<210>21 <211> 1588 <212> DNA <213> Artificial Sequence <220> <223> IgG 1 dimer sequence without tags <220> <221 > CDS <222> (45)..(1550) <400> 21 gtcagttaag cttggtaccg agctcggatc cagtaccctt cacc atg gag aca gac 56

Met Glu Thr Asp 1 aca ctc ctg eta tgg gta ctg ctg etc tgg gtt cca ggt tee act ggt 104

Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Giv Ser Thr Gly 5 10 15 20 gac gcg gea gat atc cag cac agt ggc ggc ege teg agt gag ccc aaa 152

Asp Ala Ala Asp Ile Gin His Ser Giv Giv Arg Ser Ser Glu Pro Lvs 25 30 35 tet tgt gac aaa act cac aca tgc cca ccg tgc cca gea eet gaa etc 200

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 40 45 50 ctg ggg gga ccg tea gtc tte etc tte ccc cca aaa ccc aag gac acc 248

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 55 60 65 etc atg ate tee egg acc eet gag gtc aca tgc gtg gtg gtg gac gtg 296

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 70 75 80 age cac gaa gac eet gag gtc aag tte aac tgg tac gtg gac ggc gtg 344

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 85 90 95 100 gag gtg cat aat gcc aag aca aag ccg egg gag gag cag tac aac age 392

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 105 110 115 aeg tac egg gtg gtc age gtc etc acc gtc ctg cac cag gac tgg ctg 440

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 120 125 130 aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc 488

Asn Gly Lys Glu Tyr Lys Gys Lys Val Sar Asn Lvs Ala Lau Pro Ala 135 " 140 " 145 ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca 536

Prc Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Frc -Arg Glu Pro 150 155 160 cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag 584

Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lvs Asn G_n 165 * 170 175 ~ 180 gtc age ctg acc tgc ctg gtc aaa ggc ttc tat ccc age gac atc gcc 632 val Ser Leu Thr Gys Leu val Lys Gly Phe lyr Pro Ser -Asp ile Ala 185 190 195 gtg gag tgg gag age aat ggg cag ccg gag aac aac tac aag acc aeg 680

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 200 " 2C5 " 210 cct ccc gtg ctg gac tcc gac ggc tcc ttc tcc ctc tac age aag ctc 728

Prc Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 215 220 225 acc gtg gac aag age agg tgg cag cag ggg aac gtc ttc tea tgc tcc 775

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn val Fhe Ser Cys Ser 230 ’ 235 ’ 240 gtg atg cac gag get ctg cac aac cac tac aeg cag aag age ctc tcc 824

Val Met Hi3 Glu Ala Leu H13 A3n H13 Tyr Thr Gin Ly3 Ser Leu Ser 245 250 255 260 ctg tet ccg ggt aaa agt eta gac ccc aaa tet tgt gac aaa act cac 872

Leu Ser Pro Gly Lys Ser Leu Asp Pro Lys Ser Cys Asp Lys Thr H:s 265 270 275 aca tgc cca ccg tgc cca gea cct gaa etc ctg ggg gga ccg tea gtc 920

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 280 285 290 ttc ctc ttc ccc cca aaa ccc aag gac acc czc atg atc tcc cgg acc 968

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 295 300 305 cct gag gtc aca tgc gtg gtg gtg gac gtg age cac gaa gac cct gag 1016

Prc Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 310 315 320 gtc aag ttc aac tgg tac gtg gac gcc gtg gag gtg cat aat gcc aag 1064

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 325 330 335 340 aca aag ccg cgg gag gag cag tac aac age aeg tac cgg gtg gtc age 1112

Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser 345 350 355 gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag 1160 val Leu Thr val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys 360 365 370 tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc 1208

Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 375 380 385 tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc 1256

Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro 390 395 400 cca tcc cgg gat gag ctg acc aag aac cag gtc age ctg acc tgc ctg 1304

Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu 405 410 415 420 gtc aaa ggc ttc tat ccc age gac atc gcc gtg gag tgg gag age aat 1352

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 425 430 435 ggg cag ccg gag aac aac tac aag acc aeg cct ccc gtg ctg gac tcc 1400

Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 440 445 450 gac ggc tcc ttc ttc ctc tac age aag ctc acc gtg gac aag age agg 1448

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 455 460 465 tgg cag cag ggg aac gtc ttc tea tgc tcc gtg atg cat gag get ctg 1496

Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 470 475 480 cac aac cac tac aeg cag aag age ctc tcc ctg tet ccg ggt aaa acc 1544

His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Thr 485 490 495 500 ggt tga catcatcacc atcaccattg atgagttaaa cccgctga 1588

Gly

<210> 22 <211 > 501 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 22

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Gin His Ser Gly Gly Arg Ser 20 25 30

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 35 40 45

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 50 5ο 50

Pro Lys Asp Thr Len Mot Ilo Ser Arg Thr Pro Glu Val Thr Gys Val 55 70 75 80

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 85 90 95

Val Asp Giv Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 100 105 110

Gin Tyr Asn Ser Thr Tyr Arg Val val Ser val Leu Thr Val Leu Hrs 115 120 125

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ger Asn Lys 130 135 " 140

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin 145 150 * 155 " 160

Pro Arg Glu Pro Gin val Tyr Thr Len Pro Pro Ser Arg Asp Glu Leu 155 170 175

Thr Ly3 A3n Gin Val Ser Leu Thr Cy3 Leu Val Ly3 Gly Phe Tyr Pro 180 185 190

Ser Asp Tie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn A.sn 195 200 205

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 210 215 220

Tyr Ser Lys Leu Thr Val .Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 225 230 235 240

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 245 250 255

Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Asp Pro Lys Ser Cys 260 265 270

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 275 280 285

Gly Pro Ser val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 290 295 300

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 305 310 " 315 320

Glu Asp Pro Glu Val Lys Plie Asn Trp Tyr Val Asp Giv Val Glu Val 325 330 335

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 340 345 350

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 355 360 365

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 370 375 380

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 385 390 395 400

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser 405 410 415

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 420 425 430

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 435 440 445

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 450 455 460 -Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 465 470 475 480

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 485 490 495

Pro Gly Lys Thr Gly 500

<210> 23 <211> 1636 <212> DNA <213> Artificial Sequence <220> <223> IgG 1 dimer sequence with epitope tags <220> <221 > CDS <222> (45)..(1616) <400> 23 gtcagttaag cttggtaccg agctcggatc cagtaccctt cacc atg gag aca gac 56

Met Glu Thr Asp 1 aca ctc ctg eta tgg gta ctg ctg etc tgg gtt cca ggt tee act ggt 104

Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Giv Ser Thr Gly 5 10 15 20 gac gcg gea gat atc cag cac agt ggc ggc ege teg agt gag ccc aaa 152

Asp Ala Ala Asp Ile Gin His Ser Gly Gly Arg Ser Ser Glu Pro Lys 25 30 35 tet tgt gac aaa act cac aca tgc cca ccg tgc cca gea eet gaa etc 200

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 40 45 50 ctg ggg gga ccg tea gtc tte etc tte ccc cca aaa ccc aag gac acc 248

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 55 60 65 etc atg ate tee egg acc eet gag gtc aca tgc gtg gtg gtg gac gtg 296

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 70 75 80 age cac gaa gac eet gag gtc aag tte aac tgg tac gtg gac ggc gtg 344

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 85 90 * 95 " 100 gag gtg cat aat gcc aag aca aag ccg egg gag gag cag tac aac age 392

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 105 110 115 aeg tac egg gtg gtc age gtc etc acc gtc ctg cac cag gac tgg ctg 440

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 120 125 130 aat ggc aag gag tac aag tgc aag gtc tee aac aaa gee etc cca gcc 488

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 135 140 145 ccc ate gag aaa acc ate tee aaa gcc aaa ggg cag ccc ega gaa cca 536

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 150 155 160 cag gtg tac acc ctg ccc cca tee egg gat gag ctg acc aag aac cag 584

Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin 165 " 170 175 " 180 gtc age ctg acc tgc ctg gtc aaa ggc tte tat ccc age gac atc gcc 632

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 185 190 195 gtg gag tgg gag age aat ggg cag ccg gag aac aac tac aag acc aeg 680

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr cct ccc gtg ctg gac tcc gac ggc tcc tt c tic etc tac age aag etc 728

Pre Pro Val Lau Asp Sar Asp Gly Sar Pha Pha Lau Tyr Sar Lys Lau 215 220 225 acc gtg gac aag age agg tgg cag cag ggg aac gtc tte tea tgc tcc 776

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Fhe Ser Cys Ser 230 235 240 gtg atg cat gag get ctg cac aac cac tac aeg cag aag age etc tcc 824

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 245 250 255 260 ctg tet ccg ggt aaa agt eta gac ccc aaa tet tgt gac aaa act cac 872

Leu Ser Pro Gly Lys Ser Leu Asp Pro Lys Ser Cys Asp Lys Thr Hls 265 270 275 aca tgc cca ccg tgc cca gea cct gaa etc ctg ggg gga ccg tea gtc 920

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 280 " 285 " 290 tte etc tte ccc cca aaa ccc aag gac acc etc atg ate tee egg acc 968

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 295 * 300 305 cct gag gtc aca tgc gtg gtg gtg gac gtg age cac gaa gac cct gag 1015

Pre Glu val Thr Cys val val val Asp val Ser His Glu Asp ?ro Glu 310 " 315 320 gtc aag tte aac tgg tac gtg gac gee gtg gag gtg cat aat gcc aag 1064

Val Ly3 Phe A311 Trp Tyr Val A3p Gly Val Glu Val Hi3 A3n Ala Ly3 325 330 335 340 aca aag ccg egg gag gag cag tac aac age aeg tac egg gtg gtc age 1112

Thr T,ys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser 345 350 355 gtc etc acc gtc ctg cac cag gac teg ctg aat ggc aag gag tac aag 1160

Val Leu Thr Val Leu His Gin Asp Trp Leu .Asn Gly Lys Glu Tyr Lys 360 365 370 tgc aag gtc tee aac aaa gee etc cca gee ccc ate gag aaa acc atc 1208

Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr ILe 375 380 385 tcc aaa gcc aaa ggg cag ccc ega gaa cca cag gtg tac acc ctg ccc 1256

Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro 390 395 400 cca tcc egg gat gag ctg acc aag aac cag gcc age ctg acc tgc ctg 1304

Pre Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu 405 410 415 420 gtc aaa ggc tte tat ccc age gac atc gcc gcg gag tgg gag age aat 1352

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 425 430 435 ggg cag ccg gag aac aac tac aag acc aeg cct ccc gtg ctg gac tcc 1400

Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro val Leu Asp Ser 440 445 450 gac ggc tcc tte tte etc tac age aag etc acc gtg gac aag age agg 1448

Asp Giv Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 455 460 465 tgg cag cag ggg aac gtc tte tea tgc tee gtg atg cat gag get ctg 1496

Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 470 475 480 cac aac cac tac aeg cag aag age etc tcc ctg tet ccg ggt aaa tte 1544

His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Phe 485 490 495 500 gaa ggt aag cct ate cct aac cct etc etc ggt etc gat tet aeg egt 1592

Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu -Asp Ser Thr Arg 505 510 515 acc ggt cat cat cac cat cac cat tgatgagtta aacccgctga 1636

Thr Gly His His His His His His 520

<210> 24 <211> 524 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 24

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Gin His Ser Gly Gly Arg Ser 20 25 30

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 35 40 45

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 50 55 60

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 65 70 75 80

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 85 90 95

Val A.sp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 100 105 110

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 115 120 125

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 130 135 140

Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin 145 150 155 160

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 165 170 175

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 180 185 190

Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 195 200 205

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 210 215 220

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 225 230 235 240

Phe Ser Cys Ser Val Met His Clu Ala Leu His Asn His Tyr Thr Gin 245 250 255

Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Asp Pro Lys Ser Cys 260 265 270

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 275 280 285

Gly Pro Scr Val Phe Lou Pho Pro Pro Lys Pro Lys Asp Thr Leu Mot 290 295 300

Tie Ser Arc Thr Pro Glu Val Thr Cys Val Val Va' Asp Val Ser His 305 310 315 320

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val .Asp Gly Val Glu Val 325 330 335

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 340 345 350

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 355 360 365

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 370 375 380

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 385 390 395 400

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser 405 410 415

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 420 425 430

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 435 440 445

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 450 455 460

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 465 470 475 480

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 485 490 495

Pro Gly Lys Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu 500 505 510

Asp Ser Thr Arg Thr Gly His His His His His His 515 520

<210> 25 <211> 1763 <212> DNA <213> Artificial Sequence <220> <223> lgG3/lgG1 dimer sequence with epitope tags <220> <221 > CDS <222> (45)..(1760) <400> 25 gtcagttaag cttggtaccg agctcggatc cagtaccctt cacc atg gag aca gac 56

Met Glu Thr Asp 1 aca etc ctg eta tgg gta ctg ctg etc tgg gtt cca ggt tee act ggt 104

Hir Leu Leu Leu Trp Yal Leu Leu Leu Trp Val Pro Gly Ser Thr Gly 5 10 15 20 gac gcg gca gat ate gag etc aaa acc cca cut ggt gac aca act cac 152

Asp Ala Ala Asp lie Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His 25 30 35 aca tgc cca egg tgc cca gag ccc aaa tet tgt gac aca cct ccc ccg 200

Thr Cys Pro Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro ΊΟ Ί5 50 tgc cca egg tgc cca gag ccc aaa tet tgt gac aca cct ccc cca tgc 248

Cys Pro Arg Cys Pro Glu Pro Lys Sor Cys .Asp Thr Pro Pro Pro Cys 55 60 65 cca egg tgc cca gag ccc aaa tet tet gac aca cct ccc cca tgc cca 296

Pro Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro 70 75 80 egg tgc cca gca cct gaa etc ctg gca gga ccg tea gtc ttc etc ttc 344

Arg Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 85 90 95 100 ccc cca aaa ccc aag gat acc ett atg att tee egg acc cct gag gtc 392

Pre Pro Lys Pro Lys Asp Thr Leu Met lie Sor Arg Thr Pro Glu Val 105 110 115 aeg tgc gtg gtg gtg gac gtg age cac gaa gac ccc gag gtc cag ttc 440

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin Phe 120 125 130 aag tgg tac gtg gac ggc gtg gag gtg cat aat gee aag aca aag ccg 488

Lys Trp Tyr Val Asp Gly Val G_u Val His Asn Ala Lys Thr Lys Pro 135 140 145 egg gag gag cag ttc aac age aeg ttc cgt gcg gtc age gtc etc acc 536 ?irg Glu Glu Gin Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr 150 155 160 gtc ctg cac cag gac tgg ctg aac ggc aag gag tac aag tgc aag gtc 584

Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 165 170 175 180 tee aac aaa gee etc cca gee ccc ate gag aaa acc ate tee aaa acc 632

Ser .Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Thr 185 190 195 aaa gga cag ccc ega gaa cca cag gtg tac acc ctg ccc cca tee egg 680

Ly3 Gly7 Gin Pro Arg Glu Pro Gin Val Ty7r Thr Leu Pro Pro Ser Arg 200 2C5 210 gag gag atg acc aag aac cag gtc age ctg acc tgc ctg gtc aaa ggc 728

Glu Glu Mec Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys GLy 215 220 225 ttc tac ccc age gac ate gee gtg gag tgg gag age age ggg cag ccg 776

Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Ser Gly Gin Pro 230 235 240 gag aac aac tac aac acc aeg cct ccc atg ccg gac tee gac ggc tee 824

Glu Α31Ί A3n T\?r Asn Thr Thr Pro Pro Met Leu A3p Ser A3p Gly Ser 245 250 2o5 260 ttc ttc ctc tac age aag etc acc gtg gac aag age agg tgg cag cag 872

Phe Phe Lau Tyr Oar Lys Lau Thr Val Asp Lys Sar Arg Trp Gin Gin 265 270 275 ggg aac ate ttc tea tgc tee gtg atg cat gag get ctg cac aac ege 920

Gly Asn Ile Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg 280 * 285 290 ttc aeg cag aag age etc tee ctg tet ccg ggt aaa ggc ggc ege teg 968

Phe Thr Gin Lys Ser Leu Ser Leu Ser Pro Giv Lys Gly Giv Arg Ser 295 ^ 300 ‘ 305 agt gag cec aaa tet tgt gac aaa act cac aca tgc cca ccg tgc cca 1016

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 310 315 320 gea eet gaa etc ctg ggg gga ccg tea gtc ttc etc ttc ccc cca aaa 1064

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 325 330 " 335 340 ccc aag gac acc etc atg atc tee ccg acc eet gag gtc aca tgc gtg 1112

Pre Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 345 350 355 gtg gtg gac gtg age cac gaa gac eet gag gtc aag ttc aac tgg tac 1160 val val Asp val Ser His Glu Asp Pro Glu val Lys Fhe Asn Trp Tyr 360 365 370 gtg gac ggc gtg gag gtg cat aat gee aag aca aag ccg egg gag gag 1200

Val A3p Gly Val Glu Val Hi3 A311 Ala Ly3 Thr Ly3 Pre Arg Glu Glu 375 380 385 cag tac aac age aeg tac egg gtg gtc age gtc etc acc gtc ctg cac 1256

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Len Thr Val Len H:s 390 395 400 cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tee aac aaa 1304

Gin .Asp Trp Leu Asn Gly Lys G_u Tyr Lys Cys Lys Val Ser Asn Lys 405 410 415 420 gee etc cca gee ccc ate gag aaa acc ate tee aaa gcc aaa ggg cag 1352

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin 425 430 435 ccc ega gaa cca cag gtg tac acc ctg ccc cca tee egg gat gag ctg 1400

Pre Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Len 440 445 450 acc aag aac cag gtc age ctg acc tee ctg gtc aaa ggc ttc tat ccc 1448

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 455 460 465 age gac atc gcc gtg gag tgg gag age aat ggg cag ccg gag aac aac 1496

Ser Asp Ile Ala Val Glu Irp G_u Ser Asn Gly Gin Fre Glu Asn Asn 470 475 480 tac aag acc aeg eet ccc gtg ctg gae tee gae ggc tee tte tto etc 1544

Tyr Lys Thr Thr Pro Pro val Løu Asp Ser .Asp Gly Ser Phe Phe Leu 485 490 495 500 tac age aag etc acc gtg gac aag age agg tgg cag cag ggg aac gtc 1592

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 505 510 515 ttc tea tgc tee gtg atg cat gag get ctg cac aac cac tac aeg cag 1640

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 520 525 530 aag age etc tee ctg tet ccg ggt aaa agt eta gag ggc ccg egg ttc 1688

Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe 535 540 545 gaa ggt aag eet atc eet aac eet etc etc ggt etc gat tet aeg egt 1736

Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg 550 555 560 acc ggt cat cat cac cat cac cat tga 1763

Thr Gly His His His His His His 565 570

<210> 26 <211> 572 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 26

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp lie Glu Leu Lys Thr Pro Leu Gly 20 25 30

Asp Thr Thr His Thr Cys Pro Arg Cvs Pro Glu Pro Lys Ser Cys Asp 35 40 45

Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr 50 55 60

Pro Pro Pro Cys Pro Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro 65 70 75 80

Pro Pro Cys Pro Arg Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 85 90 95

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg 100 105 110

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 115 120 125

Glu Val Gin Phe Lys Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 130 135 140

Lys Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser Thr Phe Arg Val Val 145 150 155 160

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 165 170 175

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr 180 185 190 lie Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 195 200 205

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 210 215 220

Leu Val Lys Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser 225 230 235 240

Ser Gly Cln Pro Clu Aon Aon Tyr Asn Thr Thr Pro Pro Met Leu Ago 245 250 255

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 260 265 270

Arg Trp Gin Gin Gly Asn lie Phe Ser Cys Ser Val Met His Glu Ala 275 280 285

Leu His Asn Arg Phe Thr Gin Lys Ser Leu Sor Lou Scr Pro Gly Lys 290 295 300

Gly Gly Arc Ser Ser Glu Pro Lys Ser Cys Asp T,ys Thr His Thr Cys 305 310 315 320

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 325 330 335

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu 340 345 350

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 355 360 365

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 370 375 380

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 385 390 395 400

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 405 410 415

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 420 425 430

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 435 440 445

Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys 450 455 450

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin 465 470 475 480

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 485 490 495

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 500 505 510

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 515 520 525

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu 530 535 540

Gly Pro Arg Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu 545 550 555 560

Asp Ser Thr Arg Thr Gly His His His His His His 565 570

<210> 27 <211 >2224 <212> DNA <213> Artificial Sequence <220> <223> lgE(CH2)/lgGI(hinge-CH2-CH3)/lgGI (hinge-CH2)/lgE(CH4) fusion without epitope tags <220> <221 > CDS <222> (45)..(2183) <400> 27 tg eta tgg gta ctg ctg etc tgg gtt cca ggt tee act ggt iu4 eu Leu Trp Val Leu Leu Leu Trp Val Pro Giv Ser Thr Gly 10 15 20 ca gat atc gtc tgc tee agg gac tte acc ccg ccc acc gtg 152 la Asp Ile Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val 25 30 35 ta cag teg tee tgc gac ggc ggc ggg cac tte ccc ccg acc 200 eu Gin Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr 40 45 50 te ctg tgc etc gtc tet ggg tac acc cca ggg act atc aac 248 eu Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile Asn 5 60 65 gg ctg gag gac ggg cag gtc atg gac gtg gac ttg tee acc 296 rp Leu Glu Asp Gly Gin Val Met Asp Val Asp Leu Ser Thr 75 80 cc aeg cag gag ggt gag ctg gee tee aca caa age gag etc 344 hr Thr Gin Glu Gly Glu Leu A.la Ser Thr Gin Ser Glu Leu 90 95 100 gc cag aag cac tgg ctg tea gac ege acc tac acc tgc cag 392 er Gin Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Cys Gin 105 110 115 at caa ggt cac acc ttt gag gac age acc aag aag tgt gea 440 yr Gin Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys Ala 120 125 130 gc teg agt gag ccc aaa tet tgt gac aaa act cac aca tgc 488 rg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 35 140 145 gc cca gea eet gaa etc ctg ggg gga ccg tea gtc tte etc 536 ys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 155 160 ca aaa ccc aag gac acc etc atg ate tee egg acc eet gag 584 ro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 170 175 180 gc gtg gtg gtg gac gtg age cac gaa gac eet gag gtc aag 632 ys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 185 190 195 gg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag 680 82

Plie Asn Trp Tyr Val Asp 31y Val Glu Val His Asn Ala Lys Thr Lys 200 2C5 210 ccg egg gag gag cag tac aac age aeg tac egg gtg gtc age gtc etc 723

Pre Arg Glu Glu Gin Tyr Asn Sør Thr Tyr Arg Val Val Ser Val Leu 215 220 225 acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag 775

Thr Val Leu His Gin Asp Trp Leu Asn Giv Lys Glu Tyr Lys Cys Lys 230 235 210 gtc tee aac aaa gee etc tea gee ccc ate gag aaa acc ate tee aaa 824

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 245 250 255 260 gcc aaa ggg cag ccc ega gaa cca cag gtg tac acc ctg ccc cca tee 872

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 265 270 275 egg gat gag ctg acc aag aac cag gtc age ccg acc tgc ctg gtc aaa 920

Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys 280 285 290 ggc tte tac ccc age gac atc gcc gtg gag tgg gag age aat ggg cag 968

Gly Phc Tyr Pro Ser Asp Ile A_a Val Glu Trp Glu Ser Asn Gly G_n 295 300 305 ccg gag aac aac tac aag acc aeg eet ccc gcg ctg gac tee gac ggc 1015

Pre Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 310 315 320 tee tte tte etc tac age aag etc acc gtg gac aag age agg tgg cag 1064

Ser Phc Pho Leu Tyr Ser Lys Lou Thr Val .Asp Lys Ser Arg Trp G_n 325 330 335 340 cag ggg aac gtc tte tea tgc tee gtg atg cat gag get ctg cac aac 1112

Gin Gly Asn Val Phc Ser Gys Ser Val Mot His Glu Ala Leu His Asn 345 350 355 cac tac aeg cag aag age etc tee ctg tet ccg ggt aaa agt eta gac 1160

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Asp 360 365 370 ccc aaa tea tgt gac aaa act cac aca tgc cca ccg tgc cca gea eet 1203

Pre Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 375 380 385 gaa etc ctg ggg gga ccg tea gtc tte etc tac ccc cca aaa ccc aag 1255

Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pre Ly3 Pro Ly3 390 395 400 gac acc etc atg atc tee egg acc eet gag gac aca tgc gtg gtg gtg 1304

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 405 410 415 420 gac gtg age cac gaa gac eet gag gtc aag tac aac tgg tac gtg gac 1352

Asp Val Ser Ills Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 425 430 435 ggc gtg gag gtg cat aat gcc aag aca aag ccg egg gag gag cag tac 1400

Gly Val Glu Val Hi3 A3n Ala Ly3 Thr Ly3 Pro Arg Glu Glu Gin Tyr aac age aeg tac egg gtg gtc age gtc etc acc gtc ctg cac cag gac 1448

Asn Ser Thr Tyr Arg Val Val Ser Val Len Thr Val Len His Gin Asp 455 460 465 tgg ctg aae ggc aag gag tac aag tee aag grc tee aac aaa gee etc 1496

Trp Leu Asn Gly Lys Glu lyr Lys Cys Lys Val Ser Asn Lys Ala Leu 470 475 480 cca gcc ccc ate gag aaa acc ate tee aaa gcc aaa ggg cag ccc ega 1544

Pre Ala Pro Ile Glu Lys Thr I_e Ser Lys Ala Lys Gly Gin Pro Arg 485 490 495 500 gaa cca cag gtg tac acc ctg ccc cca tee egg gat gag ctg acc aag 1592

Glu Pro Gin val lyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 505 510 515 aac cag gtc age ctg acc tgc ctg gtc aaa ggc tte tat ccc age gac 1640

Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 520 " 525 " 530 atc gcc gtg gag tgg gag age aat ggg cag ccg gag aac aac tac aag 1688

Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys 535 540 545 acc aeg ccr ccc gtg ctg gac tee gac ggc tee tte tte etc tac age 1735

Thr Thr Pro Pro val Leu Asp Ser Asp Gly Ser Phe Fhe Leu Tyr Ser 550 555 560 aag etc acc gtg gac aag age agg tgg cag cag ggg aac gtc tte tea 1784

Ly3 Leu Thr Val Asp Lv3 Ser Arg Trp Gin Gin Gly7 A3n Val Phe Ser 565 570 575 580 tgc tee gtg atg cat gag get ctg cac aac cac tac aeg cag aag age 1832

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin T.ys Ser 585 590 595 etc tee ctg tet ccg ggt aaa ggc ccg egt get gcc ccg gaa gtc tat 1880

Leu Ser Leu Ser Pro Giv Lys G_y Pro Arg Ala Ala Pre Glu Val Tyr 600 6C5 610 gcg ttt gcg aeg ccg gag tgg ccg ggg age egg gac aag ege acc etc 1928

Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu 615 620 625 gcc tgc ctg atc cag aac t.t.c atg eet gag gac atc teg gtg cag tgg 1976

Ala Cys Leu Ile Gin Asn Phe Met Pro Glu Asp Ile Ser Val Gin Trp 530 635 640 ctg cac aac gag gtg cag etc ccg gac ycc egg cac age aeg aeg cag 2024

Leu His Asn Glu Val Gin Leu Pro Asp Ala Arg His Ser Thr Thr Gin 645 650 655 660 ccc ege aag acc aag ggc tee ggc tte tte gcc tte age ege ctg gag 2072

Pre Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu G_u 565 670 675 gtg acc agg gcc gaa tgg gag cag aaa gat gag tte atc tgc egt gea 2120 val Thr Arg Ala Glu Trp Glu Gin Lys Asp Glu Phe ile Cys Arg Ala 680 685 690 gtc cat gag gea gcg age ccc tea cag acc gtc cag ega gcg gtg tet 2168

Val His Glu Ala Ala Ser Pro Ser Gin Thr Val Gin Arg Ala Val Ser 695 700 705 gta aat ccc ggt aaa tgacatcatc accatcacca ttgatgagtt aaacccgctg a 2224 Val Asn Pro Gly Lys 710

<210> 28 <211> 713 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 28

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Val Cys Ser Arg Asp Phe Thr 20 25 30

Pro Pro Thr Val Lys lie Leu Gin Ser Ser Cys Asp Gly Gly Gly His 35 40 45

Phe Pro Pro Thr lie Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro 50 55 60

Gly Thr lie Asn lie Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val 65 70 75 80

Asp Leu Ser Thr Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr 85 90 95

Gin Ser Glu Leu Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr 100 105 110

Tyr Thr Cys Gin Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr 115 120 125

Lys Lys Cys Ala Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys 130 135 140

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 145 150 155 160

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser

Arg Thr Pro Gin Val Thr Gys Val Val Val Asp Val Sar His Gin Asp 180 185 190

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 195 200 * 205

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val 210 215 220

Val Ser val Leu Thr val Leu His Gin Asp Trp Leu Asn Gly Lys Glu 225 230 235 240

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 245 250 255

Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr 260 * ’ 265 270

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin val Ser Leu Thr 275 280 285

Cy3 Leu Val Ly3 Gly Phe Tyr Pro Ser A3p Ile Ala Val Glu Trp Glu 290 295 300

Ser Asn Gly Gin Pro Glu A.sn Asn Tyr T,ys Thr Thr Pro Pro Val Leu 305 310 315 320

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 325 330 335

Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu 340 345 350

Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly 355 360 365

Lys Ser Leu Asp Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 370 375 380

Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 385 390 395 400

Pro Lys Pro Lys Asp Thr Leu Met ile Ser Arg Thr Pro Glu val Thr 405 410 415

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 420 425 430

Trp Tyr Val Asp Giv Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 435 440 445

Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 450 455 460

Leu His Gin Asp Trp Leu A.sn Gly Lys Glu Tyr Lys Cys Lys Val Ser 465 470 475 430

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 435 490 495

Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp 500 505 510

Glu Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe 515 520 525

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu 530 535 540

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 545 550 555 560

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly 555 570 575

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 580 585 590

Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Pro Arg Ala Ala 595 600 605

Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp 610 615 620

Lys A.rg Thr Leu Ala Cys Leu Ile Gin Asn Phe Met Pro Glu Asp Ile 625 630 635 640

Ser Val Gin Trp Leu His Asn Glu Val Gin Leu Pro Asp Ala Arg His 645 650 655

Ser Thr Thr Gin Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe 660 ^ 665 ~ 670

Ser A.rg Leu Glu Val Thr Arg Ala Glu Trp Glu Gin Lys Asp Glu Phe 675 630 685

Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gin Thr Val Gin 690 695 700

Arg Ala Val Ser Val Asn Pro Gly Lys 705 710

<210> 29 <211 > 31 <212> DNA <213> Artificial Sequence <220> <223> PCR primer <400> 29 gtctctagag gagcccaaat cttgtgacaa a 31 <210> 30

<211 > 34 <212> DNA <213> Artificial Sequence <220> <223> PCR primer <400> 30 gcgtaccggt tcatttaccc ggggacaggg agag 34

<210> 31 <211 > 603 <212> DNA <213> Artificial Sequence <220> <223> N-terminal Fc gamma receptor Illa - phenylalanine polymorphic variant <220> <221 > CDS <222> (1)..(600) <400> 31 atg tgg cag ctg etc etc cca act get ctg eta ett eta gtt tea get 48

Met Trp Gin Leu Leu Leu Pro Thr Ala Leu Leu Leu Leu Val Ser Ala 15 10 15 ggc atg egg act gaa gat etc cca aag get gtg gtg ttc ctg gag cct 96

Gly Mat Arg Thr Glu Asp Leu Pro Lys Ala Val Val Phe Leu Glu Pro 20 25 30 caa tgg tac agg gtg etc gag aag gac agt gtg act ctg aag tgc cag 144

Gin Trp Tyr Arg Val Leu Glu Lys Asp Ser Val Thr Leu Lys Cys Gin 35 40 45 gga gcc tac tcc cct gag gac aat tcc aca cag tgg ttt cac aat gag 192

Gly Ala Tyr Ser Pro Glu Asp Asn Ser Thr Gin Trp Phe His Asn Glu 50 55 60 age etc ate tea age cag gcc teg age tac ttc att gac get gcc aca 240

Ser Leu lie Ser Ser Gin Ala Ser Ser Tyr Phe lie Asp Ala Ala Thr 65 70 75 80 gtc gac gac agt gga gag tac agg tgc cag aca aac etc tcc acc etc 288

Val Asp Asp Ser Gly Glu Tyr Arg Cys Gin Thr Asn Leu Ser Thr Leu 85 90 95 agt gac ccg gtg cag eta gaa gtc cat ate ggc tgg ctg ttg etc cag 336

Ser Asp Pro Val Gin Leu Glu Val His lie Gly Trp Leu Leu Leu Gin 100 105 110 gcc cct egg tgg gtg ttc aag gag gaa gac cct att cac ctg agg tgt 384

Ala Pro Arg Trp Val Phe Lys Glu Glu Asp Pro lie His Leu Arg Cys 115 120 125 cac age tgg aag aac act get ctg cat aag gtc aca tat tta cag aat 432

His Ser Trp Lys Asn Thr Ala Leu His Lys Val Thr Tyr Leu Gin Asn 130 " 135 " 140 ggc aaa ggc agg aag tat ttt cat cat aat tet gac ttc tac att cca 480

Gly Lys Gly Arg Lys Tyr Phe His His Asn Ser Asp Phe Tyr lie Pro 145 150 155 160 aaa gcc aca etc aaa gac age ggc tcc tac ttc tgc agg ggg ett ttt 528

Lys Ala Thr Leu Lys .Asp Ser Gly Ser Tyr Phe Cys .Arg Gly Leu Phe 165 170 175 ggg agt aaa aat gtg tet tea gag act gtg aac ate acc ate act caa 576

Gly Ser Lys Asn Val Ser Ser Glu Thr Val Asn He Thr lie Thr Gin 180 185 190 ggt ttg cat cat cac cat cat cat tag 603

Gly Leu His His His His His His 195 200

<210> 32 <211 > 200 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 32

Met Trp Gin Leu Leu Leu Pro Thr Ala Leu Leu Leu Leu Val Ser Ala 15 10 15

Gly Met Arg Thr Glu Asp Leu Pro Lys Ala Val Val Phe Leu Glu Pro 20 25 30

Gin Trp Tyr Arg Val Leu Glu Lys Asp Ser Val Thr Leu Lys Cys Gin 35 40 45

Gly Ala Tyr Ser Pro Glu Asp Asn Ser Thr Gin Trp Phe His Asn Glu 50 55 60

Ser Leu Ile Ser Ser Gin Ala Ser Ser Tyr Phe Ile Asp Ala Ala Thr 65 70 75 30

Val Asp Asp Ser Gly Glu Tyr Arg Cys Gin Thr Asn Leu Ser Thr Leu 85 90 95

Ser Asp Pro Val Gin Leu Glu Val His Ile Gly Trp Leu Leu Leu Gin 100 105 110

Ala Pro Arg Trp Val Phe Lys Glu Glu Asp Pro Ile His Leu Arg Cys 115 120 125

His Ser Trp Lys Asn Thr Ala Leu His Lys Val Thr Tyr Leu Gin Asn 130 135 140

Gly Lys Gly Arg Lys Tyr Phe His His Asn Ser Asp Phe Tyr Ile Pro 145 150 155 160

Lys A.la Thr Leu Lys Asp Ser Gly Ser Tyr Phe Cys Arg Gly Leu Phe 165 170 175

Gly Ser Lys Asn Val Ser Ser Glu Thr Val Asn Ile Thr Ile Thr Gin 180 185 190

Gly Leu His His His His His His 195 200

<210> 33 <211 > 603 <212> DNA <213> Artificial Sequence <220> <223> N-terminal Fc gamma receptor Illa - valine polymorphic variant <220> <221 > CDS <222> (1)..(600) <400> 33 atg tgg cag ctg etc etc cca act get ctg eta ett eta gtt tea get 48

Met Trp Gin Leu Leu Leu Pro Thr Ala Leu Leu Leu Leu Val Ser Ala 15 10 15 ggc atg egg act gaa gat etc cca aag get gtg gtg tte ctg gag cct 96

Gly Met Arg Thr Glu Asp Leu Pro Lys Ala Val Val Phe Leu Glu Pro 20 25 30 caa tgg tac agg gtg etc gag aag gac agt gtg act ctg aag tgc cag 144

Gin Trp Tyr Arg Val Leu Glu Lys Asp Ser Val Thr Leu Lys Cys Gin 35 40 45 gga gee tac tee cct gag gac aat tee aca cag tgg ttt cac aat gag 192

Gly Ala Tyr Ser Pro Glu Asp Asn Ser Thr Gin Trp Phe His Asn Glu 50 55 60 age etc ate tea age cag gee teg age tac ttc att gac get gee aca 240

Ser Leu lie Ser Ser Gin Ala Ser Ser Tyr Phe lie Asp Ala Ala Thr 65 70 75 80 gtc gac gac agt gga gag tac agg tgc cag aca aac etc tee ace etc 288

Val Asp Asp Ser Gly Glu Tyr Arg Cys Gin Thr Asn Leu Ser Thr Leu 85 90 95 agt gac ccg gtg cag eta gaa gtc cat ate ggc tgg ctg ttg etc cag 336

Ser Asp Pro Val Gin Leu Glu Val His lie Gly Trp Leu Leu Leu Gin 100 105 110 gee cct egg tgg gtg ttc aag gag gaa gac cct att cac ctg agg tgt 384

Ala Pro Arg Trp Val Phe Lys Glu Glu Asp Pro lie His Leu Arg Cys 115 120 125 cac age tgg aag aac act get ctg cat aag gtc aca tat tta cag aat 432

His Ser Trp Lys Asn Thr Ala Leu His Lys Val Thr Tyr Leu Gin Asn 130 135 140 ggc aaa ggc agg aag tat ttt cat cat aat tet gac ttc tac att cca 480

Gly Lys Gly Arg Lys Tyr Phe His His Asn Ser Asp Phe Tyr lie Pro 145 150 155 160 aaa gee aca etc aaa gac age ggc tee tac ttc tgc agg ggg ett gtt 528

Lys Ala Thr Leu Lys Asp Ser Gly Ser Tyr Phe Cys Arg Gly Leu Val 165 170 175 ggg agt aaa aat gtg tet tea gag act gtg aac ate acc ate act caa 576

Gly Ser Lys Asn Val Ser Ser Glu Thr Val Asn lie Thr lie Thr Gin 180 185 190 ggt ttg cat cat cac cat cat cac tag 603

Gly Leu His His His His His His 195 200

<210> 34 <211 > 200 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Construct <400> 34 biy μθ“ Arg inr biu Asp neu Fro nys Aia vai vai fne Leu biu Fro 20 25 30

Gin Trp Tyr Arg Val Leu Glu Lys Asp Ser Val Thr Leu Lys Cys Gin 35 40 45

Gly A.la Tyr Ser Pro Glu Asp Asn Ser Thr Gin Trp Phe His Asn Glu 50 55 60

Ser Leu Ile Ser Ser Gin Ala Ser Ser Tyr Phe Ile Asp Ala Ala Thr 65 70 75 30

Val Asp Asp Ser Gly Glu Tyr Arg Cys Gin Thr Asn Leu Ser Thr Leu 85~ " 90 95

Ser Asp Pro Val Gin Leu Glu Val His Ile Gly Trp Leu Leu Leu Gin 100 105 110

Ala Pro Arg Trp Val Phe Lys Glu Glu Asp Pro Ile His Leu Arg Cys 115 120 125

His Ser Trp Lys Asn Thr Ala Leu His Lys Val Thr Tyr Leu Gin Asn 130 135 140

Gly Lys Gly Arg Lys Tyr Phe His His Asn Ser Asp Phe Tyr Ile Pro 145 150 155 160

Lys Ala Thr Leu Lys Asp Ser Gly Ser Tyr Phe Cys Arg Gly Leu Val 165 170 175

Gly Ser Lys Asn Val Ser Ser Glu Thr Val Asn Ile Thr Ile Thr Gin 180 185 190

Gly Leu His His His His His His 195 200 <210> 35 <211> 20

<212> PRT <213> Homo sapiens <220> <221 > MISC_FEATURE <223> IgK signal sequence <400> 35

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly 20 <210> 36 <211 > 12

<212> PRT <213> Homo sapiens <400> 36

Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro 1 5 10

<210> 37 <211> 88 <212> PRT <213> Saccharomyces cerevisiae <400> 37

Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Giv Lys Glu Leu Leu Gly 15 10 15

Gly Gly Ser Ile Lys Gin Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser 20 25 30

Lys Ile Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile 35 40 45

Gly Glu Arg Gly His Gly Gly Gly Ser Asn Ser Gin Val Ser His Arg 50 55 60

Tyr Pro Arg Phe Gin Ser Ile Lys Val Gin Phe Thr Glu Tyr Lys Lys 65 70 75 80

Glu Lys Gly Phe Ile Leu Thr Ser 85

<210> 38 <211> 524 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 38

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Gin His Gly Gly Arg Ser Ser 20 25 30

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 35 40 45

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 50 55 60

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 65 70 75 80

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 85 90 95

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 100 105 110

Tyr .Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin 115 " 120 125

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 130 135 140

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro 145 150 155 160

Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 165 170 175

Lys .Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 180 ~ 185 190 .Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn .Asn Tyr 195 200 205

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 210 215 " 220

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Giv Asn Val Phe 225 230 235 240

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys 245 250 255

Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Asp Glu Pro Lys Ser Cys 260 265 270

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 275 280 285

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 290 295 300

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 305 310 315 320

Glu .Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 325 330 " 335

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 340 345 350

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu .Asn Gly 355 360 365

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 370 375 380

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 385 390 395 400

Tyr Thr Leu Pro Pro Ser .Arg Asp Glu Leu Thr Lys Asn Gin Val Ser 405 410 415

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 420 425 430

Trp Glu Ser Asn Gly Gin Pro Glu Asn .Asn Tyr Lys Thr Thr Pro Pro 435 440 445

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 450 455 460

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 465 470 475 480

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 485 490 495

Pro Gly Lys Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu 500 505 510

Asp Ser Thr Arg Thr Gly His His His His His His 515 520

<210> 39 <211 >499 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 39

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Gin His Gly Gly Arp Ser Ser 20 25 30

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cvs Pro Pro Cys Pro Ala 35 40 45

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 50 55 60

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 65 70 75 80

Val .Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 85 90 95

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 100 105 110

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin 115 120 125

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 130 135 140

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro 145 150 155 160

Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 155 170 175

Lys Asn Gin Val Ser Leu Thr CyS Leu Val Lys Gly Phe Tyr Pro Ser ISO " 185 " 190

Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr 195 200 205

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 210 215 " 220

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe 225 230 235 240

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys 245 250 255

Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Glu Pro Lys Ser Cys 260 265 270

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 275 280 285

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 290 295 300

He Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 305 310 315 320

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Glv Val Glu Val 325 330 335

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 340 345 350

Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 355 350 355

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie 370 375 380

Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 385 390 395 400

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser 405 410 415

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp lie Ala Val Glu 420 425 430

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 435 440 445

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 450 455 460

Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 465 470 475 480

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 485 490 495

Pro Gly Lys <210> 40 <211 > 628 95

<212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 40

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Val Cys Ser Arg Asp Phe Thr 20 25 30

Pro Pro Thr Val Lys Ile Leu Gin Ser Ser Cys Asp Gly Gly Gly His 35 40 45

Phe Pro Pro Thr Ile Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro 50 55 60

Gly Thr Ile Asn Ile Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val 65 70 75 30

Asp Leu Ser Thr Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr 85 90 95

Gin Ser Glu Leu Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr 100 105 110

Tyr Thr Cys Gin Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr 115 120 125

Lys Lys Cys Ala Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys 130 135 140

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 145 150 155 160

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 165 170 175

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 180 " 185 190

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 195 200 205

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val 210 215 220

Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu 225 230 235 240

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 245 250 255

Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr 260 265 270

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr 275 280 285

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 290 295 300

Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 305 310 315 320 96

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 325 330 335

Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu 340 345 350

Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly 355 360 365

Lys Glu Prc Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 370 375 380

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 385 390 ’ 395 400

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 405 410 415

Val Val Asp Val Scr His Glu -Asp Pro Glu Val Lys Phe .Asn Trp Tyr 420 425 430

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 435 440 445

Gin Tyr Asn Scr Thr Tyr Arg Val Val Scr Val Leu Thr Val Leu His 450 455 460

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Scr Asn Lys 465 470 475 480

Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Pro 485 490 495

Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly 500 505 510

Arg A3p Lys Arg Thr Leu Ala Cy3 Len Ile Gin A311 Phe Met Pro Glu 515 520 525

Asp lie Ser Val Gin Trp Leu Ilis A.sn Glu Val Gin Leu Pro Asp Ala 530 535 540

Arg Ilis Ser Thr Thr Gin Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe 545 550 555 560

Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gin Lys A30 565 570 575

Glu Phe lie Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gin Thr 580 585 590

Val Gin Arg Ala Val Ser Val Asn Pro Gly Lys Phe Glu Gly Lys Pro 595 600 605 lie Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr Gly His His 610 615 620

His His His His 625

<210>41 <211> 629 <212> PRT <213> ARTIFICIAL SEQUENCE <220 <223> chemically-synthesized stradomer monomer <400 41

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Val Cys Ser Arg Asp Phe Thr 20 25 30

Pro Pro Thr Val Lys lie Leu Gin Ser Ser Cys Asp Gly Gly Gly His 35 40 45

Phe Pro Pro Thr lie Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro 50 55 60

Gly Thr lie Asn lie Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val 65 70 75 80

Asp Leu Ser Thr Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr 85 90 95

Gin Ser Glu Leu Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr 100 105 110

Tyr Thr Cys Gin Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr 115 120 125

Lys Lys Cys Gly Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys 130 135 140

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 145 150 155 160

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser 165 170 175

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 180 185 190

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 195 200 205

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Sor Thr Tyr .Arc Val 210 215 220

Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu 225 230 235 240

Tyr Lys Cys Lys Val Scr Asn Lys Ala Leu Pro Ala Pro lie Glu Lys 245 250 255

Thr lie Ser Lys Ala Lys Gly Cln Pro Arg Clu Pro Cln Val Tyr Thr 260 265 270

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr 275 280 285

Cys Lou Val Lys Gly Phe Tyr Pro Scr Asp lie Ala Val Glu Trp Glu 290 295 300

Ser A3n Gly Gin Pro Glu A311 A3n Tyr Ly3 Thr Thr Pro Pro Val Leu 305 310 315 320

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 325 330 335

Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu 340 345 350

Ala Leu His A311 H13 Tyr Thr Gin Ly3 Ser Leu Ser Leu Ser Pro Gly 355 360 365

Lys Ser Leu Asp Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro 370 375 380

Pro Cys Pro Ala Pro Gin Leu Lou Gly Gly Pro Ser Val Phe Lou Pho 385 " 390 " 395 400

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 405 410 415

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 420 425 430

Asn Trp Tyr Val Asp Gly Val Glu val His Asn Ala Lys Thr Lys Pro 435 440 445

Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 3er Val Leu Thr 450 455 " 460

Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 465 470 475 480

Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala 485 490 495

Ly3 Gly Gin Fro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg 500 505 510

Asp Glu Leu Thr T,ys Asn Gin Val Ser Leu Thr Cys Leu Va' Lys Gly 515 520 525

Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro 530 535 540

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 545 550 555 560

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin 565 570 575

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 580 585 590

Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Phe Glu Gly Lys 595 600 605

Pro lie Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr Gly His 510 615 620

His His His His His 525

<210> 42 <211> 713 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 42

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Val Cys Ser Arg Asp Phe Thr 20 25 30

Pro Pro Thr Val Lys lie Leu Gin Ser Ser Cys Asp Gly Gly Gly His 35 40 45

Phe Pro Pro Thr lie Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro 50 55 60

Gly Thr Ile Asn He Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val 65 70 75 80

Asp Leu Ser Thr Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr 85 90 95

Gin Ser Glu Leu Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr 100 105 110

Tyr Thr Cys Gin Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr 115 120 125

Lys Lys Cys Gly Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys 130 135 140

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 145 150 155 160

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser 155 170 175

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 180 185 190

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Gin Val His Asn 195 200 205

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val 210 215 220

Val Sar Val Lau Thr Val Lau His Gin Asp Trp Lau Asn Gly Lys Glu 225 230 235 240

Tyr Lys Gys Lys val Ser Asn Lys Ala Leu Pro Ala Pro ile Glu Lys 245 250 255

Thr Ile 3er Lys Ala Lys Giv Gin Pro Arg Glu Pro Gin Val Tyr Thr 260 265 270

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr 275 280 285

Cys Leu val Lys Gly Phe Tyr Pro Ser Asp Ile Ala val Glu Trp Glu 290 " " 295 300

Ser A3n Gly Gin Pro Glu A311 A3n Tyr Ly3 Thr Thr Pro Pro Val Leu 305 310 315 320

Asp Ser Asp Gly Ser Phe Phe Len Tyr Ser T,ys T,eu Thr Val Asp Lys 325 330 335

Ser .Arg Trp Gin Gin Gly .Asn Val Phe Ser Cys Ser Val Met His Glu 340 345 350

Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly 355 360 365

Lys Sar Lai: Asp Glu Pro Lys Sar Gys Asp Lys Thr His Thr Cys Pro 370 375 380

Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 385 390 395 400

Pro Pro Lys Pro Lys Asp Thr Leu Mat Ile Sar Arg Thr Pro Glu Val 405 410 415

Thr Cys val val val Asp val Ser His Glu Asp Pro Glu val Lys Phe 420 425 430

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 435 440 445

Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 450 455 460

Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 465 470 475 430

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 435 490 495

Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg 500 505 510

Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly 515 520 525

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro 530 535 540

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 545 550 555 560

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin 565 570 575

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 580 585 590

Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Pro Arg .Ala 595 600 605 .Ala Pro Glu Val Tyr .Ala Phe .Ala Thr Pro Glu Trp Pro Gly Arg .Asp 610 615 620

Lys .Arg Thr Leu Ala Cys Leu Ile Gin Asn Phe Met Pro Glu Asp Ile 625 630 635 640

Ser Val Gin Trp Leu His Asn Glu Val Gin Leu Pro Asp Ala Arg His 645 650 655

Ser Thr Thr Gin Pro .Arg Lys Thr Lys Gly Ser Giv Phe Phe Val Phe 660 665 " 670

Ser .Arg Leu Glu Val Thr .Arg Ala Glu Trp Glu Gin Lys Asp Glu Phe 575 580 585

Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gin Thr Val Gin 690 695 700

Arg Ala Val Ser Val Asn Pro Gly Lys 705 710

<210> 43 <211> 733 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 43

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Gin His Gly Gly Arg Ser Ser 20 25 " 30

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 35 40 45

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 50 55 60

Lys .Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 65 70 75 30

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 85 90 95

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 100 105 110

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin 115 120 125

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 130 135 140

Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro 145 150 155 160

Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 165 170 175

Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 180 185 190

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr 195 200 205

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 210 215 " 220

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe 225 230 235 240

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys 245 250 255

Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Asp Glu Pro Lys Ser Cys 260 265 270

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 275 280 285

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 290 295 300

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 305 310 315 320

Glu -Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 325 " 330 335

His .Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 340 345 350 .Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu .Asn Gly 355 360 365

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 370 375 380

Glu Lys Thr Ile Ser Lys -Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 385 390 " 395 400

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser 405 410 415

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 420 425 430

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 435 440 445

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 450 455 450 -Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 465 470 475 480

His Glu Ala Leu His -Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 485 490 495

Pro Gly Lys Phe Glu Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 500 505 510

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 515 520 525

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 530 535 540

Val Thr Cys Val Val Val .Asp Val Ser His Glu Asp Pro Glu Val Lys 545 550 555 560

Phe A.sn Trp Tyr Val -Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 555 570 575

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 580 585 590

Thr Val Leu His Gin -Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 595 600 605

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 510 " 515 520 -Ala Lys Gly Gin Pro -Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 625 630 635 640 -Arg A.sp Glu Leu Thr Lys A.sn Gin Val Ser Leu Thr Cys Leu Val Lys 645 550 555

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin 660 665 670

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser A.sp Gly 675 680 685

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 590 595 700

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 705 710 715 720

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 725 730

<210> 44 <211> 566 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 44 Møt Glu Thr Asp Thr Løu Leu Leu Trp Val Løu Leu Leu Trp Val Pro 15 10 15

Giv Ser Thr Gly Asp Ala Ala Asp Ile Ser Ser Lys Pro His Leu Val 20 25 30

Thr Gin Leu Thr His Ala His Gly Cys Pro Glu Pro Lys Ser Cys Asp 35 40 45

Thr Pro Pro Pro Cys Pro A.rg Cys Pro Glu Pro Lys Ser Cys Asp Thr 50 55 60

Pro Pro Pro Cys Pro Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro 65 70 75 80

Pro Pro Cys Pro Arg Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 85 90 95

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 100 105 110

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 115 120 125

Glu Val Gin Phe Lys Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 130 135 140

Lys Thr Lys Leu Arg Glu Glu Gin Tyr Asn Ser Thr Phe Arg Val Val 145 150 155 160

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 155 170 175

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 180 185 190

Ile Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 195 200 205

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 210 215 220

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 225 230 235 240

Asn Gly Gin Pro Glu Asn Asn Tyr Asn Thr Thr Pro Pro Met Leu Asp 245 250 255

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 260 265 270

Arg Trp Gin Gin Gly Asn Ile Phe Ser Cys Ser Val Met His Glu Ala 275 280 285

Leu His Asn Arg Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 290 " 295 " 300

Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 305 310 315 320

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 325 330 " 335

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 340 345 350

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 355 360 365

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 370 " 375 380

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 385 390 " 395 400

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 405 410 415

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 420 425 430

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 435 440 445

Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys 450 455 460

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin 465 470 475 480

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 485 490 495

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 500 505 510

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 515 520 525

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Phe Glu Gly 530 535 540

Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr Gly 545 550 555 560

His His His His His His 565

<210> 45 <211> 529 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 45

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Gin His Gly Gly Arg Ser Ser 20 25 " 30

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 35 40 45

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 50 55 60

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 65 70 75 80

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 85 90 95

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 100 105 110

Tyr A.sn Ser Thr Tyr -Arg Val Val Ser Val Leu Thr Val Leu Hrs Gin 115 120 125 -Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 130 135 140

Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro 145 150 155 160 -Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 155 170 175

Lys A.sn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 180 185 190 -Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn .Asn Tyr 195 200 205

Lys Thr Thr Pro Pro Val Leu Asp Ser .Asp Gly Ser Phe Phe Leu Tyr 210 215 220

Ser Lys Leu. Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe 225 230 235 240

Ser Cys Ser Val Met His Glu Ala Len His Asn His Ivr Thr Gin Lys 245 250 255

Ser Lau Ser Leu Ser Pro Giv Lys Ser Leu Glu Gly Pro Arg Phe Glu 260 265 270

Glu Pro Lys Sor Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 275 280 285

Pro Glu Leu Len Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 290 295 300

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 305 310 315 320

Val .Asp Val Ser His Glu .Asp Pro Gin Val Lys Phe Asn Trp Tyr Val 325 330 335

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 340 345 350

Tyr .Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin 355 360 365

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser .Asn Lys Ala 370 375 380

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro 385 390 395 400

Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 405 410 415

Ly3 A3n Gin Val Ser Leu Thr Cy3 Leu Val Ly3 Gly Phe Tyr Pro Ser 420 425 430

Asp Ile Ala Val Glu Trp Glu Ser .Asn Gly Gin Pro Glu Asn Asn Tyr 435 440 445

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 450 455 460

Ser Ly3 Leu Thr Val A3p Ly3 Ser Arg Trp Gin Gin Gly A311 Val Phe 465 470 475 480

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys 485 490 495

Ser Leu Ser Leu Ser Pro Gly Lys Phe Glu Gly Lys Pro Ile Pro Asn 500 505 510

Pro Leu Leu Gly Leu .Asp Ser Thr .Arg Thr Gly His His His His His 515 520 525

His

<210> 46 <211> 559 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 46

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp lie Glu Leu Lys Thr Pro Leu Gly 20 25 30

Asp Thr Thr His Thr Cys Pro Arg Cys Pro Glu Pro Lys Ser Cys Asp 35 40 45

Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr 50 55 60

Pro Pro Pro Cys Pro Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro 65 70 75 80

Pro Pro Cys Pro Arg Cys Pro Gly Gly Arg Ser Ser Glu Pro Lys Ser 85 90 95

Cys A.sp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 100 105 110

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 115 120 125

Met lie Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 130 135 140

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 145 150 155 160

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr 165 170 175

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 180 185 190

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 195 200 205 lie Glu Lys Thr lie Scr Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin 210 215 220

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val 225 230 235 240

Scr Lou Thr Cys Leu Val Lys Gly Phe Tyr Pro Sor -Asp lie .Ala Val 245 250 255

Clu Trp Clu Ser Asn Civ Cln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 260 265 270

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 275 280 285

Val .Asp Lys Scr Arg Trp Gin Gin Gly Asn Val Pho Scr Cys Scr Val 290 295 300

Met Hi3 Glu Ala Leu H13 A311 H13 Tyr Thr Gin Ly3 Ser Leu Ser Leu 305 310 315 320

Ser Pro Gly Lys Ser Leu Asp Glu Pro Lys Ser Cys Asp Lys Thr His 325 330 335

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 340 345 350

Phe Leu Phe Pro Pro Ly3 Pro Lv3 A3p Thr Leu Met lie Ser Arg Thr 355 360 365

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu jyu syo 4i u u ro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser 405 410 415 hr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys 420 425 430 al Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 35 440 445 la Lvs Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro 455 460 rg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu 470 475 480 ly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 485 490 495 ro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 500 505 510 er Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 15 520 525 ln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 535 540 is Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 550 555 r TIFICIAL SEQUENCE imically-synthesized stradomer monomer hr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 5 10 15 111

Gly Ser Thr Gly Asp Ala Ala Asp Ile Glu Leu Lys Thr Pro Leu Gly 20 25 30

Asp Thr Thr His Thr Cys Pro Arg Cys Pro Glu Pro Lys Sør Cvs Asp 35 40 45

Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr 50 55 60

Pro Pro Pro Cys Pro Arg Cys Pro Glu Pro Lys Sor Cys Asp Thr Pro 65 70 75 80

Pro Pro Cys Fro Arg Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 85 90 95

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 100 105 110

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 115 120 125

Glu Val Cln Phe Lyo Trp Tyr Val Asp Cly Val Clu Val Hic Aon Ala 130 135 140

Lys Thr Lys Lou Arg Glu Glu Gin Tyr Asn Ser Thr Phe Arg Val Val 145 150 155 160

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu -Asn Gly Lys Glu Tyr 165 170 ’ 175

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 180 185 190

Ile Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Len 195 200 205

Pro Pro Ser Arg Glu Glu Met Thr Lys A3n Gin Val Ser Leu Thr Cy3 210 215 220

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 225 230 235 240

Asn Gly Gin Fro Glu Asn -Asn Tyr Asr. Thr Thr Pro Pro Met Leu A.sp 245 250 255

Ser A-3p Gly Ser Phe Phe Leu Tyr Ser Ly3 Leu Thr Val A3p Lv3 Ser

Arg Trp Gin Gin Gly Asn Ils Phe Ser Gys Ser Val Met His Gin Ala 275 280 285

Leu His Asn Arg Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 290 " 295 * 300

Gly Giv Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 305 ‘ 310 ~ 315 " 320

Pro Pro Cys Pro Ala Pro Glu Leu Len Gly Gly Pro Ser Val Phe Leu 325 330 335

Phe Pro Pro Lys Pro Lys Asp Thr Len Met Ile Ser Arg Thr Pro Glu 340 345 350

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 355 360 365

Phe Asn Trp Tyr val Asp Gly val Gin val His Asn Ala Lys Thr Lys 370 375 330

Pro Arg Glu Glu Gin Tyr A311 Ser Thr Tyr Arg Val Val Ser Val Leu 385 390 395 400

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 405 410 415

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 420 425 430

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 435 440 445

Arg Asp Glu Len Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys 450 455 460

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin 465 470 475 480

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 485 490 495

Ser Phe Phe Leu Tyr Ser Lys Leu Thr val Asp Lys Ser Arg Trp Gin 500 505 510

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 515 520 525

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu 530 535 540

Gly Pro Arg Phe Glu Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 545 550 555 560

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 565 570 575

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu 580 585 590

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 595 600 605

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 510 615 620

Pro A.rg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 625 630 635 640

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 645 650 655

Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys 660 665 670 .Ala Lys Gly Gin Pro -Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 675 680 685 -Arg .Asp Glu Leu Thr Lys .Asn Gin Val Ser Leu Thr Cys Leu Val Lys 690 695 700

Gly Phe Tyr Pro Ser .Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin 705 710 715 720

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser .Asp Gly 725 730 735

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 740 745 750

Gin Gly .Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 755 760 765

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Phe Glu Gly 770 775 780

Lys Pro lie Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr Gly 785 790 795 800

His His His His His His 805

<210> 48 <211> 394 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 48

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp He Glu Asp Thr Cys Gly Glu Leu 20 25 30

Glu Phe Gin Asn Asp Glu Ile Val Lys Thr Ile Ser Val Lys Val He 35 40 45

Asp Asp Glu Glu Tyr Glu Lys Asn Lys Thr Phe Phe Leu Glu lie Gly 50 55 60

Lys Pro Arg Leu Val Glu Met Ser Glu Lys Lys Ala Leu Leu Leu Asn 65 70 75 80

Glu Leu Gly Gly Phe Thr He Thr Gly Lys Tyr Leu Phe Gly Gin Pro 85 90 95

Val Phe Arg Lys Val His Ala Arg Glu His Pro lie Leu Ser Thr Val 100 105 110

He Thr He Ala Asp Glu Tyr Asp Asp Lys Gin Pro Leu Thr Ser Lys 115 120 125

Glu Lys Glu Glu Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys 130 135 140

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 145 150 155 160

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met He Ser 155 170 175

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 180 185 190

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 195 200 205

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val 210 215 220

Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu 225 230 235 " " 240

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys 245 250 255

Thr He Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr 260 265 270

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr 275 280 285

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp He Ala Val Glu Trp Glu 290 " " 295 300

Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 305 310 315 320

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 325 330 335

Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu 340 345 350

Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly 355 360 355

Lys Phe Glu Gly Lys Pro He Pro Asn Pro Leu Leu Gly Leu Asp Ser 370 375 380

Thr Arg Thr Gly His His His His His His 335 390

<210> 49 <211 > 634 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 49

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Glu Asp Thr Cys Gly Glu Leu 20 25 30

Glu Phe Gin Asn Asp Glu Ile Val Lys Thr Ile Ser Val Lys Val Ile 35 40 45

Asp Asp Glu Glu Tyr Glu Lys Asn Lys Thr Phe Phe Leu Glu Ile Gly 50 55 50

Lys Pro Arg Leu Val Glu Met Ser Glu Lys Lys Ala Leu Leu Leu Asn 65 70 75 80

Glu Leu Gly Gly Phe Thr Ile Thr Gly Lys Tyr Leu Phe Gly Gin Pro 85 90 95

Val Phe Arg Lys Val His Ala Arg Glu His Pro Ile Leu Ser Thr Val 100 105 110

Ile Thr Ile Ala Asp Glu Tyr Asp Asp Lys Gin Pro Leu Thr Ser Lys 115 120 125

Glu Lys Glu Glu Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys 130 135 140

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 145 150 155 160

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 155 170 175

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 180 185 190

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 195 200 205

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val 210 215 220

Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu 225 230 235 " 240

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 245 250 255

Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr 260 265 270

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr 275 280 285

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 290 295 300

Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 305 310 315 320

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 325 330 335

Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu 340 345 350

Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly 355 360 365

Lys Ser Leu Glu Gly Pro Arg Phe Glu Glu Pro Lys Ser Cys Asp Lys 370 375 380

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 385 390 395 400

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 405 410 415

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 420 425 430

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 435 440 445

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val 450 455 460

Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu 465 470 475 480

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 485 490 495

Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr 500 505 510

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr 515 520 525

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 530 535 540

Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 545 550 555 560

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 565 570 575

Ser A.rg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu 580 585 590

Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly 595 600 605

Lys Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser 510 615 620

Thr A.rg Thr Gly His His His His His His 625 630

<210> 50 <211 > 296 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 50

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Glv Asp Ala Ala Asp Ile Gin His Ser Gly Gly Arg Ser 20 25 30

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 35 40 45

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 50 55 60

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 65 70 75 30

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 85 90 95

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 100 105 110

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 115 120 125

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 130 135 140

Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin 145 150 155 160

Pro -Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 165 170 175

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro ISO 185 190

Ser .Asp lie Ala Val Glu Trp Glu Ser .Asn Gly Gin Pro Glu .Asn Asn 195 200 205

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 210 215 220

Tyr Ser Lys Leu Thr Val -Asp Lys Ser .Arg Trp Gin Gin Gly .Asn Val 225 230 " 235 " 240

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 245 250 255

Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro -Arg Phe 260 265 " 270

Glu Gly Lys Pro lie Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg 275 280 285

Thr Gly His His His His His His 290 295

<210>51 <211 > 252 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 51

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro 20 25 30

Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 35 40 45

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 50 55 60

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 65 70 75 80

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 85 90 95

Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 100 105 110

Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 115 120 125

Ser .Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr He Ser Lys Ala 130 135 140

Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg 145 150 155 160

Asp Glu Leu Thr Lys -Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly 165 170 175

Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro 180 185 190

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 195 200 205

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin 210 215 220

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 225 230 235 240

Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 245 250

<210> 52 <211 > 336 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 52

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Gin His Ser Gly Gly Arg Ser 20 25 30

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 35 40 45

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 50 55 50

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 65 70 75 30

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 85 90 95

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 100 105 110

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 115 120 125

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 130 135 140

Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin 145 150 155 160

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 165 170 175

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 180 185 " 190

Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 195 200 205

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 210 215 220

Tyr Ser Lys T.eu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 225 230 235 240

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 245 250 255

Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe 260 265 270

Glu Glu Leu Lys Thr Pro T.en Gly Asp Thr Thr His Thr Cys Pro Arg 275 230 285

Cys Pro Glu Fro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys 290 295 300

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 305 310 315 320

Glu Pro _ivs Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro .Ala 325 330 335

<210> 53 <211> 738 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer 121 <400> 53 Møt Glu Thr Asp Thr Løu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Giv Ser Thr Giv Asp Ala Ala Asp Ile Gin His Gly Giv Arg Ser Ser 20 25 30

Glu Pro Lys Ser Cys -Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 35 40 45

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 50 55 50

Lys A-sp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 65 70 75 80

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 85 90 95

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 100 105 110

Tyr A-sn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin 115 120 125 -Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser -Asn Lys Ala 130 135 140

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro 145 150 155 160

Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 155 170 175

Lys A-sn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser ISO 185 190 -Asp Ile Ala Val Glu Trp Glu Ser -Asn Gly Gin Pro Glu -Asn .Asn Tyr 195 200 205

Lys Thr Thr Pro Pro Val Lou Asp Sar Asp Gly Sar Phe Phe Lou Tyr 210 215 " 220

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe 225 230 235 240

Ser Cys Ser Val Met His Glu Ala Len His Asn His Tyr Thr Gin Lys 245 250 255

Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Asp Glu Pro Lys Ser Cys 260 265 270

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 275 280 " 285

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 290 295 " 300

Ile Ser Arc Thr Pro Glu val Thr Cys val Val val Asp val Ser His 305 ’ 310 " 315 320

Glu A3p Pro Glu Val Lv3 Phe A3n Trp Tyr Val A3p Gly Val Glu Val 325 330 335

His Asn .Ala T,ys Thr T,ys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 340 345 350

Arg Val Val Ser Val Leu Thr Val Leu His Gin .Asp Trp Leu Asn Gly 355 360 365

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 370 375 380

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 385 390 395 400

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser 405 410 415

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 420 425 430

Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 435 440 445

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 450 455 460

Asp Lvs Ser Arg Trp Gin Gin Gly Asn Val Plie Ser Cys Ser Val Met 465 470 475 480

His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser 485 490 495

Pro Gly Lys Phe Glu Asp Gin Asp Ile Ala Ile Arg Val Phe Ala Ile 500 505 510

Pro Pro Ser Phe Ala Ser Ile Phe Leu Thr Lys Ser Thr Lys Leu Thr 515 520 525

Cys Leu Val Thr Asp Leu Thr Thr Tyr Asp Ser Val Thr Ile Ser Trp 530 535 540

Thr Arg Gin Asn Gly Glu Ala Val Lys Thr His Thr Asn Ile Ser Glu 545 550 555 560

Ser His Pro Asn Ala Thr Phe Ser Ala Val Gly Glu Ala Ser Ile Cys 555 570 575

Glu Asp Asp Trp Asn Ser Gly Glu Arg Phe Thr Cys Thr Val Thr His 580 585 590

Thr Asp Leu Pro Ser Pro Leu Lys Gin Thr Ile Ser Arg Pro Lys Gly 595 600 605

Val A.la Leu His Arg Pro Asp Val Tyr Leu Leu Pro Pro Ala Arg Glu 610 615 ’ 620

Gin Leu Asn Leu Arg Glu Ser Ala Thr Ile Thr Cys Leu Val Thr Gly 625 630 635 640

Phe Ser Pro Ala Asp Val Phe Val Gin Trp Met Gin Arg Gly Gin Pro 645 650 655

Leu Ser Pro Glu Lys Tyr Val Thr Ser Ala Pro Met Pro Glu Pro Gin 660 ~ 665 670

Ala Pro Gly Arg Tyr Phe Ala His Ser Ile Leu Thr Val Ser Glu Glu 675 680 685

Glu Trp Asn Thr Gly Glu Thr Tyr Thr Cys Val Val Ala His Glu Ala 690 695 700

Leu Pro Asn Arg Val Thr Glu Arg Thr Val Asp Lys Ser Thr Gly Lys 705 710 715 720

Pro Thr Leu Tyr Asn Val Ser Leu Val Met Ser Asp Thr Ala Gly Thr 725 730 735

Cys Tyr

<210> 54 <211 > 510 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 54

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Gin His Ser Gly Gly Arg Ser 20 25 30

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 35 40 45

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 50 55 60

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 65 70 75 80

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 85 90 95

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 100 105 110

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 115 120 125

Gin A.sp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 130 135 140

Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin 145 150 155 160

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 155 170 175

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 180 185 190

Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 195 200 205

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 210 215 220

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 225 230 " 235 " 240

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 245 250 255

Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe 260 265 270

Glu A.sp Gin Asp lie Ala lie Arg Val Phe Ala lie Pro Pro Ser Phe 275 280 285

Ala Ser lie Phe Leu Thr Lys Ser Thr Lys Leu Thr Cys Leu Val Thr 290 295 " 300

Asp Leu Thr Thr Tyr Asp Ser Val Thr lie Ser Trp Thr Arg Gin Asn 305 310 315 320

Gly Glu Ala Val Lys Thr His Thr Asn lie Ser Glu Ser His Pro Asn 325 330 335

Ala Thr Phe Ser Ala Val Gly Glu Ala Ser lie Cys Glu Asp Asp Trp 340 345 350

Asn Ser Gly Glu Arg Phe Thr Cys Thr Val Thr His Thr Asp Leu Pro 355 360 355

Ser Pro Leu Lys Gin Thr lie Ser Arg Pro Lys Gly Val Ala Leu His 370 375 380

Arg Pro Asp Val Tyr Leu Leu Pro Pro Ala Arg Glu Gin Leu Asn Leu 385 390 395 400

Arg Glu Ser Ala Thr Ile Thr Cys Leu Val Thr Gly Phe Ser Pro Ala 405 410 415

Asp Val Phe Val Gin Trp Met Gin Arg Gly Gin Pro Leu Ser Pro Glu 420 425 430

Lys Tyr Val Thr Ser Ala Pro Met Pro Glu Pro Gin Ala Pro Gly Arg 435 440 445

Tyr Phe Ala His Ser Ile Leu Thr Val Ser Glu Glu Glu Trp Asn Thr 450 455 460

Gly Glu Thr Tyr Thr Cys Val Val Ala His Glu Ala Leu Pro Asn Arg 465 470 475 480

Val Thr Glu Arg Thr Val Asp Lys Ser Thr Gly Lys Pro Thr Leu Tyr 485 490 495

Asn Val Ser Leu Val Met Ser Asp Thr Ala Gly Thr Cys Tyr 500 505 510

<210> 55 <211 > 394 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 55

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Val Cys Ser Arg Asp Phe Thr 20 25 30

Pro Pro Thr Val Lys Ile Leu Gin Ser Ser Cys Asp Gly Gly Gly His 35 40 45

Phe Pro Pro Thr Ile Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro 50 55 60

Gly Thr Ile A*sn Ile Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val 65 70 75 80

Asp Leu Ser Thr Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr 85 90 95

Gin Ser Glu Leu Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr 100 105 110

Tyr Thr Cys Gin Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr 115 * 120 * 125

Lys Lys Cys Gly Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys 130 135 140

Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 145 150 155 160

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser 155 170 175

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 180 185 190

Pro Glu Val Lys Phe Asn Trp Tyr VaL Asp Gly Val Glu Val His Asn 195 200 205

Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val 210 215 220

Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu 225 230 235 240

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys 245 250 255

Thr lie Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr 260 265 270

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr 275 280 285

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu 290 ~ ~ 295 300

Ser .Asn Gly Gin Pro Glu -Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 305 " 310 " 315 320 -Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val .Asp Lys 325 330 335

Ser .Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu 340 345 350 -Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly 355 360 365

Lys Phe Glu Gly Lys Pro lie Pro Asn Pro Leu Leu Gly Leu .Asp Ser 370 375 380

Thr .Arg Thr Gly His His His His His His 385 390

<210> 56 <211 > 362 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 56

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val Lys 2 θ' 25 30 lie Leu Gin Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr lie 35 40 45

Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr He Asn lie 50 55 60

Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val Asp Leu Ser Thr Ala 65 70 75 30

Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr Gin Ser Glu Leu Thr 35 90 95

Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Cys Gin Val 100 105 110

Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys Glu Pro 115 " 120 125

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 130 135 140

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 145 150 155 160

Thr Leu Met He Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 165 170 175

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 180 185 190

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn 195 200 205

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp 210 215 220

Leu A.sn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 225 230 235 240

Ala Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Arg Glu 245 250 255

Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 260 265 270

Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp He 275 280 235

Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr 290 295 300

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 305 310 315 320

Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys 325 330 335

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu 340 345 350

Ser Leu Ser Pro Gly Lys Phe Glu Gly Lys 355 360 <210> 57 <211 > 519

<212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 57

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Giv Ser Thr Gly Asp Ala Ala Asp Ile Glu Arg Lys Cys Cys Val Glu 20 25 30

Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu 35 40 45

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 50 55 60

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin 65 70 75 80

Phe -Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 85 90 95

Pro -Arg Glu Glu Gin Phe .Asn Ser Thr Phe Arg Val Val Ser Val Leu 100 105 110

Thr Val Val His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 115 120 125

Val Ser Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 130 135 140

Thr Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 145 150 155 160

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys 155 170 175

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin 180 185 190

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly 195 200 205

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 210 215 220

Gin Gly Asn Val Phe Ser Cvs Ser Val Met His Glu Ala Leu His Asn 225 230 235 240

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Arg Ser Ser 245 250 255

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 260 " 265 270

Pro Glu Leu Leu Giv Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 275 230 235

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 290 295 300

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 305 310 315 320

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 325 330 335

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin 340 345 350

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 355 350 355

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro 370 375 330

Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 335 390 395 400

Lys A.sn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 405 410 415

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr 420 425 430

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 435 440 445

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe 450 455 450

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys 465 470 475 480

Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe Glu 435 490 495

Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr 500 505 510

Gly His His His His His His 515

<210> 58 <211 > 488 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 58

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Glu Arg Lys Cys Cys Val Glu 20 25 " 30

Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu 35 40 45

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 50 55 50

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin 65 70 75 30

Phe A-sn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 85 90 95

Pro A.rg Glu Glu Gin Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu 100 105 110

Thr Val Val His Gin -Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 115 120 " * 125

Val Ser Asn Lys Gly Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys 130 135 140

Thr Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 145 150 155 160

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys 155 170 175

Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin 180 185 190

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly 195 200 205

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 210 215 220

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 225 230 235 240

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Arg Ser Ser 245 250 255

Glu Pro Lys Ser Cys -Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 260 " 265 270

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 275 230 235

Lys A-sp Thr Leu Met lie Ser Arg Thr Pro Glu Val Thr Cys Val Val 290 295 300

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 305 310 315 320

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 325 330 335

Tyr A-sn Ser Thr Tyr -Arg Val Val Ser Val Leu Thr Val Leu His Gin 340 345 350 -Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 355 350 355

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro 370 375 380

Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 385 390 395 400

Lys Asn Gin Val 5er Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 405 410 415

Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr 420 425 430

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 435 440 445

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe 450 455 460

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys 465 470 475 480

Ser Leu Ser Leu Ser Pro Gly Lys 485

<210> 59 <211 > 303 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 59

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp lie Glu Arg Lys Cys Cys Val Glu 20 25 30

Cys Pro Pro Cys Pro Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr 35 40 45

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 50 55 50

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser A*rg 65 70 75 80

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 85 90 95

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 100 105 110

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 115 120 " 125

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 130 135 140

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 145 150 155 160

Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 165 170 175

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 180 185 190

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 195 200 205

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 210 215 220

Ser A.sp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 225 230 235 240

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 245 250 255

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 260 265 270

Ser Leu Glu Gly Pro Arg Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu 275 280 285

Leu Gly Leu Asp Ser Thr Arg Thr Gly His His His His His His 290 295 300

<210> 60 <211 > 272 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 60

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Glv Asp Ala Ala Asp Ile Glu Arg Lys Cys Cys Val Glu 20 25 30

Cys Pro Pro Cys Pro Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr 35 40 45

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 50 55 60

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 65 70 75 80

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 85 90 95

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 100 105 110

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 115 120 125

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 130 135 140

Lys Cys Lys Val Ser -Asn Lys .Ala Leu Pro .Ala Pro lie Glu Lys Thr 145 150 155 160 lie Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 165 * 170 ~ 175

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 180 185 190

Leu Val Lys Gly Phe Tyr Pro Ser Asp lie -Ala Val Glu Trp Glu Ser 195 200 205 -Asn Gly Gin Pro Glu .Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu .Asp 210 215 220

Ser A.sp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 225 " 230 " 235 " 240 .Arg Trp Gin Gin Gly -Asn Val Phe Ser Cys Ser Val Met His Glu Ala 245 250 255

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 260 265 270

<210>61 <211 > 264 <212> PRT <213> ARTIFICIAL SEQUENCE <220 <223> chemically-synthesized stradomer monomer <400 61

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Glu Arg Lys Cvs Cvs Val Glu Cvs Pro Pro Cys Pro 20 " 25 " 30

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 35 40 45

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 50 55 60

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 65 70 75 80

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 85 90 95

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 100 105 110

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin 115 120 125

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 130 135 140

Leu Pro Ala Pro He Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro 145 150 155 160

Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 165 170 175

Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 180 185 190

Asp He Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr 195 200 205

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 210 215 220

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe 225 230 235 240

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys 245 250 255

Ser Leu Ser Leu Ser Pro Gly Lys 260

<210> 62 <211> 538 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 62

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Glu Arg Lys Cys Cys Val Glu 20 25 " 30

Cys Pro Pro Cys Pro Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr 35 40 45

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 50 55 60

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 65 70 75 80

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 85 90 95

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 100 105 110

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 115 120 "* 125

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 130 135 140

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr 145 150 155 160 lie Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 165 170 " 175

Pro Pro Scr Arg Glu Glu Mot Thr Lys Asn Gin Val Scr Leu Thr Cys 180 185 190

Leu Val Lys Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser 195 200 205

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 210 215 220

Scr .Asp Gly Scr Phe Phe Lou Tyr Scr Lys Lou Thr Val .Asp Lys Scr 225 230 235 240

Arg Trp Gin Gin Gly Aon Val Phe Ser Cys Ser Val Met His Glu Ala 245 250 255

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 260 265 270

Ser Leu Asp Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 275 280 285

Cy3 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 290 295 300

Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu Val Thr 305 310 315 320

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 325 330 335

Trp Tyr Val Asp Giv Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 340 345 350

Glu Glu Gin Tyr Asn Sar Thr Tyr Arg Val Val Ser Val Leu Thr Val 355 350 355

Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 370 375 380

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 385 390 395 400

Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu 405 410 415

Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe 420 425 430

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu 435 440 445

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 450 455 460

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly 465 470 475 480

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 485 490 495

Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro 500 505 510

Arg Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser 515 520 525

Thr .Arg Thr Gly His His His His His His 530 535

<210> 63 <211> 507 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 63

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Glu Arg Lys Cys Cys Val Glu 20 25 " 30

Cys Pro Pro Cys Pro Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr 35 40 45

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 50 55 60

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 65 70 75 80

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 85 90 95

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 100 105 110

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 115 120 125

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 130 135 140

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr 145 150 155 160 lie Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 155 170 175

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 180 185 190

Leu Val Lys Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser 195 200 205

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 210 215 220

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 225 230 235 240

Arg Trp Gin Gin Giv Asn Val Phe Ser Gys Ser Val Met His Glu Ala 245 250 255

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 260 265 270

Ser Leu Asp Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 275 280 285

Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 290 295 300

Pro Lys Pro Lys Asp Thr Leu Met Ile Ger Arg Thr Pro Glu Val Thr 305 " " 310 315 320

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 325 330 ’ 335

Trp Tyr Val Asp Gly val Glu val His Asn Ala Lys Thr Lys Pro Arg 340 345 350

Glu Glu Gin Tyr A311 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 355 360 365 T.eu His Gin Asp Trp T,eu Asn Gly T.ys Glu Tyr T,ys Cys Lys Val Ser 370 375 380

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 385 390 395 400

Gly Gin Pro A.rg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu 405 410 415

Glu Met Thr Lys Asn Gin Val Ger Leu Thr Cys Leu Val Lys Gly Phe 420 425 430

Tyr Pro Ser .Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu 435 440 445

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 450 455 460

Phe Leu Tyr Ser Lys Leu Thr val Asp Lys Ser Arg Trp Gin Gin Gly 465 470 475 480 .Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 485 490 495

Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 500 505

<210> 64 <211 > 511 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 64

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Val Cys Ser Arg Asp Phe Thr 20 25 30

Pro Pro Thr Val Lys lie Leu Gin Ser Ser Cys Asp Gly Gly Gly His 35 40 45

Phe Pro Pro Thr lie Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro 50 55 60

Gly Thr lie Asn lie Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val 65 70 75 80

Asp Leu Ser Thr Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr 85 90 95

Gin Ser Glu Leu Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr 100 105 110

Tyr Thr Cys Gin Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr 115 120 125

Lys Lys Cys Gly Gly Gly Asp lie Val Cys Ser Arg Asp Phe Thr Pro 130 135 140

Pro Thr Val Lys lie Leu Gin Ser Ser Cys Asp Gly Gly Gly Hrs Phe 145 150 155 160

Pro Pro Thr lie Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly 165 170 175

Thr Ils Asn Ils Thr Trp Len Glu Asp Giv Gin Val Met Asp Val Asp 180 185 190

Leu Ser Thr Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr Gin 195 200 * 205

Ser Glu Leu Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr Tyr 210 215 220

Thr Gys Gin Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr Lys 225 230 235 240

Lys Cys Gly Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr 245 250 " " 255

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 260 * 265 * 270

Val Phe Leu Fhe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 275 230 285

Thr Pro Glu Val Thr Cy3 Val Val Val A3p Val Ser Hi3 Glu A3p Pro 290 295 300

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 305 310 315 320

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 325 330 335

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 340 345 350

Lys Gys Lys Val Ger Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 355 360 365

Ile Ser Lys -Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 370 375 380

Pro Pro Ser .Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 385 390 395 400

Leu val _ivs Gly Phe Tyr Pro Ser Asp ile Ala val Glu Trp Glu Ser 405 410 415

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 420 425 430

Ser .Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 435 440 445

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met Hrs Glu Ala 450 455 460

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 465 470 475 480

Ser Leu Glu Gly Pro Arg Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu 485 490 495

Leu Gly Leu Asp Ser Thr Arg Thr Gly His His His His His His 500 505 510

<210> 65 <211 >480 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 65

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Giv Ser Thr Giv Asp Ala Ala Asp Ile Val Cys Ser Arg Asp Phe Thr 20 25 30

Pro Pro Thr Val Lys Ile Leu Gin Ser Ser Cys Asp Giv Gly Gly His 35 40 45

Phe Pro Pro Thr Ile Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro 50 55 60

Gly Thr Ile Asn Ile Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val 65 70 75 80

Asp Leu Ser Thr Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr 85 90 95

Gin Ser Glu Leu Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr 100 105 110

Tyr Thr Cys Gin Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr 115 120 125

Lys Lys Cys Gly Gly Gly Asp Ile Val Cys Ser Arg Asp Phe Thr Pro 130 135 140

Pro Thr Val Lys Ile Leu Gin Ser Ser Cys Asp Giv Gly Gly His Phe 145 150 155 160

Pro Pro Thr Ile Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly 165 170 175

Thr Ile Asn Ile Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val Asp 180 185 190

Leu Ser Thr Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr Gin 195 200 205

Ser Glu Leu Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr Tyr 210 215 220

Thr Cys Gin Val Thr Tyr Gin Gly His Thr Phe Glu A3p Ser Thr Ly3 225 230 235 240

Lys Cys Gly Gly Gly Arg Ser Ser Glu Pro T.ys Ser Cys Asp T.ys Thr 245 250 255

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 260 265 270

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 275 280 285

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 290 * 295 300

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 305 310 315 320

Lys Thr Lys Fro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 325 330 335

Ser Val _,eu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 340 345 350 355 360 365

Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 370 375 380

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 385 390 " 395 400

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 405 410 415

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 420 425 430

Ser A.sp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 435 440 445

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 450 455 460

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 465 470 475 480

<210> 66 <211 > 332 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 66

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Leu Gly Gly Gly Ser Ile Lys 20 25 30

Gin Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile 35 40 45

Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly His 50 55 60

Gly Gly Gly Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 65 70 75 80

Pro Pro Cys Pro Ala Pro Glu Lon Lon Gly Gly Pro Ser Val Pho Lou 85 30 35

Phe Pro Pro Lys Pro Lys Asp Thr Len Met Ile Ser Arg Tor Pro Glu 100 105 110

Val Thr Cys Val Val Val Asp Val Sor His Glu Asp Pro Glu Val Lys 115 120 125

Phe Asn Trp lyr val Asp Gly Val Gin val His Asn Ala Lys ihr Lys 130 135 140

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 145 150 " 155 160

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 165 170 * 175

Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys 180 185 190

Ala Ly3 Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 195 200 205

Arg Glu Glu Met. Thr Lys Asn Gin Val Ser T,eu Thr Cys Leu Val Lys 210 215 220

Gly Phe Tyr Pro Ser Asp He Ala Val Glu Trp Glu Ser .Asn Gly Gin 225 230 235 240

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 245 250 255

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 260 265 270

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 275 280 285

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu 290 295 300

Gly Pro Arg Phe Glu Gly Lys Pro lie Pro Asn Fro Leu Leu Gly Leu 305 310 315 320

Asp Ser Thr Arg Thr Gly His His His His His His 325 330

<210> 67 <211> 301 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 67

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp lie Leu Gly Gly Gly Ser Ile Lys 20 25 30

Gin lie Glu Asp Lys lie Glu Glu lie Leu Ser Lys Ile Tyr Hrs lie 35 40 45

Glu .Asn Glu Ile Ala Arg lie Lys Lys Leu Ile Gly Glu Arg Gly His 50 55 60

Gly Gly Gly Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 65 70 75 80

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 85 90 95

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu 100 105 110

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 115 120 125

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 130 135 140

Pro .Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 145 150 155 160

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 155 170 175

Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys 180 185 190

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 195 200 205

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys 210 215 220

Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin 225 230 235 240

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser .Asp Gly 245 250 255

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 260 265 270

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 275 280 285

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 290 " 295 300

<210> 68 <211 > 444 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 68

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp lie Leu Gly Gly Gly Ser Ile Lys 2 θ' 25 " "30

Gin lie Glu Asp Lys lie Glu Glu lie Leu Ser Lys Ile Tyr His lie 35 40 45

Glu Asn Glu Ile Ala Arg lie Lys Lys Leu Ile Gly Glu Arg Gly His 50 55 60

Gly Gly Gly Asp lie Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val 65 70 75 80

Lys lie Leu Gin Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr 85 90 95 lie Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr lie Asn 100 105 110 lie Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val Asp Leu Ser Thr 115 120 125

Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr Gin Ser Glu Leu 130 135 140

Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Cys Gin 145 150 155 160

Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys Gly 165 170 " 175

Gly Gly Arg Scr Scr Glu Pro Lys Scr Cys Asp Lys Thr His Thr Cys 180 185 190

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 195 200 205

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met He Ser Arg Thr Pro Glu 210 215 220

Val Thr Cys Val Val Val Asp Val Scr His Glu Asp Pro Glu Val Lys 225 230 235 240

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 245 250 255

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 260 265 270

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 275 280 285

Val Ser A3n Ly3 Ala Leu Pro Ala Pro lie Glu Ly3 Thr He Ser Ly3 290 295 300

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 305 310 315 320

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin 340 345 350

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 355 360 365

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 370 375 380

Gin Gly Asn Val Phe Ser Cvs Ser Val Met His Glu Ala Leu His Asn 385 390 395 400

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu 405 410 415

Gly Pro Arg Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu 420 425 430

Asp Ser Thr Arg Thr Gly His His His His His His 435 440

<210> 69 <211 > 413 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 69

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Leu Gly Gly Gly Ser Ile Lys 20 25 30

Gin Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile 35 40 45

Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly His 50 55 60

Gly Gly Gly Asp Ile Val Cvs Ser Arg Asp Phe Thr Pro Pro Thr Val 65 70 75 80

Lys Ils Leu. Gin Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr 85 90 95

Ile Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile Asn 100 105 110

Ile Thr Trp Leu Glu Asp Giv Gin Val Met Asp Val Asp Leu Ser Thr 115 120 125

Ala Ser Thr Thr Gin Glu Giv Glu Lou Ala Sor Thr Gin Ser Glu Lou 130 135 140

Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Cys Gin 145 150 155 160

Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys Gly 165 170 175

Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 180 185 190

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 195 200 205

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Sor Arg Thr Pro Glu 210 215 220

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 225 230 235 240

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 245 250 255

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 260 265 270

Thr Val Leu H13 Gin A3p Trp Leu A3n Gly Ly3 Glu Tyr Ly3 Cys Ly3 275 280 285

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 290 295 300

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 305 310 315 320

Arg Glu Glu Met Thr Ly3 A311 Gin Val Ser Leu Thr Cv3 Leu Val Ly3 325 330 335

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin 340 345 350

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 355 350 355

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 370 375 380

Gin Giv Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 385 " 390 395 400

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 405 410

<210> 70 <211> 565 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 70

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Leu Gly Giv Giv Ser Ile Lys 20 25 30

Gin Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile 35 40 45

Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly His 50 55 60

Ile Leu Gly Gly Gly Asp Ile Glu Arg Lys Cys Cys Val Glu Cys Pro 65 70 75 80

Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro 85 90 95

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 100 105 110

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Asn 115 120 125

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 130 135 140

Glu Glu Gin Fhe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val 115 150 155 160

Val His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 165 170 " 175

Asn Lys Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys 180 185 190

Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu 195 200 " 205

Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe 210 215 220

Tyr Pro Ser Asp Ile Ala Val Glu Trp Clu Ser Asn Gly Cln Pro Glu 225 230 235 240

Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe 245 250 255

Phe Lou Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly 260 265 270

Asn Val Phe Ser Cys Ser Val Met His Clu Ala Leu His Aon His Tyr 275 230 235

Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Ly3 Arg Ser Ser Glu Pro 290 ” 295 ~ ’ 300

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 305 310 315 320

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Ly3 Pro Lv3 A3p 325 330 335

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 340 345 350

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 355 350 355

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn 370 375 380

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp 385 390 395 400

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 405 410 415

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu 420 425 430

Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 435 440 445

Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 450 455 460

Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr 465 470 475 480

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 485 490 495

Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys 500 505 510

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu 515 520 525

Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe Glu Gly Lys 530 535 540

Pro Ile Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr Gly His 545 550 555 560

His His His His His 5 65

<210>71 <211> 534 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 71

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp lie Leu Gly Gly Gly Ser Ile Lys 20 25 30

Gin lie Glu Asp Lys lie Glu Glu lie Leu Ser Lys Ile Tyr His lie 35 40 45

Glu Asn Glu Ile Ala Arg lie Lys Lys Leu Ile Gly Glu Arg Gly His 50 55 60 lie Leu Gly Gly Gly Asp lie Glu Arg Lys Cys Cys Val Glu Cys Pro 65 70 75 80

Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro 85 90 95

Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu Val Thr 100 105 110

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Asn 115 120 125

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 130 135 140

Glu Glu Gin Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val 145 150 155 160

Val His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 155 170 175

Asn Lys Gly Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Thr Lys 180 185 " 190

Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu 195 200 205

Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe 210 215 220

Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu 225 230 235 240

Ann Asn Tyr Lys Thr Thr Pro Pro Mot Len Asp Sar Asp Gly Ser Phe 245 250 255

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly 260 265 270

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 275 280 285

Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Arg Ser Ser Glu Pro 290 295 300

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 305 " 310 " 315 " 320

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 325 330 * 335

Thr Leu Met Ile Ser Arg Thr Pro Gin val Thr Cys val val val Asp 340 345 350

Val Ser His Glu A3p Pro Glu Val Ly3 Phe A3n Trp Tyr Val A3p Gly 355 360 365

Val Glu Val His Asn Ala Lys Thr T,ys Pro Arg Glu Glu Gin Tyr Asn 370 375 380

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Tro 385 390 395 400

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 405 410 415

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu 420 425 430

Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 435 440 445

Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 450 455 460

Ala val Glu Trp Glu Ser Asn Gly Gin Pro Glu A*sn Asn Tyr Lys Thr 465 470 475 480

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 485 490 495

Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys 500 505 510

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu 515 520 525

Ser Leu Ser Pro Gly Lys 530

<210> 72 <211 > 344 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 72

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Glv Asp Ala Ala Asp lie Leu Gly Gly Gly Ser Ile Lys 20 25 30

Gin He Glu Asp Lys lie Glu Glu He Leu Ser Lys He Tyr His He 35 40 45

Glu Asn Glu Ile Ala Arg He Lys Lys Leu He Gly Glu Arg Gly His 50 55 60

Asp He Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Arg Ser 65 70 75 80

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 85 90 95

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 100 105 110

Pro Lys Asp Thr Leu Met He Ser Arg Thr Pro Glu Val Thr Cys Val 115 120 125

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 130 135 140

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 145 150 155 160

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 165 170 175

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 180 185 190

Ala Leu Pro Ala Pro He Glu Lys Thr He Ser Lys Ala Lys Gly Gin 195 200 205

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 210 215 220

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 225 230 235 240

Ser Asp He Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 245 250 255

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 260 265 270

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 275 280 285

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 290 295 300

Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe 305 310 315 320

Glu Gly Lys Pro He Pro A.sn Pro Leu Leu Gly Leu Asp Ser Thr Arg 325 330 335

Thr Gly His His His His His His 340

<210> 73 <211 > 313 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 73

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Leu Gly Gly Gly Ser Ile Lys 20 25 30

Gin Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile 35 40 45

Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly His 50 55 60

Asp Ile Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Arg Ser 65 70 75 30

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 85 90 95

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 100 105 110

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 115 120 125

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 130 135 140

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 145 150 155 160

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 165 170 175

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 130 135 190

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin 195 200 205

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 210 215 220

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 225 230 235 240

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 245 250 255

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 260 265 270

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 275 230 235

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 290 295 300

Lys Ser Leu Ser Leu Ser Pro Gly Lys 305 310 <210> 74 <211 > 372

<212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 74

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp Ile Leu Gly Giv Giv Ser Ile Lys 20 25 30

Gin Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile 35 40 45

Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly His 50 55 60

Ile Leu Gly Gly Gly Ser Ile Lys Gin Ile Glu Asp Lys Ile Glu Glu 65 70 75 80

Ile Leu Ser Lys Ile Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys 85 90 95

Lys Leu Ile Gly Glu Arg Gly His Gly Gly Gly Ser Ser Glu Pro Lys 100 " 105 " 110

Ser Cys Asp Lys Thr His Ihr Cys Pro Pro Cys Pro Ala Pro Gir Leu 115 120 125

Leu Giv Giv Pro Ser Val Phø Leu Phe Pro Pro Lvs Pro Lys Asp Thr 130 135 140

Leu Mas Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 145 150 155 160

Ser His Glu Asp Pro Glu Val Lys Phc Asn Trp Tyr Val Asp Giv Val 165 170 175

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser 180 185 190

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 195 200 205

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 210 215 220

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 225 230 235 240

Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 245 250 255

Val Ser Leu Thr Cvs Lou Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 260 265 270

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 275 280 285

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 290 295 300

Thr Val A3p Ly3 Ser Arg Trp Gin Gin Gly A311 Val Phe Ser Cys Ser 305 310 315 320

Val Mer Ilis Glu Ala Leu Ilis Asn Ilis Tyr Thr Gin Lys Ser Leu Ser 325 330 335

Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe Glu Gly Lys Pro 340 345 350

Ile Pro A3n Pro Leu Leu Gly Leu A3p Ser Thr Arg Thr Gly His Hi3 355 360 365

His His His His 370

<21o> 75 <211 > 341 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 75

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Asp lie Leu Gly Gly Gly Ser Ile Lys 20 25 30

Gin lie Glu Asp Lys lie Glu Glu lie Leu Ser Lys Ile Tyr His lie 35 40 45

Glu Asn Glu Ile Ala Arg lie Lys Lys Leu Ile Gly Glu Arg Gly His 50 55 60 lie Leu Gly Gly Gly Ser lie Lys Gin lie Glu Asp Lys lie Glu Glu 65 70 75 30 lie Leu Ser Lys lie Tyr His lie Glu Asn Glu lie Ala Arg lie Lys 85 90 95

Lys Leu lie Gly Glu Arg Gly His Gly Gly Gly Ser Ser Glu Pro Lys 100 105 110

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 115 120 125

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 130 " 135 140

Leu Met lie Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 145 150 155 160

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 165 170 175

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser ISO " " 185 190

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu 195 200 205

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala 210 215 220

Pro lie Glu Lys Thr lie Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro 225 230 235 240

Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 245 250 255

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp lie Ala 260 265 270

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 275 280 285

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 290 295 300

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 305 310 315 320

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 325 330 335

Leu Ser Pro Gly Lys 340

<210> 76 <211 > 412 <212> PRT

<213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 76

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Glu Arg Lys Cys Cys Val Glu Cys Pro 20 25 30

Pro Cys Pro Asp Ile Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val 35 40 45

Lys Ile Leu Gin Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr 50 55 60

Ile Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile Asn 65 70 75 80

Ile Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val Asp Leu Ser Thr 35 90 95

Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr Gin Ser Glu Leu 100 105 110

Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Cys Gin 115 120 125

Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys Gly 130 135 140

Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 145 150 155 160

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 165 170 175

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 180 " 185 190

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 195 200 205

Phe A.sn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 210 215 220

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 225 230 235 240

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 245 250 255

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 260 265 " 270 158

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 275 2S0 285

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys 290 295 300

Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin 305 310 315 320

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 325 330 335

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 340 345 350

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 355 360 365

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu 370 375 380

Gly Pro Arg Phe Glu Gly Lys Pro lie Pro Asn Pro Leu Leu Gly Leu 385 390 395 400

Asp Ser Thr Arg Thr Gly His His His His His His 405 410

<210> 77 <211 > 381 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 77

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Glu Arg Lys Cys Cys Val Glu Cys Pro 20 25 30

Pro Cys Pro Asp lie Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val 35 40 45

Lys lie Leu Gin Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr 50 55 60 159 UIVtK ΖΊΰ!)!)ΰυ li

Ile Gin Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile Asn 65 70 75 80

Ile Thr Trp Leu Glu Asp Gly Gin Val Met Asp Val Asp Leu Ser Thr 85 90 95

Ala Ser Thr Thr Gin Glu Gly Glu Leu Ala Ser Thr Gin Ser Glu Leu 100 " 105 110

Thr Leu Ser Gin Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Cys Gin 115 120 125

Val Thr Tyr Gin Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys Gly 130 135 140

Gly Gly Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 145 150 155 160

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 155 170 175

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 180 185 190

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 195 200 205

Phe A.sn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 210 215 220

Pro .Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 225 230 235 240

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 245 250 255

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 260 265 270

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser 275 280 ^ 285

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys 290 295 300

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin 305 310 315 320

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 325 330 335

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin 340 345 350

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 355 360 365

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 370 375 380

<210> 78 <211> 575 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 78 160

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Glu Arg Lys Cys Cys Val Glu Cys Pro 20 25^ " 30^

Pro Cys Pro Asp He Leu Gly Gly Gly Ser lie Lys Gin He Glu Asp 35 40 45

Lys He Glu Glu He Leu Ser Lys He Tyr His He Glu Asn Glu He 50 55 60

Ala Arg He Lys Lys Leu Ile Gly Glu Arg Gly His Gly Gly Gly Ser 65 70 75 30

Ser Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro 85 90 95

Val A.la Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 100 105 110

Leu Met lie Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 115 120 125

Ser His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr Val Asp Gly Val 130 135 140

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Phe Asn Ser 145 150 155 160

Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gin Asp Trp Leu 155 170 175

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala 180 " 185 " 190

Pro lie Glu Lys Thr lie Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro 195 200 205

Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 210 215 220

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp He Ala 225 230 235 240

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 245 250 255

Pro Pro Met Leu Asp Ser A.sp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 260 265 270

Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser 275 230 285

Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser 290 295 300

Leu Ser Pro Gly Lys Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr 305 310 315 320

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 325 330 335

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg 340 345 350

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 355 360 365

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 370 375 380

Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 385 390 " 395 " 400

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 405 410 415

Lys Cvs Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 420 425 430

Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu 435 440 445

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 450 455 460

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 465 470 475 480

Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 485 490 495

Ser .Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 500 505 510

Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 515 520 525

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 530 535 540

Ser Leu Glu Gly Pro Arg Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu 545 550 555 560

Leu Gly Leu Asp Ser Thr Arg Thr Gly His His His His His His 565 570 575

<210> 79 <211> 544 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 79

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Glu Arg Lys Cys CyS Val Glu Cys Pro 20 25 30

Pro Cys Pro Asp He Leu Gly Gly Gly Ser lie Lys Gin He Glu Asp 35 40 45

Lys He Glu Glu He Leu Ser Lys He Tyr His He Glu Asn Glu He 50 55 60

Ala -Arg He Lys Lys Leu He Gly Glu Arg Gly His Gly Gly Gly Ser 65 70 75 30

Ser Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro 85 90 95

Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 100 105 110

Leu Met He Ser Arg Thr Pro Glu Val Thr Cys Val Val Val .Asp Val 115 120 125

Ser His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr Val Asp Gly Val 130 135 140

Glu Val His Asn Ala Lys Thr Lys Pro .Arg Glu Glu Gin Phe .Asn Ser 145 150 155 160

Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gin Asp Trp Leu 155 170 175

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala 180 185 190

Pro He Glu Lys Thr He Ser Lys Thr Lys Gly Gin Pro Arg Glu Pro 195 200 205

Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin 210 215 220

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp He Ala 225 230 235 240

Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr 245 250 255

Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Len 260 265 270

Thr Val Asp Lys Ser Arg Trp Gin Gir. Gly Asn Val Phe Ser Cys Ser 275 230 235

Val Mot His Glu Ala Lou His Asn His Tyr Thr Gin Lys Sor Lcu Sor 290 295 300

Leu Ser Pro Gly Lys Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr 305 310 315 320

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 325 330 335

Val Pho Lcu Fhc Pro Pro Lys Pro Lys Asp Thr Lcu Mot Ile Ser .Arg 340 345 350

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 355 360 365

Glu Val Lys Fhc Asn Trp Tyr Val Asp Gly Val Glu Val His Asn .Ala 370 375 380

Lys Thr Lys Fro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val 385 " 390 " 395 " 400

Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr 405 410 415

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 420 425 430

Ile Ser Ly3 Ala Lv3 Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Len 435 440 445

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys 450 455 460

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 465 470 475 480 A3n Gly Gin Fro Glu A311 A3n Tyr Lys Thr Thr Pro Pro Val Leu A3p 485 490 495

Ser .Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 500 505 510 .Arg Trp Gin Gin Gly -Asn Val Phe Ser Cys Ser Val Met His Glu Ala 515 520 525

Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 530 535 540

<210> 80 <211> 315 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 80

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Glu Arg Lys Cys CyS Val Glu Cys Pro 20 25 30

Pro Cys Pro Asp Ile Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 35 40 45

Pro A.rg Ser Ser Glu Pro Lys Ser Cys .Asp Lys Thr His Thr Cys Pro 50 55 60

Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 65 70 75 80

Pro Pro Lys Pro Lys .Asp Thr Leu Met lie Ser Arg Thr Pro Glu Val 85 90 95

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 100 105 110

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 115 120 125 .Arg Glu Glu Gin Tyr .Asn Ser Thr Tyr A.rg Val Val Ser Val Leu Thr 130 135 140

Val Leu His Gin Asp Trp Leu A.sn Gly Lys Glu Tyr Lys Cys Lys Val 145 150 155 160

Ser A.sn Lys Ala Leu Pro A.la Pro lie Glu Lys Thr lie Ser Lys A.la 155 170 175

Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser A.rg 180 185 190

Glu Glu Met Thr Lys A.sn Gin Val Ser Leu Thr Cys Leu Val Lys Gly 195 200 205

Phe Tyr Pro Ser Asp lie A.la Val Glu Trp Glu Ser Asn Gly Gin Pro 210 215 220

Glu A.sn A.sn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 225 230 235 240

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin 245 250 255

Gly A.sn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 260 " 265 270

Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly 275 280 285

Pro A.rg Phe Glu Gly Lys Pro lie Pro Asn Pro Leu Leu Gly Leu A.sp 290 295 300

Ser Thr A.rg Thr Gly His His His His His His 305 310 315

<210>81 <211 > 284 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 81

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Glu Arg Lys Cys Cys Val Glu Cys Pro 20 25 30

Pro Cys Pro Asp Ile Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 35 40 45

Pro -Arg Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro 50 55 60

Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 65 70 75 80

Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu Val 85 90 95

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 100 105 110

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 115 120 125

Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 130 135 140

Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 145 150 155 160

Ser -Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Ala 165 170 175

Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg 180 185 " 190

Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly 195 200 205

Phe Tyr Pro Ser Asp lie A.la Val Glu Trp Glu Ser Asn Gly Gin Pro 210 215 220

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 225 230 235 240

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin 245 250 255

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 260 265 270

Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 275 280

<210> 82 <211 > 344 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 82

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Glu Arg Lys Cys CyS Val Glu Cys Pro 20 25 30

Pro Cys Pro Asp lie Leu Gly Gly Gly Ser lie Lys Gin lie Glu Asp 35 40 45

Lys He Glu Glu lie Leu Ser Lys He Tyr His He Glu Asn Glu He 50 55 60

Ala -Arg He Lys Lys Leu He Gly Glu Arg Gly His Gly Gly Gly Ser 65 70 75 30

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 85 90 95 -Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 100 " " 105 110

Pro Lys Asp Thr Leu Met He Ser Arg Thr Pro Glu Val Thr Cys Val 115 120 125

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 130 135 140

Val A-sp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 145 150 155 160

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 165 170 175

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 180 185 190

Ala Leu Pro Ala Pro He Glu Lys Thr He Ser Lys Ala Lys Gly Gin 195 200 205

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 210 215 220

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 225 230 235 " " 240

Ser Asp He Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 245 250 255

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 260 265 " 270

Tyr Ser Lys Leu Thr Val A.sp Lys Ser Arg Trp Gin Gin Gly Asn Val 275 280 285

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 290 295 300

Lys Ser Leu Ser Leu Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe 305 310 " 315 " 320

Glu Gly Lys Pro lie Pro Asn Pro Leu Leu Gly Leu Asp Ser Thr Arg 325 330 " 335

Thr Gly His His His His His His 340

<210> 83 <211 > 313 <212> PRT

<213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 83

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Glu Arg Lys Cys Cys Val Glu Cys Pro 20 25 30

Pro Cys Pro Asp Ile Leu Gly Gly Gly Ser Ile Lys Gin Ile Glu Asp 35 40 45

Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile Glu Asn Glu Ile

50 55 SO

Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Gly His Gly Gly Gly Ser 65 70 75 30

Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 85 90 95

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 100 105 110

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 115 120 125

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 130 135 140

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 145 150 155 160

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 165 170 175

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys ISO " 185 " " 190

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Giv Gin 195 200 205

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 210 215 220

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 225 230 235 240

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 245 250 255

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 260 265 270

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 275 280 285

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 290 295 300

Lys Ser Leu Ser Leu Ser Pro Gly Lys 305 310

<210> 84 <211> 531 <212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 84

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Giv Ser Thr Giv Asp Ala Ala Glu Arg Lys Cys Cys Val Glu Cys Pro 20 25 30

Pro Cys Pro Asp Ile Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 35 40 45

Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 50 55 60

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 65 70 75 80

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr 85 90 95

Val .Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 100 105 110

Gin Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His 115 120 125

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 130 135 140

Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gin 145 150 155 160

Pro A.rg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 165 170 175

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro ISO 185 " 190

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 195 200 205

Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu 210 215 220

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 225 230 " 235 " 240

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 245 250 255

Lys Ser Leu Ser Leu Ser Pro Gly Lys Arg Ser Ser Glu Pro Lys Ser 260 265 270

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 275 280 285

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 290 295 300

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 305 310 315 320

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 325 330 335

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr 340 345 350

Tyr A.rg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 355 360 365

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin 385 ^ 390 ~ 395 400

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val 405 410 415

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 420 425 430

Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro 435 440 445

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 450 455 460

Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val 465 470 475 480

Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu 485 490 495

Ser Pro Gly Lys Ser Leu Glu Gly Pro Arg Phe Glu Gly Lys Pro Ile 500 505 510

Pro A*sn Pro Leu Leu Gly Leu Asp Ser Thr Arg Thr Giv His His His 515 520 525

His His His 530 <210> 85 <211> 500

<212> PRT <213> ARTIFICIAL SEQUENCE <220> <223> chemically-synthesized stradomer monomer <400> 85

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 15 10 15

Gly Ser Thr Gly Asp Ala Ala Glu Arg Lys Cys Cys Val Glu Cys Pro 20 25 30

Pro Cys Pro Asp Ile Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 35 40 45

Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 50 55 60

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 65 70 75 80

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr 85 90 95

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 100 105 110

Gin Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His 115 120 125

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 130 135 140

Gly Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gin 145 150 155 160

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 155 170 175

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 180 185 190

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 195 200 205

Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu 210 215 220

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val 225 230 235 240

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin 245 250 255

Lys Ser Leu Ser Leu Ser Pro Gly Lys Arg Ser Ser Glu Pro Lys Ser 260 265 270

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 275 280 285

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 290 295 300

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 305 310 315 320

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 325 330 335

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr 340 345 350

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn 355 360 365

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin 385 390 395 400

Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gin Val 405 410 415

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 420 425 430

Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro 435 440 445

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 450 455 460

Val .Asp Lys Ser Arg Trp Gin Gin Gly .Asn Val Phe Ser Cys Ser Val 465 470 475 480

Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu 485 490 495

Ser Pro Gly Lys 500 <210> 86 <211 > 159

<212> PRT <213> Homo sapiens <400> 86

Met Lys Asn His Leu Leu Phe Trp Gly Val Leu Ala Val Phe Ile Lys 15 10 15

Ala Val His Val Lys Ala Gin Glu Asp Glu Arg Ile Val Leu Val Asp 20 25 30

Asn Lys Cys Lys Cys Ala Arg Ile Thr Ser Arg Ile Ile Arg Ser Ser 35 40 45

Glu Asp Pro Asn Glu Asp Ile Val Glu Arg Asn Ile Arg Ile Ile Val 50 55 60

Pro Leu Asn Asn Arg Glu Asn Ile Ser Asp Pro Thr Ser Pro Leu Arg 65 70 75 80

Thr Arg Phe Val Tyr His Leu Ser Asp Leu Cys Lys Lys Cys Asp Pro 85 90 95

Thr Glu Val Glu Leu Asp Asn Gin Ile Val Thr Ala Thr Gin Ser Asn 100 105 110

Ile Cys Asp Glu Asp Ser Ala Thr Glu Thr Cys Tyr Thr Tyr Asp Arg 115 120 125

Asn Lys Cys Tyr Thr Ala Val Val Pro Leu Val Tyr Gly Giv Glu Thr 130 135 140

Lys Met Val Glu Thr Ala Leu Thr Pro Asp Ala Cys Tyr Pro Asp 145 150 155 <210> 87 <211> 15

<212> PRT <213> Homo sapiens <400> 87

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 15 10 15 <210> 88 <211> 110

<212> PRT <213> Homo sapiens <400> 88

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 15 10 15

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60

Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 <210> 89 <211 > 107

<212> PRT <213> Homo sapiens <400> 89

Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp 15 10 15

Glu Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu 35 40 45

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly 65 70 75 30

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95

Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 100 105 <210> 90 <211> 11

<212> PRT <213> Homo sapiens <400> 90

Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro 1 5 10 <210> 91 <211> 109

<212> PRT <213> Homo sapiens <400> 91

Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 15 10 15

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 20 25 30

Val .Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr Val 35 40 45

Asp Gly Met Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin 50 55 60

Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gin 65 70 75 80

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly 85 90 95

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys 100 105 <210> 92 <211> 107

<212> PRT <213> Homo sapiens <400> 92 174

Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu 15 10 15

Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Giv Gin Pro Glu 35 40 45

Asn A.sn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe 50 55 60

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly 65 70 75 30

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95

Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 100 105 <210> 93 <211 > 62

<212> PRT <213> Homo sapiens <400> 93

Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys 15 10 15

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 20 25 30

Glu Pro Lys Ser Cys -Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro Glu 35 40 45

Pro Lys Ser Cys -Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 50 55 60 <210> 94 <211 > 110

<212> PRT <213> Homo sapiens <400> 94

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 15 10 15

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Lys Trp Tyr 35 40 45

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60

Gin Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 85 90 95

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys 100 105 110

<210> 95 <211 > 107 <212> PRT 175 <213> Homo sapiens <400> 95

Giv Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu 15 10 15

Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Ser Gly Gin Pro Glu 35 40 45

Asn .Asn Tyr Asn Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe 50 55 60

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly 65 70 75 80

Asn Ile Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe 85 90 95

Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 100 105 <210> 96 <211 > 12

<212> PRT <213> Homo sapiens <400> 96

Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro 1 5 ^ ^ 10 <210> 97 <211> 110

<212> PRT <213> Homo sapiens <400> 97

Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 15 10 15

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30

Val Val Asp Val Ser Gin Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr 35 40 45

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60

Gin Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 65 70 75 80

Gin .Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser -Asn Lys 85 90 95

Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 105 110 <210> 98 <211 > 107

<212> PRT <213> Homo sapiens <400> 98 176

Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Gin Glu 15 10 15

Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 ^ 30

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu 35 40 45

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60

Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gin Glu Gly 65 70 J 75 80

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95

Thr Gin Lys Ser Leu Ser Leu Ser Leu Gly Lys 100 105

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description • W02005077981A F00DT1 • US5629001A [0171] • USS336616A Γ0246] • 11369333288 [02461 • US5871986A Κί'ΛΥό] • US4679236A [02981 • US'S 770818VV [0304] • US20060074225A [Q3331 • WO80941644A Γ03341 • WQ61015547A Γ03341 • VV061015127A Γ03341

Non-patent literature cited in the description • IMBACH PBARANDUN SD'APUZZO V et al.High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.Lancet, 1981, vol. 1,82321228-31 [00841 • RUTTER ALUGER TAHigh-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skinJ Am Acad Dermatol, 2001, vol. 44, 61010-24 [0004] • SAMUELSSON, A TOWERS, T.LRAVETCH, J.V. Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc ReceptorScience, 2001, vol. 291,484-486 £00091 • FOLLEA, G. et al.Intravenous plasmin-treated gammaglobulin therapy in idiopathic thrombocytopenic purpura.Nouv Rev Fr Hematol, 1985, vol. 27, 5-10 [00081 [03331 • SOLAL-CEUGNY, P.BERNARD, J.HERRERA, ABIOVIN, P.Treatment of adult autoimmune thrombocytopenic purpura with high-dose intravenous plasmin-cleaved gammaglobulinsScand J Haematol, 1983, vol. 31,39-44 [0009] [0333] 177 • DEBRE, M.BONNET, M.-C.lnfusion of Gcgamma fragments for treatment of children with acute immune thrombocytopenic purpuraLancet, 1993, vol. 342, 945-49 [0009] [03331 • BURDACH, S.E.EVERS, K.GEURSON, R.Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: Comparative efficacy of 7S and 5S preparationsJ Pediatr, 1986, vol. 109, 770-775 f00091 Γ03331 • TOWERS, T.L.RAVETCH, J.V.Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc ReceptorScience, 2001, vol. 291.484-486 [0010] • SIRAGAM, V. et al. Intravenous immunoglobulin ameliorates ITP via activating Fc[gamma] receptors on dendritic cellsNat Med, 2006, vol. 12, 688-100101 Γ02ββ1 Γ0333Ί • CLARKSON, S. et al.Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody.N Engl J Med, 1986, vol. 314, 1236-1239 Γ00101 10333) • SIRAGAM, V. et al.Intravenous immunoglobulin ameliorates ITP via activating Fc[gamma] receptors on dendritic cells.Nat Med, 2006, vol. 12, 688- .[0010]. • BLEEKER, W.K. et al.Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolaseBlood, 2000, vol. 95, 1856-1861 100111Γ00111 f0333]

• TEEUNG, J.L et al.Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia Blood, 2001, vol. 98, 1095-1099 |001U • AUGENER, W.FRIEDMAN, B.BRITTINGER, G.Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)?Blut, 1985, vol. 50, 249-252 [0011] [0333] • KABAT, EAWU, 11 PERRY, HM GO I IbSMAN, KSFOELLER, C.Sequences of proteins of immunological interestUS Public Health Servicesi 9910000 jOOSei • MIHAESCO CSELIGMANN M.Papain Digestion Fragments Of Human IgM Globulins.Journal of Experimental Medicine, 1968, vol. 127, 431-453 Γ00731 • TAN, LKSHOPES, RJOI, VTMORRISON, SLInfluence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulinsProc Natl Acad Sci USA., 1990, vol. 87, 1162-166 F00741 • WONG, SHAN S.Chemistry of protein conjugation and cross-linkingCRC Pressl 99100001.0097]. • Nanoparticulates as Drug Carrierslmperial College Press20060900 (0099] • HARVEY R. GRALNICKSYBIL B. WILLI AM SMARGARET E. RICKProceedings of the National Academy of Sciences of the United States of AmericaBiological Sciences, 1983, vol. 80, 92771-2774 [0102] • KIMIE ASANUMAFUMIO ARISAKAHARUKO OGAWAInternational Congress Series, 2001, vol. 1223, 97-101 Γ01021 • YOO, E.M. et al.J. Immunol., 2003, vol. 170, 3134-3138 10105] . SALFELDNature Biotech, 2007, vol. 25, 1369-1372 fOIOSl . HARBURY et al.Science, 1993, vol. 262, 1401-1407 101081F01091 . O'SHEA et al.Science, 1989, vol. 243, 538- [0108] • MORRIS etal.Mol. Immunol., 2007, vol. 44, 3112-3121 [01091 • WOOF JMBURTON DR.Human antibody-Fc receptor interactions illuminated by crystal structures.Nat Rev Immunol., 2004, vol. 4, 289-99 Γ01221 • ROBERT L. SHIELDS et al.High Resolution Mapping of the Binding Site on Human lgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of lgG1 Variants with Improved Binding to the FcyRJ. Biol. Chem., 2001, vol. 276, 6591-6604 Γ01221 103001 • ROBERT L. SHIELDS et al.High Resolution Mapping of the Binding Site on Human lgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of lgG1 Variants with Improved Binding to the FcyRJ. Biol. Chem., 2001, vol. 276, 6591-6604 [0129] • ROBERT L. SHIELDS et al.Lack of Fucose on Human lgG1 N-Linked Oligosaccharide Improves Binding to Human Fc Rill and Antibody-dependent Cellular ToxicityJ. Biol. Chem., 2002, vol. 277, 26733-26740 [0130] [0302] • ANN WRIGHTSHERIE L. MORRISONEffect of C2-Associated Carbohydrate Structure on Ig Effector Function: Studies with Chimeric Mouse-Human lgG1 Antibodies in Glycosylation Mutants of Chinese Hamster Ovary Cells.J. Immunol., 1998, vol. 160.3393-3402 Γ01301 • RADAEV, S.SUN, P. Recognition of Immunoglobulins by Fey ReceptorsMolecular Immunology, 2001, vol. 38, 1073-108310133] • SHIELDS, R.L.High Resolution Mapping of the Binding Site on Human lgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of lgG1 Variants with Improved Binding to the FcyR.J. Biol. Chem., 2001, vol. 276, 96591-6604 10133] • NIMMERJAHN FRAVETCH JV. Fcgamma receptors: old friends and new family members.Immunity, 2006, vol. 24, 119-28 [01561 • F. J IN J. BALTHASARMechanisms of Intravenous Immunoglobulin Action in Immune Thrombocytopenic PurpuraHuman Immunology, 2005, vol. 66, 4403-410 [0157] • NIMMERJAHN FRAVETCH JV.The anti-inflammatory activity of IgG: the intravenous IgG paradoxJ Exp Med., 2007, vol. 204, 11-151015¾ 178 • AUGENER WFRIEDMAN BBRITTINGER G.Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)?Blut., 1985, vol. 50, 249-252 [0158] • ARASE NARASE HPARK SYOHNO HRACSAITO T. Association with FcRgamma is essential for activation signal through NKR-P1 (CD161) in natural killer (NK) cells and NK1.1 + T cellsJ Exp Med., 1997, vol. 186, 1957-1963 .[01581 • TEELING JLJANSEN-HENDRIKS TKUIJPERS TW et al.Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopeniaBlood, 2001, vol. 98, 1095-1099 [01581 • ANDERSON CFMOSSER DM .Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptorsJ Immunol., 2002, vol. 168, 3697-3701 £0153] • JEFFERIS RLUND J.Interaction sites on human IgG-Fc for Fc[gamma]R: current modelslmmunology Letters, 2002, vol. 82, 57- [01581 • BANKI ZKACANI LMULLAUER B et al.Cross-Linking of CD32 Induces Maturation of Human Monocyte-Derived Dendritic Cells Via NF-{kappa}B Signaling PathwayJ Immunol., 2003, vol. 170, 3963-3970 [0158] • SIRAGAM VBRINC DCROW ARSONG SFREEDMAN J LAZARUS AH.Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?J Clin Invest, 2005, vol. 115, 155-160 [01581 • FALK NIMMERJAHNJEFFREY RAVETCH.Fcy receptors as regulators of immune responsesNature Reviews Immunology, 2007, F01591 • F. G. VAN DER MECHEP. I. SCHMITZN. Engl. J. Med., 1992, vol. 326. 1123- Γ01901 • P. GAJDOS et al.Lancet i. 1984.406- 101901 • Y. SULTANM. D. KAZATCHKINEP. MAISONNEUVEU. E. NYDEGGERLancet ii, 1984, 765- Γ0130Ί . M. C. DALAKAS et al.N. Engl. J. Med., 1993, vol. 329,1993-10190] • D. R. JAYNEM. J. DAVIESC. J. FOXC. M. BLACKC. M. LOCKWOODLancet, 1991, vol. 337, 1137- Γ01901 • P. LEHOANGN. CASSOUXF. GEORGE N. KULLMANNM. D. KAZATCHKINEOcul. Immunol. Inflamm., 2000, vol. 8, 49- [0190] • ZAFRANSKAYAM et al. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosislmmunology, 2006, vol. 121, 129-39 [0213] • MENDEL CMMENDEL DBNon-specific' binding. The problem, and a solutionBiochem J., 1985, vol. 228, 1269-72 [0231] • ASLAN KLAKOWICZ JRGEDDES C.PIasmon light scattering in biology and medicine: new sensing approaches, visions and perspectivesCurrent Opinion in Chemical Biology, 2005, vol. 9, 538-544 [0231] • HORTON RMHUNT HDHO SNPULLEN, JKPEASE LR.Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extensionGene, 1989, vol. 77, 61-68 £027¾ • LONBERG N.Human antibodies from transgenic animals.Nat Biotechnol., 2005, vol. 23, 91117-25 [0297] • KIPRIYANOV SM LE GALL F. Generation and production of engineered antibodies.Mol Biotechnol., 2004, vol. 26, 139- • KO KKOPROWSKI H.Plant biopharming of monoclonal antibodiesVirus Res., 2005, vol. 111,193-100 [02971 • ROCKY S. TUANRecombinant Gene Expression ProtocolsHumana Pressl9970000 £0299] • ROSHNI L. DUTTONJENO M. SCHARERAdvanced Technologies for Biopharmaceutical Processing Blackwell Publishing20070000 [0299] • Recombinant Protein Production With Prokaryotic and Eukaryotic CellsOTTO-WILHELM M CRTCNContributor European Federation of Biotechnology, Section on Microbial Physiology StaffSpringer20010000 [0299] • HARRIS, CLDM LUBLINBP MORGANEfficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions.J. Immunol. Methods, 2002, vol. 268, 245-258 [0361] . FOUNTOULAKIS, MC. MESAG. SCHMIDR. GENTZM. MANNEBERGM. ZULAUFZ. DEMBICG. GAROTTAInterferon gamma receptor extracellular domain expressed as IgG fusion protein in Chinese hamster ovary cells: Purification, biochemical, characterization and stoichiometry of bindingJ. Biol. Chem., 1995, vol. 270, 3958-3964 [0301] . KANEKO YNIMMERJAHN FRAVETCH JV.Science, 2006, vol. 313, 5787627-8 .[0303], • LI, B.SONG, H.HAUSER, S.WANG, L. XA Highly Efficient Chemoenzymatic Approach Toward Glycoprotein SynthesisOrg. Lett, 2006, vol. 8, 3081-3084 [03941 • BAYRY, J et al.Inhibition of maturation and function of dendritic cells by intravenous immunoglobulinBlood, 2003, vol. 101, 2758-765 [03071 • PRECHTEL ATTURZA NMTHEODORIDIS AASTEINKASSERER A.CD83 knockdown in monocyte-derived DCs by small interfering RNA leads to a diminished T cell stimulationJ Immunol, 2007, vol. 178, 95454-64 [0308] • JONGBLOED, SARAH L. et al.Enumeration and phenotypic analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritisArthritis Res Ther., 2005, vol. 8, 1R15- [0308] • WU GFLAUFER TM.The role of dendritic cells in multiple sderosisCurr Neurol Neurosci Rep., 2007, vol. 7, 3245-52 [03101 • TARGAN SRKARP LC.Defects in mucosal immunity leading to ulcerative colitislmmunol Rev., 2005, vol. 206, 296-305 [0310] • CROW AR et al.lVIG inhibits reticuloendothelial system function and ameliorates murine passive immune thrombocytopenia independent of anti-idiotype reactivityBr J Haematol., 2001, vol. 115, 679-686 [0310] • GEORGE, JN et al.Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of HematologyBlood, 1996, vol. 88, 13-40 .[9315] . SASSANO, M.Nucleic Acids Res., 1994, vol. 22, 91768-9 [0319] . JONES, S.T.BENDIG, M.M.Biotechnology (NY), 1991, 188-9 103191 • ROMOND, EHTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNEJM, 2005, vol. 353, 1673-1684 [03211 • SEIDMAN, ADWeekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene AmplificationJournal of Clinical Oncology, 2001, vol. 19,102587-2595 (0321) . VOGEL, CLJournal of Clinical Oncology, 2002, vol. 20, 3719-726 .[0321.1 • ROBERT, F Phase I Study of Anti-Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer Journal of Clinical Oncology, 2001, vol. 19, 133234-3243 Γ03231 • BONNER, JACetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximabJournal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004, vol. 22, 14S5507- f03231 • SHIN, DM Epidermal Growth Factor Receptor-targeted Therapy with C225 and Cisplatin in Patients with Head and Neck CancerClinical Cancer Research, 2001, vol. 7, 1204-1213 [83231 • CUNNINGHAM, D et al.Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer.NEJM, 2004, vol. 351,337-345 [0323] • SMILEY, D.MG, T.Southwestern internal medicine conference: High dose intravenous gamma globulin therapy: How does it work?Am J Med Sci, 1995, vol. 309, 295-303 (0333) • NIMMERJAHN, F.RAVETCH, J.V.The antiinflammatory activity of IgG: the intravenous IgG paradoxJ. Exp. Med., 2007, vol. 204, 11-15 [0333] • SAMUELSSON, A TOWERS, T.LRAVETCH, J.V.Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc

Receptor.Science, 2001, vol. 291,484-486 [03331 • TEELING, J.L et al.Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.Blood, 2001, vol. 98,1095-1099 F03331 • TANKERSLEY, D.LPRESTON, M.S.FINLAYSON, J.S.Immunoglobulin G dimer: An idiotype-anti-idiotype complexMolecular Immunology, 1988, vol. 25, 41- [0333) • ROBERT L. SHIELDSANGELA K. NAMENUKKYU HONGY. GLORIA MENG JUUE RAEJOHN BRIGGSDONG XIEJADINE LAIANDREW STADLENBETTY LIHigh Resolution Mapping of the Binding Site on Human lgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of lgG1 Variants with Improved Binding to the FcyRJ. Biol. Chem., 2001, vol. 276, 6591-6604 Γ03331 . SONDERMANN, P.HUBER, ROOSTHUIZEN, V.JACOB, U.Nature, 2000, vol. 406, 267-273 [0333.1 • ROBERT L. SHIELDSJADINE LAIRODNEY KECKLORI Y. O'CONNELLKYU HONGY. GLORIA MENG STEFANIE H. A WEIKERTLEONARD G.Presta Lack of Fucose on Human lgG1 N-Linked Oligosaccharide Improves Binding to Human FcyRIII and Antibody-dependent Cellular ToxicityJ. Biol. Chem., 2002, vol. 277, 26733-26740 [0333] • ANN WRIGHTSHERIE L. MORRISON.Effect of C2-Associated Carbohydrate Structure on Ig Effector Function: Studies with Chimeric Mouse-Human IgG 1 Antibodies in Glycosylation Mutants of Chinese Hamster Ovary CellsJ. Immunol., 1998, vol. 160, 3393-3402 Γ03331 • CROWAR et al.lVIg inhibits reticuloendothelial system function and ameliorates murine passive immune thrombocytopenia independent of antiidiotype reactivityBr J Haematol., 2001, vol. 115, 679-686 [0333]

• JAGADEESH BAYRY SÉBASTIEN LACROIX-DESMAZESCEDRIC CARBONNEILNAMITA MISRAVLADIMIRA DONKOVAANASTAS PASHOVALAIN CHEVAILLERLUC MOUTHONBERNARD WEILLPATRICK BRUNEVAL Inhibition of maturation and function of dendritic cells by intravenous immunoglobulinBlood, 2002, vol. 101,758-765 [0333] • R. DENGJ. P. BALTHASAR.Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopeniaBlood, 2007, vol. 109, 62470-2476 [0333] • KABAT, E. AWU, T. T. PERRY, H. M.GOTTESMAN, K. S.FOELLER, C.Sequences of Proteins of Immunological Interest,National Institutes of Healthl9910000 [03331

Claims (6)

1. Forbindelse omfattende to eller flere multimeriserede enheder, hvor hver af enhederne omfatter en multimeriseringsregion og en region omfattende mindst et Fc-domæne, der kan binde til en Fcy-receptor, hvor hver af enhederne omfatter to dimeriserede monomerer, hvor hver af monomererne omfatter en multimeriseringsregionsmonomer og en region omfattende mindst en Fc-domæne-monomer, hvor dimeriseringen af de to monomerer danner en multimeriseringsregion og en region omfattende mindst et Fc-domæne, der kan binde til en Fcy-receptor, hvor multimeriseringsregionerne af de to eller flere enheder multimeriserer til dannelse af forbindelsen, og hvor forbindelsen kan binde til en første Fcy-receptor gennem et første Fc-domæne og til en anden Fcy-receptor gennem et andet Fc-domæne, hvor multimeriseringsregionen er udvalgt fra gruppen bestående af et lgG2-hængsel, et IgE CFI2-domæne, en leucin-zipper, en isoleucin-zipper og en zinkfinger, og hvor hver af de regioner, der omfatter mindst et Fc-domæne, der kan binde til en Fcy-receptor, omfatter et lgG1-hængsel, et lgG1 CFI2-domæne og et lgG1 CFI3-domæne.A compound comprising two or more multimerized moieties, each of which comprises a multimerization region and a region comprising at least one Fc domain capable of binding to a Fcγ receptor, each of the moieties comprising two dimerized monomers, each of the monomers comprising a multimerization region monomer and a region comprising at least one Fc domain monomer, wherein the dimerization of the two monomers forms a multimerization region and a region comprising at least one Fc domain capable of binding to a Fcy receptor, wherein the multimerization regions of the two or more entities multimerizes to form the compound and wherein the compound can bind to a first Fcγ receptor through a first Fc domain and to a second Fcγ receptor through a second Fc domain, wherein the multimerization region is selected from the group consisting of an IgG2 hinge; an IgE CFI2 domain, a leucine zipper, an isoleucine zipper and a zinc finger, and each of the regions comprising at least an Fc domain that can bind to a Fcγ receptor comprises an IgG1 hinge, an IgG1 CFI2 domain, and an IgG1 CFI3 domain. 2. Sammensætning omfattende en medicinsk anordning, der er implanterbar eller kan fastgøres, og mindst en forbindelse ifølge krav 1, der er bundet dertil.A composition comprising a medical device which is implantable or attachable, and at least one compound according to claim 1, which is attached thereto. 3. Farmaceutisk sammensætning omfattende en terapeutisk virksom mængde af en forbindelse ifølge krav 1, til anvendelse som et medikament i en fremgangsmåde til ændring af et immunrespons hos et individ, omfattende at indgive den farmaceutiske sammensætning til et individ, der har behov derfor.A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, for use as a medicament in a method of altering an immune response in a subject, comprising administering the pharmaceutical composition to a subject in need thereof. 4. Sammensætning omfattende et substrat med en forbindelse ifølge krav 1, der er bundet dertil, til anvendelse i en fremgangsmåde til behandling af en inflammatorisk tilstand, en autoimmun sygdom, en cancer, en lidelse relateret til knogletæthed, en akut infektion eller en kronisk infektion ved at inhibere aktiviteten af en monocytderiveret celle (MDC), hvilken metode omfatter at bringe cellen i in wVokontakt med sammensætningen.A composition comprising a substrate with a compound according to claim 1, for use in a method of treating an inflammatory condition, an autoimmune disease, a cancer, a bone density disorder, an acute infection or a chronic infection. by inhibiting the activity of a monocyte-derived cell (MDC), which method involves contacting the cell with the composition. 5. Sammensætning omfattende et substrat med en forbindelse ifølge krav 1, der er bundet dertil, til anvendelse i en fremgangsmåde til behandling, omfattende at indgive sammensætning til dyreindivid, hvor dyret har eller risikerer at udvikle en tilstand medieret af en monocytderiveret celle (MDMC), hvor MDMC er en inflammatorisk tilstand, en autoimmun sygdom, en cancer, en lidelse relateret til knogletæthed, en akut infektion eller en kronisk infektion.A composition comprising a substrate with a compound according to claim 1, for use in a method of treatment, comprising administering composition to an animal subject, wherein the animal has or is at risk of developing a state mediated by a monocyte derived cell (MDMC) , wherein MDMC is an inflammatory condition, an autoimmune disease, a cancer, a bone-related disorder, an acute infection, or a chronic infection. 6. Sammensætning til anvendelse ifølge krav 4 eller krav 5, hvor den inflammatoriske tilstand er ulcerøs kolitis eller Alzheimers sygdom, den autoimmune sygdom er reumatoid artritis, systemisk lupus erythematosus eller kronisk inflammatorisk demyeliniserende polyradikuloneuropati, eller canceren er lymfom.The composition for use according to claim 4 or claim 5, wherein the inflammatory condition is ulcerative colitis or Alzheimer's disease, the autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus or chronic inflammatory demyelinating polyradiculone neuropathy, or the cancer is lymphoma.